var title_f39_56_40832="Jumping man z-plasty";
var content_f39_56_40832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Jumping man Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40832=[""].join("\n");
var outline_f39_56_40832=null;
var title_f39_56_40833="Management Brugada syndrome-I";
var content_f39_56_40833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79568%7ECARD%2F61362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79568%7ECARD%2F61362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Management of patients with Brugada syndrome according to baseline ECG and symptoms-I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 330px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Class I designation indicates clear evidence that the procedure or treatment is useful or effective; Class II, conflicting evidence about usefulness or efficacy; Class IIa, weight of evidence is in favor of usefulness or efficacy; and Class IIb, usefulness or efficacy is less well established.",
"    <div class=\"footnotes\">",
"     BS: Brugada syndrome; NAR: nocturnal agonal respiration; and SCD: sudden cardiac death.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659. Copyright &copy; 2005 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Management of patients with Brugada syndrome according to baseline ECG and symptoms-II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 329px; background-image: url(data:image/gif;base64,R0lGODlh+gFJAeYAAP///4CAgH9/fwAAAIiIiLu7u0RERMDAwCIiIj8/PwAz/0BAQN3d3ZmZmREREWZmZr+/vzMzMwBmM+7u7szMzFVVVXd3dxFB/6qqqszW/zNc/4ig/1V3/+7x/4i4oDOFXO718czg1qq7/xFwQXeS/3etkuDg4FWZd6CgoKrMu0Rp/yAgICJO/yJ6Th8fH2BgYESPaZmt/9DQ0HBwcLCwsF9fXzAwMGaF/93k/2ajhZCQkFBQUBAQELvJ/5nCrbvWyd3r5PDw8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD6AUkBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI0qcSLGiuw0KSHzSoCADqAsXCIlQwIFQBpKNOigIaQmjxkscFIiwSFOUCI4kYyxyqZKlJo4eP4EUiXLQyZKMeiYioWDDzoyYYs4cdEFBh00qOhY6qaCrTAA3u2oQ1OGGWBJBa9LrcIGFoA03/56+7AT0o0+wRQUdTbnyksuoX6lazTSya1q9CsYO6pEYB4ANGllc0NmBg1O19E5eIKFTUIyqRWN0rapxKFDNAJiqqHoj5oXDlb2Gjdn0sVcWInpmfQ2AI22nGbIqUOF46KCRGjiq6LA3A07iAGKwEKs06+VBGDfoXulR9MqMSjGWDO61g/SuSM1+nwqAdkbrALI6T9x1JvnhjgvFPAzgpGJBZnXmmQJxYZaPel1t4J9taCng1l+mdYQaU05VhYNoBQoS03Uc9cDYXRgt15d4vSngYV+SmUcgAMYJMlJJFO6VImMa+HcVAD2Z5RRT9WUXHkknPQjeiChJFtSCAZIoFf8hVV2FHA7DlZgBDkOliKEh+23lVVcd1DUIhQbuEwNTF/yF3IsMshjSaX2B2SSagt0opVIiCJcYnSgB1RNXXo3VIl4luXTUgio1BRVZXl2QHyE+9vUimjwRycGCb22ZEZhLxinIdEvWVRWfYmGplUmJERKTgNERWGhtYcYjwqQAUMnCgi7RmGaEIkxY25t5tcfqnH1V1YONjubZkVKSLaomUSVZJ+MFHdBoI6IXIGdIoyG9aGuk0JJoJGL/pZkVeywqkB9GDgoCFGNuJZtIlqSGS6NjkHUwnU5gtgoPDiRMh190oBXII0elZdvVbqntahWcZLkXVgY/0qcBniXp2df/fSj9WVhXcTX3nGPn3dmXWRlWql2xMIoFFY9ZjWenef7WthtH5KKrEVusclTVrP3ZiZSLW/7cn6UzhVVqrO7xrO/SBbHlk5dMRy01I3+pO+rUWGet9dZcd+3112CHLfbYZJdt9tlop6322my37fbbcMct99x012333XjnrffefPft99+AN+TBCBJIUEIImRAOQiYeGC7IBxIgHjgAJRT+AyiNl6DJCRKkAEAKEpywNOiiA5CDB4lLsDgmmU9uSAuF54C545lw7rnUjX9wuCAwSIB67yFAzrnvvX8AAggSjAB5C0AMbzgIvUvQgufCF+5B8YsTXvgJIRReOAichwC+//e36w36ByOMsHjw3odAOOIjtID8CL234AHsolcOueHdew+CD9oT3fzqd7/QAaBxhZseAiXwge6JLgTRU11NoOe9EaTgfECQAAwAALkf/EB6ppOAD+YHAB9oEACKA4DtQNAC9XXwgy0IoQ8IAbsftE6FkeMc6vymQx1yUISDqFwJTOgBEjZOdrADQuVQ18HWde8DB3xe8qKIRAkAYRCN26DtAOBAALRQcmHyAOc2iL/O/TAET6Sc70iYxhSmEHIpgBwaGahG1FWOfDcMXwr7lkHv0dGEhTNe91oAA/UZ0XFyXCIOU9C61p3vkJqTYwoiCMUtOjCNBipBCRZnQtkhMP+GZ0zjEg8pOsJdcYUtBIEcRem7LC7yiIIInw/71rjS1XAQkJvh8GQHyTOOEnYhgGUaM9dLORLuB2nk3Ay7+EUDpeCOEpAdAEBAuB2uko6jTB7hYLA4BG4yeh+gXuRYWUTIKa9zqvxe+MZXuPLhDXa3q1wOtBdNQYAuctOcYusSmbzCzTCdqgNg7PI5gihGMnIIhBwU3cfALkLQf0yjZkEZQULX1QJ0G2SEIid3w0VU1KKz6J07E7FRkJr0pChNqUpXytKWuvSlMI2pTGdK05ra9KY4zalOd6qWAwTgp0ANqlCHStSiGvWoAThAKnyK1KY69alEVSowTADVqlr1qlj/raoJdIGCrHr1q0LdqiwCkAABmPWsaE2rWtfK1ra2NQEBSAVZ3UrXutrVrXANxgFccNe++vWvgA2sC6SKiwXUILCITaxaBzuLAAjAFgKIKyoci4vI6jUB40gAYW+xAAgIQ7ONfWwtLDtZ0UJWsr84AGbFAdpcdPazm30FZUeLWlPM9rSXzWxsa/HaYLQ2FredBWlPEVxaDNcXqtWtLnoLjN/CorixOG4poCsL6fIiuazdLS2Y+wvnyta0wq3tdMFrXPFed7Xh8C5vPetb7bKCuocowAA4IV9EWHcU8IXFfXWB3fS6VxbcvQQBBjDfSNT3EeptRX4xMIAHCOLAjSCA/wEWAeFC7DcU+X3FhXHR31FU+BADKIArEjyLABNCvgiYAAAeMOFETCDEkQjxhxdB4lXk1wAGcICKZ5wICVO4wIbY8CeoOwEDENgBBFiFkG3R4UUQ+MmQkDGQEQHjQRggyYW4MihqHAsTDwLFDmaxIigwZUjwOBFclit5B8GAAVAAAQ0AgHwjMAAEUAAAAx5ABO48gAYgwMgEfkABEEDgOA8ayodYcieoa4EICKIBLU6FomnRZEX0uRJnHkSVFaHlT6T5FV5+cJ9DLOYCOGAADojzIAjd4Ac8Oc4GYHWsUc0AAEgZAAhI8gQcgAE0/1cV8CWAo30s3ztXoAJkvrOYB/9QAUH4GACpBgAGHADtJJ950ptgdARqLYg2i1i+RaZzgwHAAHE3G9AGmMCc63znPNs50ebdRaUTcWlBuLrQAJj1AGbtgFrfOtcA2HWvNS1uWBOgyEduwKtNjWqDxxrgAnfEp10RajkPgAGxFjOSAdAAHX+5zA9wNI45DmOA39rPHEeAIiZu2zULgtUEZsCBCQBnlctZ5VX2cZuffPGLW9y+8RYFkR9w6gjE+QFhdvDI5cuACkSa5hOYQAQIUGwAHJsCDrizBZod5KDnYt5UfjKWVyzyCStcxCYvQH1RjnJCDCDJNM831QegYkF0euMdD3et2W7zRrCcFRVnOpn33Wb/bvtc1M4+dZ3l/nPG33rXBTD6yn+t5vjS3e4WOHAEHpBsq084546GtqoFsfEBA73yilC4uvvtcy0XHs6DQLqzBV1gmiv8yX0nBLZlAXYQj54Aile5lg+s5cc7IPKjFwSMUa5lC6A6ya4//MU7DXnJS5zyoGav5Wvt6gmX3uOIb3OvLSB8axe4+GqvfQSoPfnQHuIBXOf48Z+8bTwTeM+2FjEAsN7gQy/+9nR2eqV1CBWAZXmXbxHAddHXdE+XYhOQa5rHeVmnCLsXC71nCPUmfgBAfoxHfEl2a3i2fhgoYsw3dmSGcRZAenCnY50Wgux3fculfYbAdOS2b3J2atH2/3F2R2AIUH6Nh34H9mJjhwh/RwoZxgoViAnURXM8qH8Mpn8LWG4Edm4Elm7ydX+1lmfj1nW55Qj1lm886IMemH9B+HYjmHJyd4XjdnsNwHDR1oJCCAlFqAoVtwqmVne+5n60hXoRFmkGVmaMkISvcIGgcIceBn4w6FoyCAsRkII0hn3E5XIa5nWgcIRsxmuUkGkCmFrodQqNSAqfKIeQ2Ap1iAtzKHSS6AqCaAmWiISUeAuEiA2niAqleAuzWImp2AqrWAmtqGSvyGSd+A23aAq1SAgt2ArD6Am9OAgdV4V3RgHilms7R2COCAm7SAnLKGm/WAuxeIX6lwwzloykUP+MVjaEM6aJmCCOnJCNL9ZrE1ABDcAADuBgeFYBhSdnCRgJ1zgJGdaM+3ZnhYCOlbCPqhCLU1cI0Hh/cfaOT5aCMGePp3CMlmcI6igK5Gh3Q4gIAmkJFakJ7GiGgyBshXCP+3d5j0CQkZBf7Rhw8IgKKIkKsXh8hRCKBOBgERABO+ZosIdxKWYKEjmDgNiRoHCRCBhoP+ePTFhnUjgAKShf8nWAIolgozhekQBpgTYBNTmSh5d/1riN65iKcUgI7kYB9QVzD6Bw9qZ0EoYAS0mPm4hcwWh/ekYB95Z7EeCHZIaHLzd6mDgIzkdgdNlicJaQzGZrBXdz+KaFWtiGrGb/aDBHkVO5CkS5dBdXXwZQjQd2bPt3fPKFZbAHe1Kph5IgdRYQd4RAknnZlXx4CFbZYBOAdVpXARBmahSAliumdPVXAQ4mjwAJb104CJ23bN8oCHTpjINmCKDJeJo2cCsmmA0Qlcq3gqInbVm3aXcXZ9NWbY1HCEL5CZOZZIVXX5H3jwcGmgbQhkAmYRiQe34XmfiVizNoAHcmdQQgj1xHAPboc5Hnlo7wko/QiqR5e01YYH52Z7Ype50Gc1/IhcDQZG13nJtmCCF3goWQnH3pbIT2ABMgZrgWjxWgZ3EGY0zHc32We9HHc/cYju6ZCt9ZgzI3ZboJblbXbGSWfoOw/2sHKYqi2QhN92RcN556Vp88l5GN4J+OkF8FIJ8BN3WwqYN+xm1MV25qKQi6WaReOQtN1nlOx5WEYH1idpO1FnkdSm6xhgipFnem9ns4J2IcmIMl+Y2XSXrJV3pBuaK0uIiLsICWyYMUIHVKKW5NOWUWgIiJCFzw6YurOZIfOoXO9mS0Z2tPNmFG5gCbp5xLuZUMyomGkGf4F6EbSH+1hnFH5pA+qpe7dn8TwACEtn7P+WqQWmffxmoqp4W1WWj+p3IAWKcx6Ao/yQjdeQnZaApG2gjBegrDSgqxGAue6ml2egpE2QkMppeF+lyHqgrHugjFKqxXyntxeQvL6gm/2v8JzxoL4cqL1aqNiRpevwkO5boJ4woL7cqP5+qS25oJ2VoK1yoKyWoN8ZoJ7/oK/ZqS82qs9aqEA0uv60oJz/YIG5kKAXsJ/zpizTpkB4uvBQusFQuYJDcIdMZtWlh/+nixrkCI3yqWftgIDVuOPyZ2gvCXrtl+ighbjVVWilWzbJVXAxhjPbixN5ijphmKqtmg3ep2w3kIC+sIKYuRP5aF1DZttQaN3EaEE1sKhmWzVvtXjMV7YBVUC7AAWwtUUyuvkvB2SHag8GhzcfeARBqIItsKF3hvF8epvYlnCFB0KraoOHlij8mhsIe3eCigbYiDyUeDW0edRZuHudBVX0v/VCvwAotLVGLVDD9VDMXaZwNmegIHeXK5hSGbsGcYnH4IdWorbCqWoyr4c3z7nHlrusqJd4iohi8rbM/3iNywAGGrDZNLDJXbAA9IYCTnqHRLdpOQr6FAsiRoc8cZki1mAEjHc26ZovOVunDLuYxHkltJgw9YjZvJnIfwsIV1u9mQu8Owu7+bb44Ibj/Ln/3ZtqxAsr2mpaE7YfKoutJ6uqaHpmeat4YQp9oJfHiIvblWkyqGdYfLneA7DLYbD+IrDOSLaz3XmwFsc6q6thTIvqtAiPfGAHIrlj5Kpa7KjPc3X6qqZ9G2qAvKhm44uDxXAeombiCJuNqQwPCwwMFw/6+kQLygsK/V4L2cdcDXQMPAYMOjgMOfoMPUwMO2IMPvAMS/IMSiQMSeYMTTgMS85cPWwMS+4MShAMWdIMXSQMXbZcXVgMW9oMWgwMWc4MXRAMYlJsbUQMa8YMafgMaboMbQwMYA5sbTAMe7IMeeQMeaYMfPgMddpsfSwMe64MedAMiZIMjOQMiwoMTugMi5MFdXe8lmhbOpxVeY3MmeTFdZG8OGHA2UzGGP27WP+1OjDApUlcpZhcqunFWRmw2S3A6lvMcWrA+3DBC1zA67TMq5nA+/7A+9vA7D3AwrwHM80BDJ/GTLnBBBQKI2sMTBbAwvwHM70BDX/GTZrBALwP9zM0DN34ACPKcDDUHOT2bOChEAPEcD4uwNJsBzMtAQ8fxk86wQB8BzM1zNxmADBLYCD+HPAwDQDMEDBLYA+wwOM0BgL/AQCz0ADc0QO0Bg/DzGFU0MNEBgKPAQGT0AG80QOkBg9zzJF00MBDbLDHHSDSEDA/DM7/wNCzDNEBHTD7EC3fzS3hAA4QwROv0QL6DOON0NMuDOEDHUD4ECKO3LJc1TTJ0Ix9zUUA0JTx3VVI2tS13VUD3Vk8BUsdzVXp1Vq2wJivvVqfzRzzDWZA1WSS25V40IlvzJcB3XfaXJvHVYcn21NYDQ0FC1d61YoQwNWi0JilwNjPwIEYsKEKD/189w2KQAybbV1ocw2NRQ2I7A2KaQ2NFg2aLg2NMF2YYg2dNA2Y2g2aSA2XuNp7TA2Ubo2YUA2tIg2oxA2qNg2ouN2rOg2vjF2oTg2tEA24sg26JA284A3OAa1s+l24PA29Dg24pA3KAg3M3g3JyA20KH3IIA2r2qsL4rCdk9kNYdCdLtCdDNDIxdsplA3Rj23a04vcmHCN1tjBR8o+adp/FNCcydCBE7jYuHeySoeEpKCeO9DM+qhflZwJqA3pWo3tUqe4/w3io7ZoDY4PU9vN8NCfmNqZfmvwPgji0J4Io93LaNCOR3ZxjnlKGA4EOm4I3A4C+na7wGtwbnbWgI/+OA63/Jx2qCJrhyV6Yh+WQUoGVj6cDsZmt+pr6+yVkhzggkqXxxlmwvbAkBrgxEeaHKJ2LoFnWARm02rqOHrOKMwN5xZ5r2JnJCeryEEHKti50v2Hiuq3eEUKPl2KSFu2opWJhWWlhJvgj6jXNHh6uApqGVEOXJQJSYmn+iO3UyKqfUyeXAnLOLwOIBd3ySB3w8KHcyjnKUvngn+mRRW1/Wi3EZ2XYYKaB1tqHAO9+6V+GGneeKsOSv+m43CrSSIOjIMOXtTWr0mJXOh2T6Xegw2+iRuOLq+wB1m6obvoE+eGmxpoEcyL9uemIF9n1FlpFwjpFN+miXV6moPgj3jf8IFx61RP5lSkqfgf7h0c3qhEB+IlbiISa6AEecF/fsodnljq4I7F2DWAZoOwvk9yd8Yfi7jFnpOniDDaecHAyY/B5oS4kADrbtgtDth3DhuBfu3WbC8TcJtH4Mzwq3DyDjV66GDnarjA7YXv4OEG8I4d0JGW8MKX/exi1bJe8OJ18ILb8JK18MNX8JKK6MMd8OM08IOZ8JN08MQV8JO79oPc8OPz8IRX8JQ4/A6I6ML+8KgS2wt+DguqjqlY2n87u/E87d5thvhvD0wuBlRnayZBjhzIrL9Q72n4B+e4jkEqq9Dy4JeUZ7mp6RRysIZB8MJjZt9Zv2pnD065j0kID/9ZOA+Igq96dpkln29T3WYmNICC8G7gDQ98BgYnuvaTZaCoSfbYb/ZY2pqinYaIt5ZRnnqv5HAALqYBI2YD1KYB9YANOYt4u65kuZn6h6oBqa5Yi5oJm6XoXQAKG3uT+eZLLap77vsnP7bMQnbm7Jupdv7uS9iNPYqnMp+EuZgqxbAXQPcIVHc3YLmWwf7IkQbdlpn2ypnAYAsmOuncNPdzQnYjRXa3DfbRte/4awpVoJCBgNAwAADw8FAxOFAA4NABgOjJOMAgGUmJmam5ydCxCUBA+FFAMFjAYEkwgWiYuFAxiZBAaFiYUGFQClFIUPqpMQC53ExcbHyJ+YtLsD/70Ptaa3FboUDgUWugajDhSDAwgACKoMAwwECBMT45gJB8jw8fLFAZfz8gECm+UD/eYAg2QBSIULGAEH/RCUY8CoQQR/52oZGjVQlSkKBvw1OJQJwSNSGfs1GORrlIUBDgjwg7jJ0r2XxZRNElWoQThUBCY88GcSpSp0Ax68KsQMwK2KsD7+oiQMptOnm2TOrGXTVjhphDziahCpAYEIkTCxW1h0W7t3UNOqBVBvbad8nBxNYuCggsKBFgoCKCfLQriUjFhBMlcUnTp2ph5EADBhgNe7lCpINLS4cYNEDBhEoNiM7sdOLt0+lVpzcbNTBQct2syoFMNCchkVPUoQw/8/ABGAMWoqujc80kRr8QIgGQBW4tVMNXJwri4mswQI1/J81rd1ZG2vT4K7qQCChAzYVYgw4VsDggMThiuAcACB6OCkF5rw0AHiAuzjPwopiZHmfhXk991+KG2WSD+jeJcQJ6FpFw9w5bwCnzOp/AcOIjxN0B55siF4YDghuTffbbsN4+CJlAAHQGH9RNDLcRbmRVwtlmFy4EPn+KNLdSj2yEh2J3Ln45BqNUgkJyo+ICORRQVj4pHXqdhjk5m4A2WQ9gSpz5VcymNkl5OoSN2Q7L3mJJi9SYkilTyiKRqQDgrp5pyZfOmmmnTyRidUeIJp5Z5qwamdnIDuaSeafbr/qWehLyXK5Z+MOiXodYRGiuahYDoK5qKWPggKo5B2Os+k1lUq6pWYdqlpl5yeasyqR4bqKnZZxrnlrFymyiWsV7aKK5KfFirrr8SQ6lsACQig7LLMNuvss9BGK+201FZrLbQJ1DrnAjVc6+231dbwJLGedAvuuei6gBa59Gh73QH1xCvvvPTWa++9+NazwAL59uvvv/WuSycKAAO8b8EAo8AuMQQj7PDD85qwcLsTQ2VsxbhejPHGHKelccdvuQvyqR+PbPLJnJSM8nYir1yoyi7HPDLMLtMsM5Q236wzuzmf3PPOKP4M9NCdCg2y0UQf23LSTGe8NJ3wQuzvwVLf/ytwx0FUjS/VWt8rcdNgK00yv12XbfDTCx+wgtls+7vC1WHH/RTSPdI9pN2FHjDuqQvALfffo6LtJt51C06u3r/2DfjiLxE+qOFzOg713qIqzvjl8Eg+T9T5co2v325xvjXZ+YJ+pAn+vrB2vwo72HC+K7zg79eYX645Psmi22y2ceau+7K8u3mAC78zK+6J3Ba/rLq1Y357PKZ6CTlM0cej65AHJACVr6Lxysmwzcf9fOa3wnS9xeW/dH6P2W9PeZrBwgR++GCPj13696wvKf7z6H9i+0/hnlu8t4n50Y9p9jtG9eDhv8bxT3pzAqBTBLgWAmrCgAckWgKNsUBkNP/wHh08xgffpb0Avq978XsJBjMItA3S44HWm54DoTJC60gQJhRUiwWrZDoWtlCGvQmhMWoIPRjKhjMtASIJiUGTTuQwLTtskw+b5sJiGdGDSsTHFVeERE0QsTc31EQTOfFEPqXwHiucosyq+JYtDjGLRWRiF+sERzCWkBNj3EQZR3PGeaRRjTWro8euuJOggEaQCoThSvyBGjpG8I6YWGQ/GomJPTolUd9xTCf+CEiUsTFlbizGF+8nR2KMMnSQFOMcK3nCAfZRHpzspMk+uQkhihKRHNxiHr2IS7WEcRarZEorK/jKeMRSlkfrJfVCaUpltrGUh3wkNMk4TB0WEx7/x0Qmx2ipCVs201Y0dOZTfjkPS8IkipTIpjYxxs1MeDOag2ImPNFETnmYs1HXRIY61zmxdmLinQwSZy3lGVBpmhB5+TzGPvnJM4FqMZzgfMop11LPeNzzHuicxEIZSix/UgKgSYyoUybqy1Te46LzyCgjNspRp3UJWcpTVvAo5bvizRRMw4upAI7noOTFlHktjZlHJyG6e3nOag4qqr2Oaq8eDgl1/VKdv1qnndfhK3azC6pQHRpErpbKq11CHK4sp9X6gXUtQw3cycQ6K7KWlWgr8McAeFC0s77JrlBiq6vc+lagvUCuO4hUXP1B104Nth+F3dgC5DoA2jEqCIy1/0Ffh4YCueogUn/1R2A7ldl+bHZjOpDrCvgm1xlMFmgmkKsMIlVZf1y2U63tx2s3JgO5voBkcqXBaYFmg36MNlKp9cdqOxXcfgyXYzzwh25FdQC57hZoM+jHbS3V2wH8VlTVvS7HduCPILgquQOo5nNBRoN+UJVR0R3AdEWV3vVyrLWSdRV3B4DX8c6pH44tVHkHcF5L7be/GAuuaV0V2gEc174xW0B8O4XfWTV4ZHF1Kp1qm1gEC3XAnVLwWBcMsuj+agWftbDLZLDcomGYZCfuGA3Eu6cXzFbEMM4EiXE1Y5MF4cWnQkF+Y8zjHvv4x0AOspCHTOQiA1KpbXvYuv+gmuQmx4t2SHZy1SSsCSZLuWwAtuqVtbZjI6espjrV3UxzGuYyOwuobAGzmZV3U2SQec065WmYzAXnn1LZy4UAqW8aVFE6QUrPKCJin1lFOZVah6VABrRo+GxSYa1L0Q4SdKMVVeiEXgnRP4b0Whh9qj8T1EeSjlSrDO0bTPtY00XK0qDd5OlIhZpRo7Y0lEzdY1SnhdOiajWjXl2oWEeK1jy2NUQLsWo06bpQvAaUr0F1ZzwLW6KqnvSejj0P9CwajsWG0rLvoZzeADvG74TPKCZQAX/kJZMDqICZ3siIbGuCJTZpUQG+AQ7d+PHRBJ2Quq3tlmQjIySPoMBD6r3/yCVZtNLw0Hc5KLmWb8MYoEWJAIcKsBitMMAA6cBiu6VtDOXYRikEqMqKAINGfCPDL724eAH4vWlsc7wTBKELRQig7n9QfEcHxwSvUL4XAySC4WpxuIghLhxFUEIrsBEIu4n9cmIopwIGB8hNVmSae/9Ing5Qul7g46IJ8McomfzMLTfX9E0Q5CuUWAgpjJ7zFMk66ZRQTkgMoI6vK0iTCm22l4kOdrF8huXzdPe7T2EAsUudEUexep7lSaKCDAcarmCEXMIiQpff4+xdVDssgF6MbRej8cYpgGHoQ4DIw+YRlDeG0C3Md9cc/TNZ1zjTYfL0Loqc6io0+TFigxOR/3sHACdJiSTXPU94CJ4SZ596ITRfiqEgw/PE4P3mOcJF4Ptk+HnHcy4TLhGJM4Ti4njExZU/9tm/xOMiMkTIb3IQw2NT98bwyylUnorhFGftY2Kg5atNDuesqObfxxr2hHDHIH8993Ojxw74J33Zp31WhAzi1nP94ADnpiPOV34AcHxx1w8McRD94HP0hnQld3XwUEhBcXE/0SIUcCCGdHfkV3xuVnaZAHBGMXC5sUj2Bg/QRwwm+AALlx4DQHcsmCCZ9ILfo3dG9mwjFW2dBn+A4m95QoCO5oAPeClMmGtOaCj712tSCCirh2BKaD5X2CnUpoVkJ2pdOG1IWGRhqP8+Y2gpZUgnUDgnOzgnX2hfpiKAU/EUaIcJuEYJFsAhk5B4vmEAUVcIcZgek4EToRdpW1gIgXiBhAgV3UYUVVcIdZgRi7h5k1hqa0hkleIQs7CJx/AhekEJf+gfzGEjhFBtIhGBmKAhQBeHkXCBelGJ1pFsdEF8RtGK8gBwEYiLSFEiOndGtZgJx+EgdzhelYIAWicbpFiKvogBL5iKvnCIvfgS6MEmk2ABcxSH3HiLnNdvj6gkmdCJ/2YQEiGM1HgmbrcM0Rh66Cgay/hchBIhVtEP71ELJvgIJ9EPFPCPzjCIvtgYvTAJ1igOAmEhAUII9DYKDdAeBCBwAIJ86lj/CEV4kKm3Ulm4El6hgkghdx84AdkwE5coDuRgDonwEAhwkAj5iM7ICOWGErfwkAAhkRSZbhYZHLAwcB9hkMT4jnOhEVz3IvhBCDGCG/YGdUeXkueAAAghiBr1iUNGKL8HG7pBJYphHEoXC+foi+LAcAl5G/eXjQ2hCIYoGyfJiCuyiYKxF2CJiFnYls3wDLVAEKYwerkRFtBAHCG3IGOhkgNJDX74iLeBDq9BiKqRlpaoCdu4jj/RH2EZlGFyRszweNFwlMixC9dQkmbRDd8QDoH5lIeRgwBQj7tllTeheXTpgeCwIt8hFEAhFAS5CmL5hrDwGiJYkwOnkg9hABTA/wDlFgGG95iM0YPLF5enOZfM4HsgYhEFQH2i0BgYYIgR6ZIY6ZRHgQ6FeYaMcBvUl40OAREUF4TBOZzFeZGNiBkY2Ug72Jw38XvHgXSF1xVfsZHZCZcRgQvfSJVCdo9sR3JtyRfAp3y8J32JB5QvuXFiIRBleQuCYRtmUgGcwZ2TYJyqgRsUgZ/LSYKhUHS9UBx4KXrpsA6qUAGOYA2SiQqjEB0McBR6WAkwKRCIaQtZkRcSKpMVSn7G2Yh+MSIu+Z4gOiPySAiEWQqn4ADMcRA4x6IrIh/5x5FU+ExHJxD54R7MEBIIkA4boiEtMhSmCAnViJuGICMMeQvw8R0Xl/8QFDAhYgeMCGIhCEAR3tgmlcIiA+AiIUl4IzlyqzFHNyKYLcKLyWaOuDCBaJoQ5qClbaoRF/qKCGIcCYEa7UiZjKAieKqnMDJwMlIcNUIJgZojFSlFU/pP+COK1gF4CbmLRyKLdvppajGPhaCLq3gk/FaHaxKPclmqA5UJMboWfYiKZAp8UtkjjJlOc9kjsgoA/haJTHKSuHoi4SilvOpOsNobCTmFi+dqj7gn0eon/hlkbZg/w+qFyeomc0hpxfhr4Zpo13ptDIqFHops3RqF68ps1Wqt6FquajivT1ivdJiGftaumfau5BivZHiuVuidXHiv2pqv26FmdVYtY0b/PBNbZmgGUxdrU9hmsRurO3J2qXT2seeCZhBLbGXDVBCzZE6msl0DZVtmNlRpZTErNVlWsy97sm6RVrSisz7LQjyrQPX1s0S7MEHLQUNbtErrKoc1V4IlVxW2tFJLNJ01ACHWYoA1tVpLNLE1ADg2MJa1tWKrM8VlYMClWmObtjGTXZ3Ctmr7tifTXp0it3BbtypmXp3yX3a7txvzYJbit3wbuMSiYZXDYYJ7uK4SACnGKIqLuI7rKjXWKZH7uJRbuZZ7uZibuZq7uSdLszj7uaAbumwDYJw7RW9GsqibuqobZiFbumqkgT+LUq4rN7Drs7I7u2FTuzp7u7jbNLp7/7K827tJ87sQG7zCOzTEm6/Ge7w7k7zVurzMezPO2ynTaqOgOkkdA73RGzO/hG6EoSOMwR+mCSjVa5aMkBsLA3jau70r071ix53hQQCBWBO6OiflO4nXkL6mub7su1YmJYKwWQgUGoi82IuJ8JHg0AsTsoIIIRcY94HfsYrxERQtIsBfupIoocD+UAt39wh3B5aFpBCc2pYuygj9aH0AGZH6SBxfmpMV4HUTOBCZ9MCrOJPkgcGg6aiW2r+X071y9ZSc2QA6EZVilwiqYA29kA1IKnmqEJFeRxXKgRiq8AAKsXBfsRqlJ3cPsMTMMHmSABiT+HTVcA3oMI5b6ZW4sP8kV6yUwWp6AwHFpzAOa5wbPzcQo6C+LMbDTOO+M8ETlJCh1gsQcuURU6d5i6oKtAGddBl6JhgUR3EIIkcLw2dzcRnFH1F43Oia4TCbE1CewNnIPoie1gcYBJHIoPzId7y/eazHRMPHsqF8FQAMTox4rYjErVGJgHEQXofIrTiii5yXUonK9lcL0pfLlXwKR5qXm0igPyp5n0GhaxwKU+capdzL7xHMrcgRx7rDrPw3PgwRFkoURUhJiTchLeoPDIwS+8HL4vjLyKwRqGwILcLBRSjIeXrMezHC3KilXPqljMrCkCoSQ4gUiQzQjhHP5uGO3bw401uq/LvQGNPQU/r/0BA9MRJNhRRd0exy0Q6Y0RpNLLULHxUDeDBB0qPYIx790bgCu40xjmSinI0Ic+OrjTPNk4vMRPVrDCmt0q4Cu6XgJssq02th0jZdvm6x0zzNXDI4d+sQqaQwcDV3ClWBDlE5AbTgov5AHg+wI4ZoIS26pXna1ODwc47xdBP4g1VBEBlpHDbBGStxw6ZQ1m1tAAM3CuygIeaMDt8B1xE8k3nBDCcskNipCUid1JZSbHqZxaFQdWi9ySUqxwhASXyBGa5BoXvRDYipIZfRika8eTUKl1L9nKuQFzqZCZOdfqVtABxsDlUx1RKR2Y5QxwgAxTdNGVx5DIVt2IxSbNKJ/yFph56NvcjbUBQY4aipUKfe6xUS4RFHkXiJ4dbKkdY5gZzCWNwC7YvdFnPmIIvEuchFwdzWnI3MoMmwGRS2yEq6vcdll4CKPQtXsR+bPB2OUBRbWSMRmb+WDY0YudmL4NwkaiaahHEVkaGsIYz1fdDYjRra3YER0B99+N2brRdoagDMbKDuh97p3cpLPZKT6KZPmqebDL6zgRADgpESYSHyEX70MdYJDoSSwHXPKaejIIwCguDfqeBOyRjpZw1BAeEFPeFAuKVeGtbEkNsZDjUy6BRGvTLscd4+YuRHLjxJDhNLjjIRgI1DAuVRjlNTXrRavuVcwtHa9+VgnlddTma0ZF7mRCLmeJbmau4jbO5lbv7mKBLnRjbndJ5UHru6fN7nfj4trZvnIOO5olvohn7o+EK6gr7ojN7ojv7okB7pkj7plF7pln7pmJ7pmr7pnN7pnv7poB7qoj7qpF7qpn7qqI4xgQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Class I designation indicates clear evidence that the procedure or treatment is useful or effective; Class II, conflicting evidence about usefulness or efficacy; Class IIa, weight of evidence is in favor of usefulness or efficacy; and Class IIb, usefulness or efficacy is less well established.",
"    <div class=\"footnotes\">",
"     BS: Brugada syndrome; NAR: nocturnal agonal respiration; and SCD: sudden cardiac death.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659. Copyright &copy; 2005 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40833=[""].join("\n");
var outline_f39_56_40833=null;
var title_f39_56_40834="Balloon dilation of eustachian tube";
var content_f39_56_40834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F83639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F83639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Balloon dilation of eustachian tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Preoperative 30 degree angled rigid endoscopic view of left eustachian tube nasopharyngeal orifice showing inflamed, edematous mucosa circumferentially and especially at the posterior cushion. The lumen is swollen closed.",
"    <br/>",
"    (B) Intraoperative inflation of a 7 mm diameter by 16 mm long balloon placed within the cartilaginous eustachian tube.",
"    <br/>",
"    (C) Immediate postdilation view of the eustachian tube lumen showing some minor mucosal laceration and significant persistent widening of the lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figures reprinted with permission from: Dennis S Poe, MD, Children&rsquo;s Hospital Boston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40834=[""].join("\n");
var outline_f39_56_40834=null;
var title_f39_56_40835="Patient information: Controlling your blood pressure through lifestyle (The Basics)";
var content_f39_56_40835=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16171\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/29/5586\">",
"         Sources of sodium in your diet",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/35/11827\">",
"         Patient information: Diet and health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/37/30290\">",
"         Patient information: High blood pressure in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/21/44371\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/54/33635\">",
"         Patient information: High blood pressure in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/28/38337\">",
"         Patient information: High blood pressure in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/58/931\">",
"         Patient information: High blood pressure treatment in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/8/9347\">",
"         Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/controlling-your-blood-pressure-through-lifestyle-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10571112\">",
"      <span class=\"h1\">",
"       What does my lifestyle have to do with my blood pressure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The things you do and the foods you eat have a big effect on your blood pressure and your overall health. Following the right lifestyle can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lower your blood pressure or keep you from getting high blood pressure in the first place",
"       </li>",
"       <li>",
"        Reduce your need for blood pressure medicines",
"       </li>",
"       <li>",
"        Make medicines for high blood pressure work better, if you do take them",
"       </li>",
"       <li>",
"        Lower the chances that you'll have a heart attack or stroke, or develop kidney disease",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571119\">",
"      <span class=\"h1\">",
"       Which lifestyle choices will help lower my blood pressure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Here's what you can do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lose weight (if you are overweight)",
"       </li>",
"       <li>",
"        Choose a diet rich in fruits, vegetables, and low-fat dairy products, and low in meats, sweets, and refined grains",
"       </li>",
"       <li>",
"        Eat less salt (sodium)",
"       </li>",
"       <li>",
"        Do something active for at least 30 minutes a day on most days of the week",
"       </li>",
"       <li>",
"        Limit the amount of alcohol you drink",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have high blood pressure, it's also very important to quit smoking (if you smoke). Quitting smoking might not bring your blood pressure down. But it will lower the chances that you'll have a heart attack or stroke, and it will help you feel better and live longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571126\">",
"      <span class=\"h1\">",
"       Start low and go slow",
"      </span>",
"      &nbsp;&mdash;&nbsp;The changes listed above might sound like a lot, but don't worry. You don't have to change everything all at once. The key to improving your lifestyle is to &ldquo;start low and go slow.&rdquo; Choose 1 small, specific thing to change and try doing it for a while. If it works for you, keep doing it until it becomes a habit. If it doesn't, don't give up. Choose something else to change and see how that goes.",
"     </p>",
"     <p>",
"      Let&rsquo;s say, for example, that you would like to improve your diet. If you're the type of person who eats cheeseburgers and French fries all the time, you can't switch to eating just salads from one day to the next. When people try to make changes like that, they often fail. Then they feel frustrated and tend to give up. So instead of trying to change everything about your diet in 1 day, change 1 or 2 small things about your diet and give yourself time to get used to those changes. For instance, keep the cheeseburger but give up the French fries. Or eat the same things but cut your portions in half.",
"     </p>",
"     <p>",
"      As you find things that you are able to change and stick with, keep adding new changes. In time, you will see that you can actually change a lot. You just have to get used to the changes slowly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571133\">",
"      <span class=\"h1\">",
"       Lose weight",
"      </span>",
"      &nbsp;&mdash;&nbsp;When people think about losing weight, they sometimes make it more complicated than it really is. To lose weight, you have to either eat less or move more. If you do both of those things, it's even better. But there is no single weight-loss diet or activity that's better than any other. When it comes to weight loss, the most effective plan is the one that you'll stick with.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571140\">",
"      <span class=\"h1\">",
"       Improve your diet",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no single diet that is right for everyone. But in general, a healthy diet can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lots of fruits, vegetables, and whole grains",
"       </li>",
"       <li>",
"        Some beans, peas, lentils, chickpeas, and similar foods",
"       </li>",
"       <li>",
"        Some nuts, such as walnuts, almonds, and peanuts",
"       </li>",
"       <li>",
"        Fat-free or low-fat milk and milk products",
"       </li>",
"       <li>",
"        Some fish",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To have a healthy diet, it&rsquo;s also important to limit or avoid sugar, sweets, meats, and refined grains. (Refined grains are found in white bread, white rice, most forms of pasta, and most packaged &ldquo;snack&rdquo; foods.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571147\">",
"      <span class=\"h1\">",
"       Reduce salt",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people think that eating a low-sodium diet means avoiding the salt shaker and not adding salt when cooking. The truth is, not adding salt at the table or when you cook will only help a little. Almost all of the sodium you eat is already in the food you buy at the grocery store or at restaurants (",
"      <a class=\"graphic graphic_figure graphicRef60316 \" href=\"mobipreview.htm?5/29/5586\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      The most important thing you can do to cut down on sodium is to eat less processed food. That means that you should avoid most foods that are sold in cans, boxes, jars, and bags. You should also eat in restaurants less often.",
"     </p>",
"     <p>",
"      To reduce the amount of sodium you get, buy fresh or fresh-frozen fruits, vegetables, and meats. (Fresh-frozen foods have had nothing added to them before freezing). Then you can make meals at home, from scratch, with these ingredients.",
"     </p>",
"     <p>",
"      As with the other changes, don&rsquo;t try to cut out salt all at once. Instead, choose 1 or 2 foods that have a lot of sodium and try to replace them with low-sodium choices. When you get used to those low-sodium options, find another food or 2 to change. Then keep going, until all the foods you eat are sodium-free or low in sodium.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571154\">",
"      <span class=\"h1\">",
"       Become more active",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to be more active, you don't have to go to the gym or get all sweaty. It is possible to increase your activity level while doing everyday things you enjoy. Walking, gardening, and dancing are just a few of the things that you might try. As with all the other changes, the key is not to do too much too fast. If you don't do any activity now, start by walking for just a few minutes every other day. Do that for a few weeks. If you stick with it, try doing it for longer. But if you find that you don't like walking, try a different activity.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571161\">",
"      <span class=\"h1\">",
"       Drink less alcohol",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are a woman, do not have more than 1 &ldquo;standard drink&rdquo; of alcohol a day. If you are a man, do not have more than 2. A &ldquo;standard drink&rdquo; is:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A can or bottle that has 12 ounces of beer",
"       </li>",
"       <li>",
"        A glass that has 5 ounces of wine",
"       </li>",
"       <li>",
"        A shot that has 1.5 ounces of whiskey",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571168\">",
"      <span class=\"h1\">",
"       Where should I start?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to improve your lifestyle, start by making the changes that you think would be easiest for you. If you used to exercise and just got out of the habit, maybe it would be easy for you to start exercising again. Or if you actually like cooking meals from scratch, maybe the first thing you should focus on is eating home-cooked meals that are low in sodium.",
"     </p>",
"     <p>",
"      Whatever you tackle first, choose specific, realistic goals, and give yourself a deadline. For example, do not decide that you are going to &ldquo;exercise more.&rdquo; Instead, decide that you are going to walk for 10 minutes on Monday, Wednesday, and Friday, and that you are going to do this for the next 2 weeks.",
"     </p>",
"     <p>",
"      When lifestyle changes are too general, people have a hard time following through.",
"     </p>",
"     <p>",
"      Now go. You can do it!",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10571310\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/37/30290?source=see_link\">",
"       Patient information: High blood pressure in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/35/11827?source=see_link\">",
"       Patient information: Diet and health (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"       Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"       Patient information: High blood pressure in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/28/38337?source=see_link\">",
"       Patient information: High blood pressure in children (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=see_link\">",
"       Patient information: High blood pressure treatment in children (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/56/40835?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16171 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40835=[""].join("\n");
var outline_f39_56_40835=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571112\">",
"      What does my lifestyle have to do with my blood pressure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571119\">",
"      Which lifestyle choices will help lower my blood pressure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571126\">",
"      Start low and go slow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571133\">",
"      Lose weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571140\">",
"      Improve your diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571147\">",
"      Reduce salt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571154\">",
"      Become more active",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571161\">",
"      Drink less alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571168\">",
"      Where should I start?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10571310\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16171\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/29/5586\">",
"      Sources of sodium in your diet",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/21/44371?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/28/38337?source=related_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/37/30290?source=related_link\">",
"      Patient information: High blood pressure in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=related_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_56_40836="Premature atrial contractions";
var content_f39_56_40836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Arrhythmia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The quick upswings of the fetal heart rate pattern are due to very brief intervals between successive heartbeats. This pattern is suggestive of premature atrial contractions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40836=[""].join("\n");
var outline_f39_56_40836=null;
var title_f39_56_40837="Birth center consent 3";
var content_f39_56_40837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Birth center consent form (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 520px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Association of Birth Centers. Copyright &copy;2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40837=[""].join("\n");
var outline_f39_56_40837=null;
var title_f39_56_40838="Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)";
var content_f39_56_40838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40838/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40838/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40838/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40838/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40838/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40838/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40838/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/56/40838/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of apparent mineralocorticoid excess (AME), a genetic disorder, and chronic ingestion of licorice (the root of glycyrrhiza glabra) or licorice-like compounds (such as carbenoxolone) can result in findings similar to those in primary aldosteronism: hypertension, hypokalemia, metabolic alkalosis, and low plasma renin activity. However, plasma aldosterone levels are low in these disorders, rather than elevated, as in primary aldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of these disorders has been elucidated. Summarized briefly, renal mineralocorticoid receptors bind aldosterone and cortisol with similar affinity. Although the plasma concentration of cortisol is approximately 100-fold higher than aldosterone, activation of mineralocorticoid receptors by cortisol is normally limited due to its conversion to inactive cortisone at the sites of aldosterone action by the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/1\">",
"     1",
"    </a>",
"    ]. This conversion is impaired in AME because of a mutation in the 11-beta-HSD2 gene and with licorice ingestion because of a compound in licorice (glycyrrhetinic acid) that inhibits the enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    By somewhat different mechanisms, hypersecretion of cortisol can also induce an excess mineralocorticoid state in patients with ectopic ACTH syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Ectopic ACTH syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other hypermineralocorticoid states and a review of cortisol metabolism are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/1/9240?source=see_link\">",
"     \"Metabolism of adrenal steroids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYNDROME OF APPARENT MINERALOCORTICOID EXCESS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64559743\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of apparent mineralocorticoid excess (AME) is a rare form of severe juvenile hypertension that is usually transmitted as an autosomal recessive trait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/4\">",
"     4",
"    </a>",
"    ]. AME is characterized by low birth weight, failure to thrive, onset of severe hypertension in early childhood with extensive target organ damage, hypercalciuria and nephrocalcinosis from an unknown mechanism, and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/5\">",
"     5",
"    </a>",
"    ]. These manifestations are accompanied by all of the findings of primary aldosteronism (hypertension, hypokalemia, metabolic alkalosis, and low plasma renin activity) except for the low plasma aldosterone concentration. Affected patients may also have polyuria due to nephrogenic diabetes insipidus that is presumably induced by the chronic hypokalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A late-onset syndrome has been reported in adults with compound heterozygous mutations who have a milder phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/7\">",
"     7",
"    </a>",
"    ]. The heterozygous mothers of two probands had a phenotype indistinguishable from essential hypertension. Another patient with a different mutation also had less severe disease with low-renin hypertension in the absence of hypokalemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of AME is due to deficiency in the 11-beta-hydroxysteroid dehydrogenase enzyme type 2 isoform (11-beta-HSD2), which is the kidney isoform of 11-beta-HSD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    11-beta-HSD2 normally converts cortisol to cortisone, a steroid that does not bind to the mineralocorticoid receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/9\">",
"     9",
"    </a>",
"    ]. This effect is physiologically important, because cortisol binds as avidly as aldosterone to the mineralocorticoid receptor, and the plasma cortisol concentration is approximately 100-fold higher than the plasma aldosterone concentration.",
"   </p>",
"   <p>",
"    Thus, cortisol would be the primary mineralocorticoid if it were not converted by 11-beta-HSD2 to cortisone at the aldosterone-sensitive sites. The persistence of cortisol resulting from deficiency in 11-beta-HSD2 leads to an often marked elevation in net mineralocorticoid activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defect in the syndrome of apparent mineralocorticoid excess is due to a mutation in the 11-beta-HSD2 gene, located on chromosome 16, which encodes the kidney isoform of 11-beta-HSD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/10\">",
"     10",
"    </a>",
"    ]. A number of different mutations have been found, and a defect has been noted in all patients tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/5,7,11\">",
"     5,7,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of these mutations result only in partial inhibition of the 11-beta-HSD2 gene. There is a rough correlation between the severity of the enzymatic defect induced by these mutations and the clinical findings, including the ratio of cortisol to cortisone metabolites and the clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/4,8\">",
"     4,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant clinical features of the syndrome of AME are hypertension and, in infants, low birth weight, failure to thrive, and muscle weakness due to hypokalemia. Patients with full expression of the syndrome may also have hypercalciuria, nephrocalcinosis, and renal insufficiency.",
"   </p>",
"   <p>",
"    The biochemical abnormalities suggesting the diagnosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypokalemia",
"     </li>",
"     <li>",
"      Metabolic alkalosis",
"     </li>",
"     <li>",
"      Low plasma renin activity",
"     </li>",
"     <li>",
"      Low plasma aldosterone levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The urinary free cortisol to urinary free cortisone ratio as measured on a 24-hour urine collection is a sensitive diagnostic test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/12\">",
"     12",
"    </a>",
"    ]. If 11-beta-HSD is functioning normally, urinary free cortisone levels exceed urinary cortisol levels, and the ratio of cortisol to cortisone is approximately 0.3 to 0.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most patients with a defective enzyme, the urinary free cortisone levels are very low or undetectable, so the ratio of cortisol to cortisone is very high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/5\">",
"     5",
"    </a>",
"    ]. In classically affected patients with the syndrome of AME, the ratio was 5 in children and 18 in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing to confirm the diagnosis of the syndrome of AME is commercially available. A list of clinically approved molecular genetic diagnostic laboratories is available at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms and signs of AME are similar to those of primary aldosteronism, but the plasma aldosterone concentration is low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Licorice ingestion and ectopic ACTH syndrome, which are described below, can present with biochemical findings that are similar to those of the syndrome of AME. However, measurement of urinary free cortisol and cortisone levels permits differentiation of these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With licorice ingestion, urinary free cortisone is only modestly decreased, and the ratio is therefore only modestly elevated.",
"     </li>",
"     <li>",
"      Ectopic ACTH production may result in a similarly elevated urinary free cortisol to cortisone ratio, but urinary cortisol and cortisone levels are markedly increased in contrast to the very low levels of urinary free cortisone excretion in the syndrome of AME. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=see_link\">",
"       \"Establishing the cause of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Apparent mineralocorticoid excess must also be distinguished from other rare causes of mineralocorticoid excess in which aldosterone levels are reduced, including Liddle syndrome (due to a gain-of-function mutation in the collecting tubule sodium channel), deoxycorticosterone-secreting tumors, deficiency in the 5-reductase enzyme (leading to defective conversion and thus persistently high levels of cortisol), and two forms of congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/14\">",
"     14",
"    </a>",
"    ]. Urinary cortisol metabolites are normal in the first two disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Nonaldosterone mineralocorticoid excess'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15878?source=see_link\">",
"     \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=see_link&amp;anchor=H2#H2\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\", section on 'CYP17 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of the syndrome of AME has been directed at reducing endogenous cortisol production or blocking the mineralocorticoid receptor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    has been given in doses of 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to suppress ACTH and reduce endogenous cortisol production without appreciably activating the mineralocorticoid receptor. However, dexamethasone does not correct the hypokalemia and hypertension in all patients, and long-term therapy has adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, we use dexamethasone only if mineralocorticoid blockade is not effective or not tolerated.",
"   </p>",
"   <p>",
"    We prefer therapy based upon blockade of mineralocorticoid effects, which can be achieved by decreasing sodium channel activity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    or by direct mineralocorticoid receptor blockade with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39128?source=see_link\">",
"     \"Mechanism of action of diuretics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct comparison of these agents is unavailable, but it has been suggested that high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (with a higher likelihood of side effects) are required to block the mineralocorticoid effects of cortisol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/1\">",
"     1",
"    </a>",
"    ]. It seems reasonable to initiate therapy with drugs with fewer side effects, particularly in men (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ). The end point of therapy has not been clearly defined, but normalization of the plasma potassium concentration seems reasonable. A similar goal is recommended in patients with primary aldosteronism who are treated medically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potassium supplements may be required initially to treat hypokalemia, but should not be needed after the attainment of mineralocorticoid antagonism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thiazide is indicated if hypercalciuria or nephrocalcinosis is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention of recurrent calcium stones in adults\", section on 'Hypercalciuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cure has been reported in one patient after transplantation of a kidney with normal 11-beta-HSD2 activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LICORICE INGESTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic ingestion of licorice or licorice-like compounds (such as carbenoxolone) induces a syndrome with findings similar to those with the syndrome of AME: hypertension, hypokalemia, metabolic alkalosis, low plasma renin activity and low plasma aldosterone levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relatively small amounts of confectionery licorice, as little as 50 g daily for two weeks, produce a rise in blood pressure in normal people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/18\">",
"     18",
"    </a>",
"    ]. Licorice contains a steroid, glycyrrhetinic acid, that inhibits (both competitively and by reducing gene expression) 11-beta-HSD2, the same enzyme that is deficient in AME [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/19\">",
"     19",
"    </a>",
"    ]. As in AME, normal levels of cortisol can markedly increase net mineralocorticoid activity in patients chronically ingesting licorice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis is typically based upon the biochemical abnormalities and an elicited history of licorice ingestion. The source of the ingested licorice may not be obvious; it is present, for example, in some forms of flavored chewing gum and chewing tobacco [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/20\">",
"     20",
"    </a>",
"    ]. As noted above, urinary free cortisone and cortisol levels may help make the diagnosis, but such testing is not necessary if a history of licorice ingestion has been obtained. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cessation of licorice ingestion (or other source of glycyrrhetinic acid) is usually the only treatment necessary. Potassium supplements or a potassium-sparing diuretic may be initially required to treat hypokalemia but should not be needed once the effect of licorice has worn off (typically less than one week).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ECTOPIC ACTH SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortisol can contribute to the excess mineralocorticoid effect in Cushing's syndrome due to ectopic ACTH release (most commonly arising from small cell carcinoma of the lung) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/21\">",
"     21",
"    </a>",
"    ]. This can occur by the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cortisol secretion may be so high that it exceeds the metabolic capacity of 11-beta-HSD2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Very high circulating levels of ACTH may inhibit 11-beta-HSD2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypersecretion of nonaldosterone mineralocorticoids such as deoxycorticosterone and corticosterone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40838/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of the ectopic ACTH syndrome is suggested by hypokalemia, the demonstration of markedly increased 24-hour urinary free cortisol excretion, and elevated serum ACTH. A Cushingoid appearance may be present but these features can be minimal in patients with malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital (syndrome of apparent mineralocorticoid excess) and acquired (chronic licorice ingestion) deficiencies of the 11-beta-hydroxysteroid dehydrogenase enzyme type 2 isoform (11-beta-HSD2) lead to failure of conversion of cortisol to cortisone at aldosterone binding sites, such as the renal cortical collecting tubules. Cortisol binds avidly to the mineralocorticoid receptor in the kidneys, and without the normal conversion to cortisone, usual levels of cortisol production induce a mineralocorticoid excess state. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Excess mineralocorticoid activity leads directly to sodium retention, hypertension, hypokalemia, metabolic alkalosis, low plasma renin activity, and, in contrast to primary aldosteronism, low plasma aldosterone. In addition, the syndrome of AME, a rare autosomal recessive disorder, is characterized by low birth weight, failure to thrive, muscle weakness, and severe hypertension in early childhood, often with hypercalciuria, nephrocalcinosis, polyuria due to hypokalemia-induced nephrogenic diabetes insipidus, and renal failure. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Syndrome of apparent mineralocorticoid excess'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cortisol can also contribute to the mineralocorticoid excess in Cushing's syndrome due to ectopic ACTH release via a variety of mechanisms. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Ectopic ACTH syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of these disorders is largely based upon the history, clinical features, and the associated biochemical abnormalities, including the low plasma renin activity and aldosterone level. If a history of chronic licorice ingestion is not elicited, we suggest obtaining a 24-hour urine collection to measure the urinary free cortisol and free cortisone, and determining the ratio. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Differential diagnosis'",
"    </a>",
"    above.) The diagnosis of ectopic ACTH is characterized by markedly increased 24-hour urinary free cortisol excretion and elevated serum ACTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;With licorice ingestion, therapy simply involves stopping the ingestion of licorice (or other source of glycyrrhetinic acid). The treatment of Cushing's syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal therapy of the syndrome of AME is unknown. We suggest the following approach (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Therapy'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potassium repletion, if required for hypokalemia. This can probably be discontinued once therapy with mineralocorticoid antagonism is instituted. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link\">",
"       \"Clinical manifestations and treatment of hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest antagonism of mineralocorticoid effects with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who have hypercalciuria or nephrocalcinosis, we suggest therapy with a thiazide diuretic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      to suppress ACTH and reduce endogenous cortisol production only if mineralocorticoid antagonism is not effective or not tolerated (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The end point of therapy has not been clearly defined, but normalization of the plasma potassium concentration seems reasonable. A similar goal is recommended in patients with primary aldosteronism who are treated medically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/1\">",
"      Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003; 88:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/2\">",
"      Stewart PM. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol 2003; 149:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/3\">",
"      Ulick S, Wang JZ, Blumenfeld JD, Pickering TG. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1992; 74:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/4\">",
"      Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998; 83:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/5\">",
"      Morineau G, Sulmont V, Salomon R, et al. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol 2006; 17:3176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/6\">",
"      Bockenhauer D, van't Hoff W, Dattani M, et al. Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases. Nephron Physiol 2010; 116:p23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/7\">",
"      Lavery GG, Ronconi V, Draper N, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 2003; 42:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/8\">",
"      Wilson RC, Dave-Sharma S, Wei JQ, et al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci U S A 1998; 95:10200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/9\">",
"      Funder JW. 11 beta-Hydroxysteroid dehydrogenase: new answers, new questions. Eur J Endocrinol 1996; 134:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/10\">",
"      Mune T, Rogerson FM, Nikkil&auml; H, et al. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995; 10:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/11\">",
"      Carvajal CA, Gonzalez AA, Romero DG, et al. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 2003; 88:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/12\">",
"      Palermo M, Delitala G, Mantero F, et al. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone. J Endocrinol Invest 2001; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/13\">",
"      Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996; 45:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/14\">",
"      Ulick S, Tedde R, Wang JZ. Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab 1992; 74:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/15\">",
"      Speiser PW, Riddick LM, Martin K, New MI. Investigation of the mechanism of hypertension in apparent mineralocorticoid excess. Metabolism 1993; 42:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/16\">",
"      Palermo M, Cossu M, Shackleton CH. Cure of apparent mineralocorticoid excess by kidney transplantation. N Engl J Med 1998; 339:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/17\">",
"      Farese RV Jr, Biglieri EG, Shackleton CH, et al. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/18\">",
"      Franzson L, Manhem K, Ragnarsson J, et al. Liquorice-induced rise in blood pressure: a linear dose-response relationship. J Hum Hypertens 2001; 15:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/19\">",
"      Whorwood CB, Sheppard MC, Stewart PM. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 1993; 132:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/20\">",
"      de Klerk GJ, Nieuwenhuis MG, Beutler JJ. Hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum. BMJ 1997; 314:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/21\">",
"      Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002; 970:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/22\">",
"      Walker BR, Campbell JC, Fraser R, et al. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1992; 37:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40838/abstract/23\">",
"      CHRISTY NP, LARAGH JH. Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. N Engl J Med 1961; 265:1083.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2346 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40838=[""].join("\n");
var outline_f39_56_40838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYNDROME OF APPARENT MINERALOCORTICOID EXCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64559743\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LICORICE INGESTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ECTOPIC ACTH SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15878?source=related_link\">",
"      Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39128?source=related_link\">",
"      Mechanism of action of diuretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/1/9240?source=related_link\">",
"      Metabolism of adrenal steroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_56_40839="Metabolic pathways that regulate high-density lipoprotein";
var content_f39_56_40839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 633px\">",
"   <div class=\"ttl\">",
"    Metabolic pathways that regulate high-density lipoprotein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 613px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Metabolic pathways that regulate high-density lipoprotein (HDL).",
"    <div class=\"footnotes\">",
"     LRP: lipoprotein receptor-related protein; SR-BI: scavenger receptor class B type I; LDL: low-density lipoprotein; LDLR: LDL receptor; CETP: cholesteryl ester transfer protein; Tg and TG: triglycerides; CE: cholesterol efflux.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rosenson RS, Brewer HB Jr, Davidson SW, et al. Cholesterol Efflux and Atheroprotection : Advancing the Concept of Reverse Cholesterol Transport. Circulation 2012; 125:1905. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40839=[""].join("\n");
var outline_f39_56_40839=null;
var title_f39_56_40840="Gross examination of the placenta";
var content_f39_56_40840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gross examination of the placenta",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40840/contributors\">",
"     Drucilla J Roberts, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40840/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40840/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40840/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40840/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/56/40840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placenta is a fetal organ consisting of an umbilical cord, membranes (chorion and amnion), and parenchyma (",
"    <a class=\"graphic graphic_picture graphicRef62366 \" href=\"mobipreview.htm?11/19/11573\">",
"     picture 1",
"    </a>",
"    ). Maternal or fetal disorders may have placental sequelae since the mother and fetus interface at this site. Conversely, primary placental abnormalities can affect both maternal and fetal health. Thus, examination of the placenta may yield information on the impact of maternal disorders on the fetus or the cause of preterm delivery, fetal growth restriction, or neurodevelopmental impairment. Placental examination is an essential component of the autopsy in cases of fetal or neonatal death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38839?source=see_link\">",
"     \"Evaluation of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This examination also aids in a number of difficult situations, such as [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Legal issues regarding the presence of acute versus chronic perinatal stresses and insults, and the timing of these insults",
"     </li>",
"     <li>",
"      Diagnosis of the specific etiologies of adverse pregnancy outcomes",
"     </li>",
"     <li>",
"      Identification of zygosity and pathology (eg, twin to twin transfusion) in multifetal gestation",
"     </li>",
"     <li>",
"      Identification of potentially recurrent disorders, potentially leading to changes in management and improved outcome of subsequent pregnancies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The gross examination of the placenta is discussed here. Histopathology is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a general consensus that all placentas should be examined grossly, either by the delivering clinician or a pathologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/2\">",
"     2",
"    </a>",
"    ]. At a minimum, the clinician should determine the number of vessels in the cord, and if there are any gross abnormalities such as discoloration, multiple lobes, or focal lesions. It is easier for the clinicians to measure the length of the umbilical cord since the portion of the cord attached to the infant is discarded and not available to the pathologist. The pathologist usually measures placental weight since the placenta is weighed without the cord and membranes. All of this information should be recorded in the medical record (",
"    <a class=\"graphic graphic_form graphicRef52233 \" href=\"mobipreview.htm?3/13/3280\">",
"     form 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A full pathologic examination is obtained in specific cases. The delivering physician is usually responsible for determining when further examination by a pathologist is necessary, although some institutions have guidelines for their staff. A list of potential indications for histopathological examination is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef71399 \" href=\"mobipreview.htm?20/47/21244\">",
"     table 1",
"    </a>",
"    ); the list is not all-inclusive and should be guided by clinical judgment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. We feel histological examination of the placenta is indicated in the absence of a normal delivery (vaginal or cesarean) of a healthy term infant from an uncomplicated pregnancy.",
"   </p>",
"   <p>",
"    The institutional cost of pathologic evaluation of the placenta is minimal. Pathology assistants and technicians can be trained to perform placental gross examination. Most placentas have just a few and quite characteristic lesions, which can be easily recognized. Those that fall out of this realm should be referred to a pathologist for evaluation. The reimbursement for pathologic examination is usually at a level 5 (88307) and is typically not contested by any of the major insurers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HANDLING AND STORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information regarding the gestational age and pregnancy history should be provided by the delivering caregiver, typically on a pathology requisition sheet. The placentas in multiple gestations should be marked in order to correctly pair each infant with its umbilical",
"    <span class=\"nowrap\">",
"     cord/placenta.",
"    </span>",
"   </p>",
"   <p>",
"    Fresh",
"    placentas should be refrigerated (not frozen) at 4 degrees Celsius and may be stored this way for three to seven days. A fresh placenta is preferable to a fixed specimen for appreciating placental surface changes, making membrane rolls, and palpating for solid lesions. Cultures, cytogenetic studies, and injection of twin placentas to detect anastomoses can only be performed on fresh tissue.",
"   </p>",
"   <p>",
"    Bacterial cultures are rarely needed, but can be performed with good results if necessary. In cases of live births or stillbirths in which an autopsy examination is permitted, culturing the infant, fetal blood, or lung is best. For placental microbiologic cultures, we believe the best procedure is to peel the amnion off the chorion for a significant amount of the fetal surface, and then swab the exposed (and untouched) surface with a sterile swab several times before using the swab for culture innoculation. We have performed this technique for research studies and in cases in which the fetus was stillborn and no autopsy permission was obtained, and have had good results. This technique is especially useful in detecting group B streptococcus, which can cause lethal fetal sepsis in the setting of intact membranes and mild chorioamnionitis.",
"   </p>",
"   <p>",
"    The best placental source of tissue for karyotype is the umbilical cord, as it is free of maternal \"contaminant.\" A small portion of chorionic plate can also be obtained for karyotype, with minimal maternal contamination.",
"   </p>",
"   <p>",
"    After these examinations, the placenta can be placed in fixative (eg, formalin) if necessary; however, it is prudent to refrigerate a small sample of placenta in normal saline in case any special studies are needed after histologic examination has been performed or clinical consultation obtained.",
"   </p>",
"   <p>",
"    We believe that the safest procedure for placental handling and storage is to have all placentas sent to the pathology department. The pathologist can then triage them based on clinical history. Those with indications for full pathologic examination are accessioned and examined that day. All others are kept refrigerated for a specified period of time (the Massachusetts General Hospital keeps them for at least seven days). During this refrigerated storage time, the Neonatal Intensive Care Unit (NICU) admission list is checked daily for infants transferred from the regular nursery and the maternal readmission list is checked. After seven days, if the infant has not been admitted to the NICU and the mother has not been readmitted, we feel the placenta can be safely discarded.",
"   </p>",
"   <p>",
"    This practice will help identify those infants with onset of complications after the immediate delivery period and those placentas which should be examined to evaluate maternal post-delivery complications (as an example, postpartum hemorrhage or sepsis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     UMBILICAL CORD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical cord is normally composed of two umbilical arteries and an umbilical vein supported by loose gelatinous tissue called Wharton's Jelly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical cord should have a smooth, white, opaque, shiny appearance with spiraling consisting of about three half spirals over a 5 cm length of cord. Abnormal coloring suggests infection (",
"    <a class=\"graphic graphic_picture graphicRef57888 \" href=\"mobipreview.htm?30/3/30783\">",
"     picture 2",
"    </a>",
"    ), meconium, or the sequelae of fetal demise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link&amp;anchor=H2#H2\">",
"     \"Histopathology of placental disorders\", section on 'Umbilical cord'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nodules on the cord suggest abscesses and may be a sign of candidal infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild edema of the umbilical cord is common and of no clinical significance (",
"    <a class=\"graphic graphic_picture graphicRef74326 \" href=\"mobipreview.htm?13/56/14213\">",
"     picture 3",
"    </a>",
"    ). Massive edema (resulting in regional or diffuse cord diameters of greater than 3 cm) can cause vascular compromise and is often associated with acute changes in the fetal heart rate pattern. Some pathologists have termed areas of massive cord edema \"angiomyxoma\" due to the histologic appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A stricture may be artifactual or the result of torsion or amniotic bands. Strictures can be important findings, as they have been implicated in the etiology of fetal demise or compromise. They should be carefully described and sampled on both sides of the stricture and through the stricture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Coiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical cord has a characteristic twist or coil (",
"    <a class=\"graphic graphic_picture graphicRef69238 \" href=\"mobipreview.htm?41/43/42672\">",
"     picture 4",
"    </a>",
"    ). Twisting is usually to the left (like a barber pole), but the direction of twist (left versus right) is not an important factor in pregnancy outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Coiling of the umbilical cord is thought to protect it from compression, kinking, and torsion, thus preventing disruption of the blood supply to the fetus. Coiling may also facilitate umbilical venous blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/11\">",
"     11",
"    </a>",
"    ]. The genesis of cord twist is unclear, but likely reflects fetal movement or differences in the growth rates of the fetal vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination of the umbilical cord provides information about fetal growth and activity in utero. Cords with no coiling are associated with poor fetal growth and decreased activity, and may result from severe neural and musculoskeletal anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Several studies have reported an increased frequency of adverse pregnancy outcome, including congenital anomalies, growth restriction, fetal heart rate abnormalities, preterm birth, and intrauterine death in patients with an uncoiled umbilical cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Both hypocoiled and hypercoiled umbilical cords are associated with an increased frequency of small for gestational age neonates (15 to 16 percent versus 5 percent with normocoiled cords for both) and nonreassuring fetal heart rate patterns (22 to 29 percent versus 11 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Placental insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical cord normally inserts centrally or slightly eccentrically and directly into the placental disk. Fewer than 10 percent of insertions occur at the margin of the placenta (battledore placenta) (",
"    <a class=\"graphic graphic_picture graphicRef81936 \" href=\"mobipreview.htm?35/35/36404\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A velamentous cord insertion refers to a cord that inserts into the membranes rather than the placental disk. The velamentous vessels are surrounded only by fetal membranes, with no Wharton's jelly, thus they are prone to compression or disruption. Velamentous vessels can also occur between lobes of a bilobed placenta. Velamentous umbilical cord has been associated with several obstetrical complications, including fetal growth restriction, prematurity, congenital anomalies, and low Apgar score. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/18/20775?source=see_link\">",
"     \"Velamentous umbilical cord insertion and vasa previa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A furcate (forked) cord is a rare variation of the velamentous cord. The fetal vessels are also unsupported by Wharton's jelly, but they separate from each other and fan out to form a vascular \"tent\" just above the disk. Although the appearance is worrisome, furcate cords are rarely associated with an adverse pregnancy outcome.",
"   </p>",
"   <p>",
"    Abnormalities of umbilical cord insertion are more common in pregnancies resulting from in vitro fertilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and in multiple gestations. Abnormal cord insertions should be noted and histologic examination should be undertaken to look for thrombi and vascular anomalies, which are associated with these abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Length",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord length increases with advancing gestational age. The average length at term is 55 cm, with a wide normal range (35 to 70 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/14\">",
"     14",
"    </a>",
"    ]. The length should be noted and compared with published standards (",
"    <a class=\"graphic graphic_table graphicRef76589 \" href=\"mobipreview.htm?6/19/6459\">",
"     table 2",
"    </a>",
"    ). The length measurement should include the portion of cord on the infant after cord transection at delivery as well as the part remaining with the placenta, thus it is best determined in the delivery room. If the length of the cord attached to the infant is not provided to the pathologist,",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    cannot determine whether the total length of cord (placental portion plus infant portion) is shorter than normal and will not make the diagnosis of \"short umbilical cord\" (",
"    <a class=\"graphic graphic_table graphicRef76589 \" href=\"mobipreview.htm?6/19/6459\">",
"     table 2",
"    </a>",
"    ). A \"long umbilical cord\" is diagnosed when more than 70 cm of cord is received at term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/9,25,26\">",
"     9,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The length of the umbilical cord can be of critical importance when evaluating a case of perinatal morbidity or mortality. Cord length is determined in part by hereditary factors, but also by the tension the fetus places on the cord when it moves. For this reason, short cords are associated with fetal inactivity related to fetal malformations, myopathic and neuropathic diseases, oligohydramnios, and some syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/15,27\">",
"     15,27",
"    </a>",
"    ]. Long cords may be caused by a hyperactive fetus and have been associated with cord accidents, such as entanglement, knotting, and prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/14\">",
"     14",
"    </a>",
"    ]. Long cords are also associated with placental lesions indicative of intrauterine hypoxia, as well as fetal death, fetal growth restriction, and long term adverse neurologic outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, the longer route that blood must travel to and from the fetal heart when the cord is very long may result in fetal heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Knots",
"    </span>",
"    &nbsp;&mdash;&nbsp;False knots are tortuousities of the umbilical vessels that form bulges (",
"    <a class=\"graphic graphic_picture graphicRef68053 \" href=\"mobipreview.htm?32/38/33377\">",
"     picture 6",
"    </a>",
"    ); they are not associated with any adverse outcome.",
"   </p>",
"   <p>",
"    True knots occur in 1 percent of births and are generally single and loose (",
"    <a class=\"graphic graphic_picture graphicRef62702 \" href=\"mobipreview.htm?30/54/31584\">",
"     picture 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/29\">",
"     29",
"    </a>",
"    ]. However, tight (",
"    <a class=\"graphic graphic_picture graphicRef71345 \" href=\"mobipreview.htm?37/63/38911\">",
"     picture 8",
"    </a>",
"    ) or multiple true knots and knots associated with coiling or twisting of the cord increase the risk of intrauterine demise, particularly if the cord is long and during the second trimester when the fetus has a lot of room to move. The medical record should document the presence of a true knot, the tightness or laxity of the knot, the presence of unilateral edema of the cord relative to the knot, and whether there are thrombi in the vessels. A pathologist should obtain a section through the knot for histologic examination. The appropriate management of true knots identified by ultrasound examination antepartum is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single umbilical vein conducts blood from the placenta back to the fetus and is essential for fetal survival. The two umbilical arteries shunt blood from the fetus to the placenta. Their redundancy is evident, given that the presence of a single umbilical artery or hypoplastic second umbilical artery is not lethal.",
"   </p>",
"   <p>",
"    The number of umbilical vessels are best counted by cutting the cord in a relatively uniform region (away from bulges of false knots) at least 5 cm from the placental insertion since the two arteries sometimes fuse near the insertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/24\">",
"     24",
"    </a>",
"    ]. Two vessel cords should be documented in the medical record and confirmed by histological examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link&amp;anchor=H34#H34\">",
"     \"Histopathology of placental disorders\", section on 'Single umbilical artery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vessels that are expanded and contain laminated thrombi are abnormal and should be investigated. Possible etiologies include cord compression from a true knot, cord prolapse, or head compression; marginal or membranous cord insertion; a fetal hypercoagulable state (eg, sepsis, hereditary thrombophilia); and maternal diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematomas due to trauma at delivery are commonly observed near the cord clamp and at the insertion of the cord into the placental disk. True spontaneous hematomas of the umbilical cord do occur, but are rare and often lethal.",
"   </p>",
"   <p>",
"    True hemangiomas of the umbilical cord are also rare, and associated with fetal death. These present as mass-like lesions of considerable length and diameter (",
"    <a class=\"graphic graphic_picture graphicRef53360 \" href=\"mobipreview.htm?0/15/243\">",
"     picture 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematomas resulting from trauma during delivery are relatively common (",
"    <a class=\"graphic graphic_picture graphicRef70927 \" href=\"mobipreview.htm?37/22/38255\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Rare anomalies of the cord sometimes noted macroscopically include teratomas, cysts, and aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/33-38\">",
"     33-38",
"    </a>",
"    ]. All of these unusual findings should be documented by a full histopathologic examination.",
"   </p>",
"   <p>",
"    Umbilical cord cysts may arise from embryonic remnants of the vitelline duct and urachus. They can occur anywhere along the length of the cord. First trimester umbilical cord cysts noted on ultrasound are often transient and have no clinical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Persistent cysts have been associated with a variety of fetal anomalies (particularly patent urachus and omphalocele), but the true prevalence of fetal anomalies in these patients cannot be determined from the small retrospective case reports and series that have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Preparation for histologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the gross examination described above has been performed, the cord is transected at the disk and three sections are isolated and placed in formalin for histologic examination; a random piece of cord should also be included. These specimens should incorporate the most distal, most proximal, and mid sections of the cord, as well as any areas that appear abnormal. Cords that are abnormally colored, especially due to meconium, should be extensively sectioned (at least three cassettes). The sections should be labeled so they can be oriented by the pathologist. Abnormalities, such as true knots, should not be sectioned by the clinician so the gross abnormality can be viewed by a pathologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placental membranes are composed of two layers: the layer nearest the fetus (facing the amniotic cavity) is the amnion and the outer layer is the chorion. The amnion and chorion are derived from extraembryonic tissues of the zygote. A space, which is a remnant of the early gestational sac, separates the two layers until approximately 12 weeks of gestation, at which time the amnion and chorion adhere to one another.",
"   </p>",
"   <p>",
"    The structure and function of the fetal membranes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43175?source=see_link\">",
"     \"Fetal membranes: Anatomy and biochemistry\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Color",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal membranes are translucent, slightly gray, and glistening (",
"    <a class=\"graphic graphic_picture graphicRef65014 \" href=\"mobipreview.htm?25/0/25606\">",
"     picture 11",
"    </a>",
"    ). Abnormal membrane color or clarity suggests the presence of pathology. As an example, meconium stains the membrane",
"    <span class=\"nowrap\">",
"     green/yellow,",
"    </span>",
"    hemosiderin stains the membrane brown, and infection stains the membrane yellow (",
"    <a class=\"graphic graphic_picture graphicRef69217 graphicRef77902 \" href=\"mobipreview.htm?42/39/43641\">",
"     picture 12A-B",
"    </a>",
"    ); a tan membrane may represent a combination of these problems (",
"    <a class=\"graphic graphic_picture graphicRef66875 \" href=\"mobipreview.htm?2/15/2294\">",
"     picture 13",
"    </a>",
"    ). Mild infection might just increase membrane opacity and dullness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surface",
"    </span>",
"    &nbsp;&mdash;&nbsp;The membranes should be smooth. Small, flat, pearly white lesions that adhere to the amnion near the cord insertion site may represent squamous metaplasia, a normal finding (",
"    <a class=\"graphic graphic_picture graphicRef68291 \" href=\"mobipreview.htm?23/33/24081\">",
"     picture 14",
"    </a>",
"    ). Subchorionic nodules of fibrin deposits are also a common, normal finding. By comparison, nodules on the fetal surface of the amnion are unusual and suggest a disease process, such as abscesses or amnion nodosum. These nodules should be evaluated histologically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link&amp;anchor=H14#H14\">",
"     \"Histopathology of placental disorders\", section on 'Fetal disorders affecting the membranes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insertion of the membranes at the placental disk should also be noted, although the significance of various types of insertions is controversial. The membranes usually emerge from the disk smoothly and flush with the margin; this is referred to as a marginal insertion. There may be an increased risk of fetal morbidity when the membranes originate from just inside the margin of the disk (circummarginate) or from deep inside the margin (circumvallate) due to abnormally deep implantation in the disk (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Circumvallate placenta'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H26\">",
"     'Circummarginate placenta'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Preparation for histologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;After inspection of the membranes, the care provider should obtain two membrane rolls: one at the site of rupture and one from an unruptured area. A 2 cm wide strip of membranes should be cut from the area most distal from the disk to the disk, including a small portion of disk margin. Any membranous vessels (either due to velamentous insertion of the umbilical cord or a \"wandering\" membranous vessel) should be sampled in a roll. The membranes can be wrapped like a \"jelly roll\" around a pair of forceps (or similar instrument) while holding the marginal piece of placenta and placed in formalin. One transverse section from each roll is submitted for histologic examination (",
"    <a class=\"graphic graphic_picture graphicRef76740 \" href=\"mobipreview.htm?30/28/31172\">",
"     picture 15",
"    </a>",
"    ). The remaining membranes can be trimmed off the disk and discarded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PARENCHYMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placental parenchyma is composed of a branching, highly vascularized stromal compartment lined or covered by trophoblast. The stroma is mesoderm derived from the zygote and filled with vascular and lymphatic channels. The trophoblast expresses unique antigens (HLA-G and Fas ligand) that promote its graft-like immunological acceptance (tolerance) by the antigenically dissimilar maternal host with whom it interfaces. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41256?source=see_link\">",
"     \"Placental development and physiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36201?source=see_link\">",
"     \"Immunology of the maternal-fetal interface\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disk (without membranes and umbilical cord) should be weighed and the weight compared with standards (",
"    <a class=\"graphic graphic_table graphicRef72177 \" href=\"mobipreview.htm?7/12/7374\">",
"     table 3",
"    </a>",
"    ). The amount of blood in the placenta comprises a significant proportion of total weight and is affected by iatrogenic factors, such as whether the placenta is drained prior to delivery.",
"   </p>",
"   <p>",
"    Placental weight correlates with birth weight; normal values of the fetal-to-placenta weight ratio change during the course of gestation (1:4 at 27 weeks increasing to 1:7 at term). Placental weights significantly deviating from the normal range are an indication for special studies, such as viral cultures, flow cytometry, or karyotype. Maternal diabetes mellitus, fetal or maternal anemia, fetal hydrops, and congenital syphilis are associated with high placental weight. Preeclampsia, fetal growth restriction, and some aneuploidies (not trisomy 21) and infections are associated with low placental weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dimensions and appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal term placenta is a single, relatively symmetrical discoid organ that occupies about one-fifth of the surface of the chorionic sac. The dimensions of the placenta should be recorded. A normal term placenta is at 2 to 4 cm thick and about 20 cm in diameter. Thickness is measured after cutting, and size is represented by the major and minor diameters of the",
"    <span class=\"nowrap\">",
"     ovoid/round",
"    </span>",
"    disk.",
"   </p>",
"   <p>",
"    The maternal surface is maroon and divided into lobules or cotyledons, which should be inspected to ensure that all are present. Blood clot (fresh or organized) adherent to the maternal surface, especially if it distorts the cotyledons, may represent an abruption.",
"   </p>",
"   <p>",
"    The parenchyma should be a spongy, soft, red tissue. Mottled colors and firm areas may be abnormal and should be noted. Firm areas in the placenta may be related to fibrin deposition or infarction. Fresh infarcts are red, while older infarcts and fibrin deposits are gray (",
"    <a class=\"graphic graphic_picture graphicRef82377 \" href=\"mobipreview.htm?14/41/14993\">",
"     picture 16",
"    </a>",
"    ). Infarcts or fibrin occupying less than 5 percent of the placental mass are not clinically important, but larger areas are associated with fetal growth restriction, stillbirth, and neurological sequelae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link&amp;anchor=H21#H21\">",
"     \"Histopathology of placental disorders\", section on 'Ischemic lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21929?source=see_link\">",
"     \"Placental pathology in cases of neurologically impaired infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mass lesions, which may consist of infarcts, thrombi (",
"    <a class=\"graphic graphic_picture graphicRef53438 \" href=\"mobipreview.htm?25/7/25717\">",
"     picture 17",
"    </a>",
"    ), cysts, tumors, or abscesses, are abnormal and should be examined histologically.",
"   </p>",
"   <p>",
"    An orange rind-like band of fibrin deposition along the maternal floor is suspicious for a maternal floor infarction, a lesion that carries significant morbidity and recurrence risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link&amp;anchor=H29#H29\">",
"     \"Histopathology of placental disorders\", section on 'Maternal floor infarction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcification (calcium speckling) may be observed and palpated over the basal surface of the cotyledons. It is a normal part of placental maturation in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], and occurs earlier in smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/47\">",
"     47",
"    </a>",
"    ]. Placental calcification in the second trimester is an abnormal finding; most studies have found an association with adverse pregnancy outcomes (eg, fetal growth restriction, fetal distress) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/48\">",
"     48",
"    </a>",
"    ]. Second trimester calcification is often associated with placental infarction or perivillous fibrin deposition, which are signs of placental insufficiency.",
"   </p>",
"   <p>",
"    Severe fetal anemia may cause the placenta to appear pale (",
"    <a class=\"graphic graphic_picture graphicRef50241 \" href=\"mobipreview.htm?1/18/1320\">",
"     picture 18",
"    </a>",
"    ). One should consider all of the etiologies of fetal anemia, including maternal-fetal hemorrhage and ABO incompatibilities, and, if the clinical situation supports it, consideration of maternal antibody and Kleihauer-Betke analysis might be suggested based on the placental examination alone.",
"   </p>",
"   <p>",
"    The fetal surface of the placenta is shiny, gray, and translucent. The chorionic vessels along the fetal surface of the placenta can be examined easily through the transparent amnion and chorion covering them. The fetal surface is inspected to look for large vessels coursing to the edge, which suggest a placental lobe (succenturiate or accessory lobe) may have torn away and left behind in the uterus. It is also important to note the presence of cysts, subchorionic hematomas, squamous metaplasia, amnion nodosum, and thrombi or calcification of vessels. Hemorrhage between the amnion and chorion is usually an artifact related to traction on the cord during delivery of the placenta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Placental variants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Placenta succenturiata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta succenturiata refers to a placenta with an additional lobe or lobes of placental tissue located a few centimeters away. A placental artery and vein extend from and within the membrane of the main placental mass to each lobe and then divide into smaller vessels supplying individual cotyledons. The ancillary lobes function normally, but can be associated with complications such as placenta previa or vasa previa. In addition, the succenturiate lobe(s) may be retained after the main placental disk has been delivered. This can result in postpartum hemorrhage or infection days or weeks after delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Placenta membranacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta membranacea refers to a rare type of placenta in which the chorionic sac is covered by functional placental tissue. These placentas are very thin and deeply implanted (with occasional placenta accreta), thus requiring manual removal. They are associated with slightly increased risks of second trimester miscarriage, preterm birth, and antepartum and postpartum bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Duplex placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplex placenta (ie, bilobed placenta) refers to complete separation of the placenta into two lobes with separate umbilical arteries and veins that unite in a single umbilical cord.",
"    <strong>",
"     Bipartite",
"    </strong>",
"    (bidiscoidal) and",
"    <strong>",
"     tripartite",
"    </strong>",
"    (tridiscoidal) placentas do not have as complete a separation between lobes as the duplex placenta. The incomplete parenchymal separation typically occurs in the area of the cord insertion site, which may be very thin or absent (fenestrate placenta).",
"   </p>",
"   <p>",
"    The umbilical cord may insert into a chorionic bridge between lobes. More commonly, membranous vessels extend between lobes or from either lobe to the cord. When the vessels are membranous (velamentous), vasa previa, compression, and thrombosis are major concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Circumvallate placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumvallate placenta refers to a placenta with an unusually small chorionic plate, but with growth of extrachorial placental tissue (",
"    <a class=\"graphic graphic_picture graphicRef67822 \" href=\"mobipreview.htm?37/26/38307\">",
"     picture 19",
"    </a>",
"    ). A double layer of amnion and chorion, as well as necrotic villi and fibrin, form a raised white ring around the surface of the placental disk at a variable distance from the umbilical cord insertion site; the fetal vessels do not extend beyond this ring. The extrachorionic tissue constitutes a small proportion of the placenta and usually does not compromise fetomaternal exchange. However, these placentas are more prone to premature separation and second trimester bleeding is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Circummarginate placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ring of membrane is flat and near the edge of the disk (",
"    <a class=\"graphic graphic_picture graphicRef55004 \" href=\"mobipreview.htm?7/21/7510\">",
"     picture 20",
"    </a>",
"    ). It is not associated with adverse outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Preparation for histologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal surface of the placental disk is cut into 2 cm wide strips. In addition to specimens from all of the abnormal areas, histologic sampling of the parenchyma should include at least one region which is grossly normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     GROSS PLACENTAL FINDINGS OF CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most important placental pathologic findings are detected on histological examination. These abnormalities include infections; predictors of neurologic compromise in the infant; and predictors of",
"    <span class=\"nowrap\">",
"     reproductive/obstetrical",
"    </span>",
"    pathology in future pregnancies, such as massive chronic intervillositis.",
"   </p>",
"   <p>",
"    Examples of gross lesions that are important include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abscesses, which are almost due to Listerial placentitis and may be a sign that the infant is infected",
"     </li>",
"     <li>",
"      Green discoloration, especially of the umbilical cord, may be meconium myonecrosis, which may be associated with perinatal morbidity",
"     </li>",
"     <li>",
"      Yellow-green discoloration of umbilical cord may be umbilical \"vasculitis,\" which may be associated with perinatal sepsis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic compromise",
"     </li>",
"     <li>",
"      Organized thrombi in umbilical vessels",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chorionic plate vessels may be associated with congenital stroke or visceral infarcts",
"     </li>",
"     <li>",
"      Orange rind-like change of maternal floor may be maternal floor infarction, which often recurs and is associated with fetal complications",
"     </li>",
"     <li>",
"      Incomplete maternal floor may indicate retained placenta.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21929?source=see_link\">",
"     \"Placental pathology in cases of neurologically impaired infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PATHOLOGY REPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providing a clear and succinct report is essential for the clinician. We strongly suggest that the placental pathology report be included in both the infant's and the mother's medical charts. Having a routine standard gross and histologic evaluation and report is extremely helpful for the clinician in counseling the family and in improving neonatal care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/6,50,51\">",
"     6,50,51",
"    </a>",
"    ]. An important secondary gain in good placental pathology is the avoidance of litigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40840/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The placenta is a fetal organ consisting of an umbilical cord, membranes (chorion and amnion), and parenchyma (",
"      <a class=\"graphic graphic_picture graphicRef62366 \" href=\"mobipreview.htm?11/19/11573\">",
"       picture 1",
"      </a>",
"      ). Maternal or fetal disorders may have placental sequelae since the mother and fetus interface at this site. Conversely, primary placental abnormalities can affect both maternal and fetal health. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The umbilical cord, membranes, and placental disk should be examined for abnormalities. A minimum examination should include the number of cord vessels, length of the umbilical cord, color of the placental membranes, and placental weight (less cord and membranes). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest histological examination of the placenta in the absence of a normal delivery of a healthy term infant from an uncomplicated pregnancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A fresh placenta can be refrigerated (not frozen) at 4 degrees Celsius for three to seven days. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Handling and storing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before placing the placenta in fixative, it is prudent to refrigerate a small sample in normal saline in case any special studies (culture, cytogenetics) are needed after histologic examination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Handling and storing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/1\">",
"      Stoeckmann A. Placental examination as a risk management tool. J Healthc Risk Manag 1994; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/2\">",
"      Salafia CM, Vintzileos AM. Why all placentas should be examined by a pathologist in 1990. Am J Obstet Gynecol 1990; 163:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/3\">",
"      Salafia CM. Recurrent obstetric complications: how placental pathology can contribute to cost-effective clinical evaluation and a rational clinical care plan. Curr Womens Health Rep 2002; 2:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/4\">",
"      Khong TY. From delivery suite to laboratory: optimizing returns from placental examination in medico-legal defence. Aust N Z J Obstet Gynaecol 1997; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/5\">",
"      Kaplan C, Lowell DM, Salafia C. College of American Pathologists Conference XIX on the Examination of the Placenta: report of the Working Group on the Definition of Structural Changes Associated with Abnormal Function in the Maternal/Fetal/Placental Unit in the Second and Third Trimesters. Arch Pathol Lab Med 1991; 115:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/6\">",
"      Langston C, Kaplan C, Macpherson T, et al. Practice guideline for examination of the placenta: developed by the Placental Pathology Practice Guideline Development Task Force of the College of American Pathologists. Arch Pathol Lab Med 1997; 121:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/7\">",
"      Kiran H, Kiran G, Kanber Y. Pseudocyst of the umbilical cord with mucoid degeneration of Wharton's jelly. Eur J Obstet Gynecol Reprod Biol 2003; 111:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/8\">",
"      Yavner DL, Redline RW. Angiomyxoma of the umbilical cord with massive cystic degeneration of Wharton's jelly. Arch Pathol Lab Med 1989; 113:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/9\">",
"      Lacro RV, Jones KL, Benirschke K. The umbilical cord twist: origin, direction, and relevance. Am J Obstet Gynecol 1987; 157:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/10\">",
"      Kalish RB, Hunter T, Sharma G, Baergen RN. Clinical significance of the umbilical cord twist. Am J Obstet Gynecol 2003; 189:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/11\">",
"      Reynolds SR. Mechanisms of placentofetal blood flow. Obstet Gynecol 1978; 51:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/12\">",
"      Georgiou HM, Rice GE, Walker SP, et al. The effect of vascular coiling on venous perfusion during experimental umbilical cord encirclement. Am J Obstet Gynecol 2001; 184:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/13\">",
"      Dado GM, Dobrin PB, Mrkvicka RS. Venous flow through coiled and noncoiled umbilical cords. Effects of external compression, twisting and longitudinal stretching. J Reprod Med 1997; 42:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/14\">",
"      Rayburn WF, Beynen A, Brinkman DL. Umbilical cord length and intrapartum complications. Obstet Gynecol 1981; 57:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/15\">",
"      Naeye RL. Umbilical cord length: clinical significance. J Pediatr 1985; 107:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/16\">",
"      Strong TH Jr, Elliott JP, Radin TG. Non-coiled umbilical blood vessels: a new marker for the fetus at risk. Obstet Gynecol 1993; 81:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/17\">",
"      Rana J, Ebert GA, Kappy KA. Adverse perinatal outcome in patients with an abnormal umbilical coiling index. Obstet Gynecol 1995; 85:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/18\">",
"      Degani S, Leibovich Z, Shapiro I, et al. Early second-trimester low umbilical coiling index predicts small-for-gestational-age fetuses. J Ultrasound Med 2001; 20:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/19\">",
"      de Laat MW, Franx A, Bots ML, et al. Umbilical coiling index in normal and complicated pregnancies. Obstet Gynecol 2006; 107:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/20\">",
"      Predanic M, Perni SC, Chasen ST, et al. Ultrasound evaluation of abnormal umbilical cord coiling in second trimester of gestation in association with adverse pregnancy outcome. Am J Obstet Gynecol 2005; 193:387.",
"     </a>",
"    </li>",
"    <li>",
"     Rogers, MS, Ip, YW, Qin, Y, Rogers, SM, et al. Relationship between umbilical cord morphology and nuchal cord entanglement. Acta Obstet Gynecol Scand 2003; 82;32.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/22\">",
"      Schachter M, Tovbin Y, Arieli S, et al. In vitro fertilization is a risk factor for vasa previa. Fertil Steril 2002; 78:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/23\">",
"      Englert Y, Imbert MC, Van Rosendael E, et al. Morphological anomalies in the placentae of IVF pregnancies: preliminary report of a multicentric study. Hum Reprod 1987; 2:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/24\">",
"      Fujikura T. Fused umbilical arteries near placental cord insertion. Am J Obstet Gynecol 2003; 188:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/25\">",
"      Heifetz SA. The umbilical cord: obstetrically important lesions. Clin Obstet Gynecol 1996; 39:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/26\">",
"      Stefos T, Sotiriadis A, Vasilios D, et al. Umbilical cord length and parity--the Greek experience. Eur J Obstet Gynecol Reprod Biol 2003; 107:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/27\">",
"      Krakowiak P, Smith EN, de Bruyn G, Lydon-Rochelle MT. Risk factors and outcomes associated with a short umbilical cord. Obstet Gynecol 2004; 103:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/28\">",
"      Baergen RN, Malicki D, Behling C, Benirschke K. Morbidity, mortality, and placental pathology in excessively long umbilical cords: retrospective study. Pediatr Dev Pathol 2001; 4:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/29\">",
"      Spellacy WN, Gravem H, Fisch RO. The umbilical cord complications of true knots, nuchal coils, and cords around the body. Report from the collaborative study of cerebral palsy. Am J Obstet Gynecol 1966; 94:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/30\">",
"      Stempel LE. Beyond the pretty pictures: giving obstetricians just enough (umbilical) cord to hang themselves. Am J Obstet Gynecol 2006; 195:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/31\">",
"      Vern TZ, Alles AJ, Kowal-Vern A, et al. Frequency of factor V(Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol 2000; 31:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/32\">",
"      Caldarella A, Buccoliero AM, Taddei A, et al. Hemangioma of the umbilical cord: report of a case. Pathol Res Pract 2003; 199:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/33\">",
"      Clausen I. Umbilical cord anomalies and antenatal fetal deaths. Obstet Gynecol Surv 1989; 44:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/34\">",
"      Carvounis EE, Dimmick JE, Wright VJ. Angiomyxoma of umbilical cord. Arch Pathol Lab Med 1978; 102:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/35\">",
"      Ghidini A, Romero R, Eisen RN, et al. Umbilical cord hemangioma. Prenatal identification and review of the literature. J Ultrasound Med 1990; 9:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/36\">",
"      Kamitomo M, Sueyoshi K, Matsukita S, et al. Hemangioma of the umbilical cord: stenotic change of the umbilical vessels. Fetal Diagn Ther 1999; 14:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/37\">",
"      Kreczy A, Alge A, Menardi G, et al. Teratoma of the umbilical cord. Case report with review of the literature. Arch Pathol Lab Med 1994; 118:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/38\">",
"      Lee MC, Aterman K. An intestinal polyp of the umbilical cord. Am J Dis Child 1968; 116:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/39\">",
"      Sepulveda W, Leible S, Ulloa A, et al. Clinical significance of first trimester umbilical cord cysts. J Ultrasound Med 1999; 18:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/40\">",
"      Rempen A. Sonographic first-trimester diagnosis of umbilical cord cyst. J Clin Ultrasound 1989; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/41\">",
"      Skibo LK, Lyons EA, Levi CS. First-trimester umbilical cord cysts. Radiology 1992; 182:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/42\">",
"      Ross JA, Jurkovic D, Zosmer N, et al. Umbilical cord cysts in early pregnancy. Obstet Gynecol 1997; 89:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/43\">",
"      Zangen R, Boldes R, Yaffe H, et al. Umbilical cord cysts in the second and third trimesters: significance and prenatal approach. Ultrasound Obstet Gynecol 2010; 36:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/44\">",
"      Naftolin F, Khudr G, Benirschke K, Hutchinson DL. The syndrome of chronic abruptio placentae, hydrorrhea, and circumvallate placenta. Am J Obstet Gynecol 1973; 116:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/45\">",
"      TINDALL VR, SCOTT JS. PLACENTAL CALCIFICATION A STUDY OF 3,025 SINGLETON AND MULTIPLE PREGNANCIES. J Obstet Gynaecol Br Commonw 1965; 72:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/46\">",
"      JEACOCK MK. CALCIUM CONTENT OF THE HUMAN PLACENTA. Am J Obstet Gynecol 1963; 87:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/47\">",
"      Brown HL, Miller JM Jr, Khawli O, Gabert HA. Premature placental calcification in maternal cigarette smokers. Obstet Gynecol 1988; 71:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/48\">",
"      Chen KH, Chen LR, Lee YH. Exploring the relationship between preterm placental calcification and adverse maternal and fetal outcome. Ultrasound Obstet Gynecol 2011; 37:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/49\">",
"      Ekoukou D, Ng Wing Tin L, Nere MB, et al. [Placenta membranacea. Review of the literature, a case report]. J Gynecol Obstet Biol Reprod (Paris) 1995; 24:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/50\">",
"      Gersell DJ. ASCP survey on placental examination. American Society of Clinical Pathologists. Am J Clin Pathol 1998; 109:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/51\">",
"      Spencer MK, Khong TY. Conformity to guidelines for pathologic examination of the placenta. Arch Pathol Lab Med 2003; 127:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40840/abstract/52\">",
"      Kraus FT. Perinatal pathology, the placenta, and litigation. Hum Pathol 2003; 34:517.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5393 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40840=[""].join("\n");
var outline_f39_56_40840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HANDLING AND STORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      UMBILICAL CORD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Coiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Placental insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Knots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Preparation for histologic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Color",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surface",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Preparation for histologic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PARENCHYMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dimensions and appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Placental variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Placenta succenturiata",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Placenta membranacea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Duplex placenta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Circumvallate placenta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Circummarginate placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Preparation for histologic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      GROSS PLACENTAL FINDINGS OF CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PATHOLOGY REPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5393\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5393|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?3/13/3280\" title=\"form 1\">",
"      Template for dictation of placental findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5393|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/19/11573\" title=\"picture 1\">",
"      Normal placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/3/30783\" title=\"picture 2\">",
"      Necrotizing funisitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/56/14213\" title=\"picture 3\">",
"      Cord edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/43/42672\" title=\"picture 4\">",
"      Umbilical cord spiraling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/35/36404\" title=\"picture 5\">",
"      Marginal cord insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/38/33377\" title=\"picture 6\">",
"      False knot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/54/31584\" title=\"picture 7\">",
"      Umbilical cord knot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/63/38911\" title=\"picture 8\">",
"      True knot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/15/243\" title=\"picture 9\">",
"      Cord hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/22/38255\" title=\"picture 10\">",
"      Hematoma umbilical cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/0/25606\" title=\"picture 11\">",
"      Fetal membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/58/8103\" title=\"picture 12A\">",
"      Chorioamnionitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/43/35507\" title=\"picture 12B\">",
"      Chorioamnionitis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/15/2294\" title=\"picture 13\">",
"      Discordant twin placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/33/24081\" title=\"picture 14\">",
"      Squamous metaplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/28/31172\" title=\"picture 15\">",
"      Fetal membrane roll",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/41/14993\" title=\"picture 16\">",
"      Placental infarct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/7/25717\" title=\"picture 17\">",
"      Intervillous thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/18/1320\" title=\"picture 18\">",
"      Hydropic placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/26/38307\" title=\"picture 19\">",
"      Circumvallate placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/21/7510\" title=\"picture 20\">",
"      Circummarginate placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5393|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/47/21244\" title=\"table 1\">",
"      Indications placental exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/19/6459\" title=\"table 2\">",
"      Umbilical cord length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/12/7374\" title=\"table 3\">",
"      Placental weight",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38839?source=related_link\">",
"      Evaluation of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/10/43175?source=related_link\">",
"      Fetal membranes: Anatomy and biochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36201?source=related_link\">",
"      Immunology of the maternal-fetal interface",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41256?source=related_link\">",
"      Placental development and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21929?source=related_link\">",
"      Placental pathology in cases of neurologically impaired infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/18/20775?source=related_link\">",
"      Velamentous umbilical cord insertion and vasa previa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_56_40841="Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis";
var content_f39_56_40841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40841/contributors\">",
"     Jane G Boggs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40841/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40841/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40841/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40841/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/56/40841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of seizures and epilepsy specific to the elderly patient is important for many reasons. A high proportion (nearly 25 percent) of new seizures occur in individuals over the age of 65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The causes and clinical manifestations of seizures and epilepsy differ in this age group and affect the diagnostic approach. Treatment issues are complicated in elderly patients. Finally, there are significant implications of a seizure diagnosis in the older person already vulnerable to loss of independence, driving restrictions, impaired self confidence, and risk of falls, which result in physical injury and other sequelae and contribute to lower health-related quality of life compared to seniors without epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute symptomatic seizures are provoked events that are not expected to recur in the absence of a particular trigger (eg, hypoglycemia, alcohol withdrawal). Epilepsy is a condition in which recurrent unprovoked seizures are expected in the absence of treatment. This topic will cover the etiology, clinical presentation, and differential diagnosis of seizures and epilepsy in older patients. The treatment of seizures and epilepsy in the elderly patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=see_link\">",
"     \"Treatment of seizures and epilepsy in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The highest incidence and prevalence of epilepsy is in patients over 65 years. In Rochester, Minnesota, the reported incidence of new-onset epilepsy was 134 cases per 100,000 elderly individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Similar rates are reported in other populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. One study estimated the prevalence of epilepsy to be almost 9 per 1000 individuals over the age of 65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/12\">",
"     12",
"    </a>",
"    ]. The annual incidence of epilepsy rises with each decade over 60 years (",
"    <a class=\"graphic graphic_figure graphicRef73655 \" href=\"mobipreview.htm?6/36/6733\">",
"     figure 1",
"    </a>",
"    ). Data from the VA Cooperative Study (VACS) #428, a clinical trial of antiepileptic medications in elderly people with epilepsy, suggests that seizures in older patients are frequently underdiagnosed; hence, the incidence of epilepsy in elderly patients may be two to three times higher, with an incidence six to seven times greater than younger individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among US Medicare beneficiaries age 65 years and older, average annual incident rates in 2001 to 2005 were higher in African Americans (4.1 per 1000) and lower in Asian and Native Americans (1.6 and 1.1 per 1000) than in whites (2.3 per 1000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute symptomatic seizures are common in older patients as well. The incidence of acute seizures in patients over 60 years is estimated at 50 to",
"    <span class=\"nowrap\">",
"     100/100,000,",
"    </span>",
"    with linear increases every decade over 30 years (",
"    <a class=\"graphic graphic_figure graphicRef54496 \" href=\"mobipreview.htm?12/41/12957\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/8,10,13\">",
"     8,10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both acute symptomatic seizures and epilepsy occur as a consequence of diseases and conditions that predominantly affect older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute symptomatic seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of acute symptomatic seizures include acute intracranial events as well as systemic illness and drug intoxication (",
"    <a class=\"graphic graphic_table graphicRef76342 \" href=\"mobipreview.htm?19/39/20091\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Acute stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older adults, acute stroke is the most common cause accounting for up to one-half of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/8,13,15\">",
"     8,13,15",
"    </a>",
"    ]. Seizures occur in 4 to 9 percent of acute cerebrovascular events; all stroke subtypes, including TIAs, are associated with seizure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Risk factors for acute seizures (defined as those occurring within two to four weeks after the event) include hemorrhage, large size, and cortical involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/19\">",
"     19",
"    </a>",
"    ]. Most acute seizures occur within 48 hours of ischemic stroke onset; in subarachnoid hemorrhage, seizures generally occur within hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Intracerebral hemorrhage, subdural hematoma, global hypoxic ischemic brain injury, and hypertensive encephalopathy may also present with a seizure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Metabolic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute metabolic disturbances that can precipitate seizures in individuals of any age are common in elderly patients because of the increased prevalence of multiple medical conditions, polypharmacy, and complications. Both hypoglycemia and nonketotic hyperglycemia occurring in poorly controlled diabetes, as well as hyponatremia, hypocalcemia, and uremic and hepatic encephalopathy are all causes of acute symptomatic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These cause approximately 6 to 30 percent of acute symptomatic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/8,13,15\">",
"     8,13,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications have been implicated as a cause of acute seizures in late life (",
"    <a class=\"graphic graphic_table graphicRef78226 \" href=\"mobipreview.htm?16/47/17148\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Elderly individuals are likely to be particularly susceptible to seizures as a consequence of drugs because of a high prevalence of polypharmacy, impaired drug clearance, and a heightened sensitivity to the proconvulsant effects of medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1\">",
"     1",
"    </a>",
"    ]. Seizures can occur with alcohol, benzodiazepine, or barbiturate withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/26\">",
"     26",
"    </a>",
"    ]. Overall, drugs and drug withdrawal contribute to up to 10 percent of acute symptomatic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/8,13,15\">",
"     8,13,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;While elderly patients are susceptible to head trauma, they may be less likely to suffer acute seizures as a result than are younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/5,27\">",
"     5,27",
"    </a>",
"    ]. Trauma underlies 4 to 17 percent of acute symptomatic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/8,13,15\">",
"     8,13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While seizures are a common symptom of intracranial infections, these represent less than 3 percent of acute seizures in the elderly population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/8,13,15\">",
"     8,13,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major causes of epilepsy in the elderly population include cerebrovascular disease, dementia, and trauma; a significant portion (one-third to one-half) are of unknown or cryptogenic origin (",
"    <a class=\"graphic graphic_table graphicRef76342 \" href=\"mobipreview.htm?19/39/20091\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/6,8,10,15\">",
"     6,8,10,15",
"    </a>",
"    ]. For all etiologies, the risk of developing epilepsy is highest in the first one to two years after the onset of the precipitating factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrovascular disease is the most common known cause of epilepsy in elderly people, causing one-third to one-half of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1,6,8,10,15,29,30\">",
"     1,6,8,10,15,29,30",
"    </a>",
"    ]. Risk factors for poststroke epilepsy (hemorrhage, cortical involvement, large size) are similar to those for acute symptomatic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/19\">",
"     19",
"    </a>",
"    ]. Acute symptomatic seizures and recurrent stroke are also risk factors for poststroke epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/31\">",
"     31",
"    </a>",
"    ]. Approximately 35 percent of individuals with acute stroke-related seizures will develop poststroke epilepsy, compared with an overall 5 to 9 percent risk of poststroke epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/17,31\">",
"     17,31",
"    </a>",
"    ]. The risk of unprovoked seizures is highest in the first year after a stroke, but remains substantially elevated for at least seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cryptogenic seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrovascular disease is also believed to underlie epilepsy in most of those with cryptogenic seizures. Evidence for this includes the fact that elderly epileptic patients both with and without a stroke history have a relative preponderance of stroke risk factors, particularly hypertension, but also hypercholesterolemia, coronary disease, and peripheral vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1,14,33\">",
"     1,14,33",
"    </a>",
"    ]. Elderly patients with epilepsy also have a greater risk of future stroke (OR 2.89) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alzheimer disease (AD) is a risk factor for epilepsy. Between 9 to 16 percent of patients with AD will develop seizures, usually in the later stages of disease, a rate 10 times otherwise expected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. A premorbid diagnosis of either AD or non-Alzheimer dementia are more common in patients presenting with a first unprovoked seizure compared with age-matched hospitalized controls (OR=6 and 8, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/40\">",
"     40",
"    </a>",
"    ]. In prospective cohort studies, younger age at onset and more severe dementia have been identified as independent risk factors for incident epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/39,41,42\">",
"     39,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures in the setting of dementia account for 9 to 17 percent of elderly people with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/6,8,10,15\">",
"     6,8,10,15",
"    </a>",
"    ]. Dementia may coexist and possibly interact with other causes of epilepsy. In a prospective study, preexisting dementia increased the risk of post-stroke epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/43\">",
"     43",
"    </a>",
"    ]. In another retrospective case series, 40 percent of patients with dementia and seizures had another potential structural cause (usually stroke) for their seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial tumors (most commonly gliomas, meningiomas, and metastases) also cause seizures in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/30\">",
"     30",
"    </a>",
"    ]. Interestingly, while these are more common in older than younger patients, seizures may be less likely to be the presenting symptom in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/45\">",
"     45",
"    </a>",
"    ]. Arteriovenous malformations usually manifest in younger adults; when first diagnosed in an elderly patient, seizures are much less likely to be the presenting symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Head trauma underlies 2 to 21 percent of epilepsy in the elderly population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/6,8,15\">",
"     6,8,15",
"    </a>",
"    ]. Older patients are particularly susceptible to head trauma, which may cause epilepsy as well as acute seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/27,47\">",
"     27,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obstructive sleep apnea, a condition more prevalent in older adults, probably does not cause seizures. However, it has been hypothesized that it may contribute to the emergence of seizures or increased frequency of seizures in older adults who have another established etiology. In one small case-control study, older patients with late-onset or worsening seizures had a higher apnea-hypopnea index compared with those who were seizure free or who had improved seizure frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7836251\">",
"    <span class=\"h2\">",
"     Seizure type and semiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most seizures in elderly patients are partial onset, with or without secondary generalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/47\">",
"     47",
"    </a>",
"    ]. When generalized, the partial onset may be unobserved or unrecognized, and the patient incorrectly classified as having primary generalized seizures. Late-onset primary generalized epilepsy, while rare, has been described in older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/49\">",
"     49",
"    </a>",
"    ]. It is possible that these were lifelong conditions, previously undiagnosed.",
"   </p>",
"   <p>",
"    Complex partial seizure was the most common seizure type in older patients in the VACS#428; 38.3 percent of patients experienced complex partial seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to younger patients, complex partial seizures in older adults are more often extratemporal, usually frontal, in origin, and therefore have an \"atypical\" clinical presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/50\">",
"     50",
"    </a>",
"    ]. Classic descriptions of seizure aura, such as deja vu and olfactory hallucinations, are uncommon. Patients may instead report antecedent symptoms that are atypical and nonspecific, such as vaguely localized paresthesias, dizziness, and muscle cramps. Observers often note episodic confusion, sleepiness, or clumsiness rather than motor manifestations such as tonic or clonic movements, or automatisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Postictal states are frequently more prolonged in elderly patients, particularly if there is underlying brain dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the \"atypical\" symptomatology, elderly patients with seizures may be frequently misdiagnosed. In the VACS#428, 73.3 percent of patients ultimately diagnosed with epilepsy had a different referral diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1\">",
"     1",
"    </a>",
"    ]. These included altered mental status, confusion, blackout spells, memory disturbance, syncope, dizziness, and dementia. In another series, transient ischemic attack (TIA), depression, and metabolic or psychiatric disorders were also among the initial misdiagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/54\">",
"     54",
"    </a>",
"    ]. Misdiagnosis is more common in patients with partial complex and partial simple seizures than with generalized tonic-clonic seizures. Despite the known association of seizures and cerebrovascular disease, a history of stroke or TIA was associated with a 1.7-year delay to diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/55\">",
"     55",
"    </a>",
"    ]. Similarly, comorbid dementia can obscure the recognition of seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Convulsive and nonconvulsive status epilepticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Status epilepticus (SE) is not infrequent in elderly patients; in one hospital-based study this was the mode of presentation for first seizure in 30 percent of elderly individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/28,56\">",
"     28,56",
"    </a>",
"    ]. The incidence of SE in the elderly population (90 per 100,000) is almost twice that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/57\">",
"     57",
"    </a>",
"    ]. Stroke, either acute or remote, is the most frequent underlying etiology (in about one-third of patients) of convulsive SE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/56\">",
"     56",
"    </a>",
"    ]; other associated conditions include a history of epilepsy, dementia, and electrolyte imbalance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/58\">",
"     58",
"    </a>",
"    ]. Associated mortality is higher in older patients, 38 percent in those over 60, and over 50 percent in those over 80 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/56,59\">",
"     56,59",
"    </a>",
"    ]. Mortality is associated with the duration of the ictus, and also with the number of medical comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonconvulsive status epilepticus (NCSE) is both a particularly common and challenging diagnosis in the elderly patient. It manifests as an altered mental status with confusion, psychosis, lethargy, or coma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/54,60-62\">",
"     54,60-62",
"    </a>",
"    ]. This nonspecific presentation can be associated with a delay to diagnosis, up to five days in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/54\">",
"     54",
"    </a>",
"    ]. A series of 236 patients without overt seizure activity received an EEG as part of a coma evaluation; 8 percent had NCSE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/63\">",
"     63",
"    </a>",
"    ]. Occasionally, NCSE may present as a more focal cognitive disturbance with aphasia or a neglect syndrome, even in the absence of underlying structural pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/54,61,64,65\">",
"     54,61,64,65",
"    </a>",
"    ]. EEG correlates of NCSE include focal rhythmic discharges, often arising from frontal or temporal lobes or generalized spike or sharp and slow wave activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/54,62,66\">",
"     54,62,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than half of NCSE cases occur in the setting of acute medical conditions, such as organ failure, drug toxicity, alcohol and benzodiazepine withdrawal, and other metabolic disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. Less commonly, NCSE complicates a known diagnosis of epilepsy or occurs as a first presentation of epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/62,67,69,70\">",
"     62,67,69,70",
"    </a>",
"    ]. Every cause of acute symptomatic seizures and epileptic seizures has been associated with NCSE.",
"   </p>",
"   <p>",
"    In the setting of severe medical illness, NCSE presents a difficult diagnostic and treatment challenge. A high index of suspicion for the diagnosis is required, as the underlying illness may often be deemed a sufficient explanation for altered sensorium. In one series of NCSE in critically ill elderly patients, most patients had underlying brain pathology (defined by history or neuroimaging), but only 2 of 38 had a previous diagnosis of epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/67\">",
"     67",
"    </a>",
"    ]. Mortality is high (27 to 52 percent) in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/61,67,69,70\">",
"     61,67,69,70",
"    </a>",
"    ]. Aggressive treatment of NCSE may actually contribute to mortality through induced hypotension, cardiac arrhythmias, and prolonged sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/61,67,71\">",
"     61,67,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more detailed discussion of the manifestations, diagnosis, and treatment of SE is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to epilepsy, other episodic disorders are common in older adults and must be carefully considered in the differential diagnosis depending upon the clinical setting. These include cardiac arrhythmias, metabolic disturbances, and transient ischemic attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope in an elderly patient can be accompanied by incontinence, and recovery is often slow, mimicking a postictal state. In addition, abnormal motor movements including brief convulsions may accompany syncope. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18074?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Transient ischemic attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ischemic attacks (TIAs) may be mistaken for seizures, but they may also induce seizures (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Acute stroke'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Brain ischemia produces reduced neural activity and \"negative\" symptoms such as hemiparesis or hemisensory loss. In contrast, seizures usually cause \"positive\" symptoms from neural overactivity. So called \"limb-shaking\" TIAs may represent a source of diagnostic confusion in this regard. This somewhat unusual manifestation of cerebral ischemia typically occurs in the setting of high-grade carotid stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\", section on 'Ischemic symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain symptoms, such as aphasia, can occur in TIA or seizure. While an isolated episode of aphasia is more likely to be a TIA than a seizure, aphasic seizures are well described. In general, ictal aphasia is progressive, developing over minutes from dysphasia to paraphasic errors, and culminating in a global aphasia. In contrast, TIA symptoms develop abruptly and typically do not evolve. Although TIA is commonly considered as a cause for confusional episodes, confusion is rarely a manifestation of TIA.",
"   </p>",
"   <p>",
"    Chronic, recurrent stereotyped events are much more likely to be seizure than TIA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36439?source=see_link\">",
"     \"Differential diagnosis of transient ischemic attack and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Transient global amnesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient global amnesia (TGA) occurs in older individuals and is characterized by striking amnesia with preservation of other cognitive domains. TGA episodes last longer than most seizures (usually several hours) and are without postictal lethargy or other motor manifestations of seizures.",
"   </p>",
"   <p>",
"    Episodes of amnesia that are epileptic in origin will typically also include olfactory hallucinations, abnormal behaviors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    motor automatisms, features that are absent in TGA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/74\">",
"     74",
"    </a>",
"    ]. However, these symptoms may not be volunteered and should be specifically elicited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38328?source=see_link\">",
"     \"Transient global amnesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Drop attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drop attacks are characterized by a sudden fall to the ground without warning. In typical cases, the patient can arise soon after the fall and denies loss of consciousness. A brief postictal confusional state may occur. Atonic seizure, cataplexy, vertebrobasilar TIA, and vestibular pathologies are potential causes of drop attacks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While atonic seizures are more commonly associated with generalized rather than partial epilepsy, epileptic drop attacks have been observed in patients with frontal, temporal, and other localization-related epilepsies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/75\">",
"       75",
"      </a>",
"      ]. In these cases, drop attacks are not the sole or even the predominant seizure type.",
"     </li>",
"     <li>",
"      Vertebrobasilar TIAs usually (but not invariably) include other symptoms of brainstem or cerebellar ischemia (eg, diplopia, dysarthria, vertigo, lateralized numbness or weakness) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39273?source=see_link\">",
"       \"Posterior circulation cerebrovascular syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vestibular pathologies including Meniere disease and aminoglycoside toxicity can present with drop attacks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/78-80\">",
"       78-80",
"      </a>",
"      ]. Patients often have a sensation of being pushed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link&amp;anchor=H12#H12\">",
"       \"Approach to the patient with vertigo\", section on 'Drop attacks'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Psychogenic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric disorders (eg, anxiety, depression) underlie some nonepileptic events in elderly patients who are monitored by video EEG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7836566\">",
"     'Electroencephalography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These late-onset psychogenic nonepileptic attacks are distinct from those occurring in younger patients with respect to antecedent psychogenic trauma: in older patients, health-related traumatic events are more likely, while in younger patients, antecedent sexual abuse is more likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/82\">",
"     82",
"    </a>",
"    ]. The clinical manifestations are similar in both age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium or acute toxic-metabolic encephalopathy may be difficult to distinguish from partial complex seizures and nonconvulsive status epilepticus (NCSE), particularly in a patient with baseline neurologic impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/84\">",
"     84",
"    </a>",
"    ]. Episodic, dramatic changes in mental status with a return to normal or baseline cognition strongly suggest seizures, but the presentation may be more subtle.",
"   </p>",
"   <p>",
"    When present, stereotyped motor movements or automatisms suggest seizure. However, tremor, asterixis, and myoclonus are not uncommon in delirium. Hallucinations may be a feature of either condition. Causes of delirium and seizures overlap, and delirium and seizures can coexist. EEG can identify or exclude seizures in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sleep disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid eye movement (REM) sleep disorder can be mistaken for epilepsy. This is a parasomnia characterized by vivid dreams in REM sleep without the usual accompanying muscle atonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. This causes individuals to \"act out\" their dreams, especially when they are vivid or frightening. Injuries to the patient and bed partner can result. Patients are usually able to describe the dream, a feature that is helpful in distinguishing this from seizures. Episodes may last a few minutes to a half-hour (longer than a typical epileptic seizure), can recur during the night, and preferentially occur in the second half of sleep when there is the greatest preponderance of REM sleep.",
"   </p>",
"   <p>",
"    While sometimes occurring as an isolated idiopathic condition, REM sleep behavior disorder is also associated with neurologic diseases including dementia with Lewy bodies and Parkinson disease. It usually presents after the age of 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/30\">",
"     30",
"    </a>",
"    ]. The diagnosis can be confirmed with polysomnography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1914?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\", section on 'REM sleep disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7836559\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reliable history and description of the event from an eyewitness are invaluable and superior to testing in the diagnosis of epileptic seizures. Accounts of premonitory symptoms and behavior, ictal pallor, urinary incontinence, tongue biting, and motor and other symptoms, as well as postictal confusion, drowsiness, paresis, or speech disturbance are very helpful. Often, however, this information is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7836566\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with altered mental status, EEG is a useful tool to exclude or identify seizure activity, especially nonconvulsive status epilepticus (NCSE), as a cause. However, an interictal EEG in the elderly person has limited utility, with low sensitivity and specificity for the diagnosis of epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32425?source=see_link\">",
"     \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonspecific EEG abnormalities such as intermittent focal slowing are seen in 12 to 38 percent of older individuals without seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Usually, these abnormalities make up a small portion (1 or 2 percent) of the tracing; more intrusive and more epileptiform abnormalities increase the likelihood of associated epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A normal EEG does not rule out the possibility of epilepsy and is seen in about one-third of patients with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/50,88,89\">",
"     50,88,89",
"    </a>",
"    ]. Activation procedures (hyperventilation and photic stimulation) and repeated evaluations add little to the diagnostic yield of the test in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/89\">",
"     89",
"    </a>",
"    ]. More frequent seizures increase the likelihood of an abnormal interictal EEG.",
"   </p>",
"   <p>",
"    Video or ambulatory EEG monitoring is infrequently performed in an elderly patient but can be useful in the evaluation of possible epilepsy, particularly when combined with ECG monitoring. Several case series have found a high yield with events recorded in 55 to 83 percent of elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1,81,86,90,91\">",
"     1,81,86,90,91",
"    </a>",
"    ]. In the largest of these, 46 of 94 patients had documented epileptic events and 27 documented nonepileptic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/86\">",
"     86",
"    </a>",
"    ]. Nonepileptic diagnoses made in this setting include syncope, cerebrovascular events, obstructive sleep apnea and other sleep disorders, hypotension, and psychogenic events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7836573\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brain imaging study should be obtained in all older individuals with possible epilepsy due to the frequency of stroke or other structural disease as an etiology. In the VA Cooperative Study (VACS) #428, only 18 percent of patients were found to have normal CT scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1\">",
"     1",
"    </a>",
"    ]. Stroke was seen in 42.6 percent, encephalomalacia in 9.1, and tumors in 1.5. Other nonspecific findings (atrophy, small vessel disease, hydrocephalus) were identified in the remaining and were probably incidental.",
"   </p>",
"   <p>",
"    Contrast increases the ability to identify tumors, inflammatory disease, and abscesses, but is usually not required if these conditions are not specifically suspected. Unless a CT done in the emergency setting is diagnostic, the more sensitive examination, MRI, should be pursued, especially if there are focal symptoms, exam findings, or EEG patterns. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/49/13082?source=see_link\">",
"     \"Neuroimaging in the evaluation of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7836580\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because metabolic abnormalities can precipitate seizures in patients with and without epilepsy, patients with acute seizures should have blood analyzed for electrolytes, BUN, creatinine, glucose, calcium, magnesium, and liver function tests. Complete blood count, differential, and platelets should also be performed in anticipation of initiating antiepileptic drugs (AEDs).",
"   </p>",
"   <p>",
"    Because cerebrovascular disease is the most common identifiable etiology for seizures in elderly patients, laboratory evaluation for stroke risk factors (eg, fasting lipid panel) should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lumbar puncture for cell count, protein, glucose, and stains with cultures should be performed whenever there is suspicion of meningitis or encephalitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"       \"Patient information: Seizures (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/27/34229?source=see_link\">",
"       \"Patient information: Seizures in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A first seizure is not uncommon in elderly persons and can represent an acute symptomatic seizure, a provoked event that is not expected to recur in the absence of that trigger or new-onset epilepsy, a condition in which recurrent unprovoked seizures are expected in the absence of treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In this age group, acute symptomatic seizures are most often seen in the setting of acute stroke and metabolic encephalopathy. Cerebrovascular disease and degenerative dementia are common causes of epilepsy in elderly patients, but one-third to one-half of cases are of cryptogenic origin. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overwhelming majority of late-onset epilepsy is partial or localization-related and presents with partial complex seizures, with and without secondary generalization. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should maintain a high level of suspicion for possible seizures in older patients presenting with intermittent or fluctuating confusional states. The usual clues to the possibility of underlying seizures are often absent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Considerations in the differential diagnosis of seizures in older patients include syncope and transient cerebral ischemia, as well as other disorders. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A reliable history and description of the event from an eyewitness are invaluable and superior to testing in the diagnosis of epileptic seizures. EEG monitoring, particularly video EEG monitoring, can be very helpful in the evaluation of patients with recurrent events. A brain imaging study should be obtained in all older individuals with possible epilepsy due to the frequency of stroke or other structural disease as an etiology. Because metabolic abnormalities can precipitate seizures in patients with and without epilepsy, patients with acute seizures should have blood analyzed for electrolytes, BUN, creatinine, glucose, calcium, magnesium, and liver function tests. (See",
"      <a class=\"local\" href=\"#H7836559\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/1\">",
"      Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004; 62:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/2\">",
"      Sander JW, Hart YM, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990; 336:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/3\">",
"      Laccheo I, Ablah E, Heinrichs R, et al. Assessment of quality of life among the elderly with epilepsy. Epilepsy Behav 2008; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/4\">",
"      Lees A. Retrospective study of seizure-related injuries in older people: a 10-year observation. Epilepsy Behav 2010; 19:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/5\">",
"      Hauser WA. Seizure disorders: the changes with age. Epilepsia 1992; 33 Suppl 4:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/6\">",
"      Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/7\">",
"      L&uuml;hdorf K, Jensen LK, Plesner AM. Epilepsy in the elderly: incidence, social function, and disability. Epilepsia 1986; 27:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/8\">",
"      Loiseau J, Loiseau P, Duch&eacute; B, et al. A survey of epileptic disorders in southwest France: seizures in elderly patients. Ann Neurol 1990; 27:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/9\">",
"      Sillanp&auml;&auml; M, Lastunen S, Helenius H, Schmidt D. Regional differences and secular trends in the incidence of epilepsy in Finland: a nationwide 23-year registry study. Epilepsia 2011; 52:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/10\">",
"      Tchalla AE, Marin B, Mignard C, et al. Newly diagnosed epileptic seizures: focus on an elderly population on the French island of R&eacute;union in the Southern Indian Ocean. Epilepsia 2011; 52:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/11\">",
"      Faught E, Richman J, Martin R, et al. Incidence and prevalence of epilepsy among older U.S. Medicare beneficiaries. Neurology 2012; 78:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/12\">",
"      Cossu P, Deriu MG, Casetta I, et al. Epilepsy in Sardinia, insular Italy: a population-based prevalence study. Neuroepidemiology 2012; 39:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/13\">",
"      Annegers JF, Hauser WA, Lee JR, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. Epilepsia 1995; 36:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/14\">",
"      Li X, Breteler MM, de Bruyne MC, et al. Vascular determinants of epilepsy: the Rotterdam Study. Epilepsia 1997; 38:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/15\">",
"      Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet 2000; 355:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/16\">",
"      Giroud M, Gras P, Fayolle H, et al. Early seizures after acute stroke: a study of 1,640 cases. Epilepsia 1994; 35:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/17\">",
"      Sung CY, Chu NS. Epileptic seizures in thrombotic stroke. J Neurol 1990; 237:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/18\">",
"      Bladin CF, Alexandrov AV, Bellavance A, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000; 57:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/19\">",
"      Lancman ME, Golimstok A, Norscini J, Granillo R. Risk factors for developing seizures after a stroke. Epilepsia 1993; 34:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/20\">",
"      Asconap&eacute; JJ, Penry JK. Poststroke seizures in the elderly. Clin Geriatr Med 1991; 7:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/21\">",
"      Kilpatrick CJ, Davis SM, Tress BM, et al. Epileptic seizures in acute stroke. Arch Neurol 1990; 47:157.",
"     </a>",
"    </li>",
"    <li>",
"     Loiseau P. Pathologic processes in the elderly and their association with seizures.. In: Seizures and epilepsy in the elderly, Rowan AJ, Ramsay RE (Eds), Butterworth-Heinemann, Boston 1997. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/23\">",
"      Malouf R, Brust JC. Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol 1985; 17:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/24\">",
"      Messing RO, Closson RG, Simon RP. Drug-induced seizures: a 10-year experience. Neurology 1984; 34:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/25\">",
"      Franson KL, Hay DP, Neppe V, et al. Drug-induced seizures in the elderly. Causative agents and optimal management. Drugs Aging 1995; 7:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/26\">",
"      Hauser WA, Ng SK, Brust JC. Alcohol, seizures, and epilepsy. Epilepsia 1988; 29 Suppl 2:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/27\">",
"      Bruns J Jr, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia 2003; 44 Suppl 10:2.",
"     </a>",
"    </li>",
"    <li>",
"     Hauser WA. Epidemiology of seizures and epilepsy in the elderly, -Henemann, Boston 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/29\">",
"      Hart YM, Sander JW, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 1990; 336:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/30\">",
"      Roberts MA, Godfrey JW, Caird FI. Epileptic seizures in the elderly: I. Aetiology and type of seizure. Age Ageing 1982; 11:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/31\">",
"      So EL, Annegers JF, Hauser WA, et al. Population-based study of seizure disorders after cerebral infarction. Neurology 1996; 46:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/32\">",
"      Adel&ouml;w C, Andersson T, Ahlbom A, Tomson T. Prior hospitalization for stroke, diabetes, myocardial infarction, and subsequent risk of unprovoked seizures. Epilepsia 2011; 52:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/33\">",
"      Ng SK, Hauser WA, Brust JC, Susser M. Hypertension and the risk of new-onset unprovoked seizures. Neurology 1993; 43:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/34\">",
"      Shinton RA, Gill JS, Zezulka AV, Beevers DG. The frequency of epilepsy preceding stroke. Case-control study in 230 patients. Lancet 1987; 1:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/35\">",
"      Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004; 363:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/36\">",
"      Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986; 36:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/37\">",
"      McAreavey MJ, Ballinger BR, Fenton GW. Epileptic seizures in elderly patients with dementia. Epilepsia 1992; 33:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/38\">",
"      Romanelli MF, Morris JC, Ashkin K, Coben LA. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol 1990; 47:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/39\">",
"      Scarmeas N, Honig LS, Choi H, et al. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 2009; 66:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/40\">",
"      Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology 1996; 46:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/41\">",
"      Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 2006; 47:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/42\">",
"      Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol 2012; 69:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/43\">",
"      Cordonnier C, H&eacute;non H, Derambure P, et al. Influence of pre-existing dementia on the risk of post-stroke epileptic seizures. J Neurol Neurosurg Psychiatry 2005; 76:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/44\">",
"      Rao SC, Dove G, Cascino GD, Petersen RC. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav 2009; 14:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/45\">",
"      Smith DF, Hutton JL, Sandemann D, et al. The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management. J Neurol Neurosurg Psychiatry 1991; 54:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/46\">",
"      Hashimoto H, Iida J, Kawaguchi S, Sakaki T. Clinical features and management of brain arteriovenous malformations in elderly patients. Acta Neurochir (Wien) 2004; 146:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/47\">",
"      Hiyoshi T, Yagi K. Epilepsy in the elderly. Epilepsia 2000; 41 Suppl 9:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/48\">",
"      Chihorek AM, Abou-Khalil B, Malow BA. Obstructive sleep apnea is associated with seizure occurrence in older adults with epilepsy. Neurology 2007; 69:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/49\">",
"      Loiseau J, Crespel A, Picot MC, et al. Idiopathic generalized epilepsy of late onset. Seizure 1998; 7:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/50\">",
"      Ramsay RE, Pryor F. Epilepsy in the elderly. Neurology 2000; 55:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/51\">",
"      Tinuper P, Provini F, Marini C, et al. Partial epilepsy of long duration: changing semiology with age. Epilepsia 1996; 37:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/52\">",
"      Kellinghaus C, Loddenkemper T, Dinner DS, et al. Seizure semiology in the elderly: a video analysis. Epilepsia 2004; 45:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/53\">",
"      Theodore WH. The postictal state: effects of age and underlying brain dysfunction. Epilepsy Behav 2010; 19:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/54\">",
"      Sheth RD, Drazkowski JF, Sirven JI, et al. Protracted ictal confusion in elderly patients. Arch Neurol 2006; 63:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/55\">",
"      Spitz, MC, Bainbridge, JL, Ramsay, RE, et al. Observations on delay in diagnosis of seizures in the elderly. Epilepsia 2002; 43 Suppl 7:166  [abstract].",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/56\">",
"      Sung CY, Chu NS. Status epilepticus in the elderly: etiology, seizure type and outcome. Acta Neurol Scand 1989; 80:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/57\">",
"      Waterhouse EJ, DeLorenzo RJ. Status epilepticus in older patients: epidemiology and treatment options. Drugs Aging 2001; 18:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/58\">",
"      Canou&iuml;-Poitrine F, Bastuji-Garin S, Alonso E, et al. Risk and prognostic factors of status epilepticus in the elderly: a case-control study. Epilepsia 2011; 52:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/59\">",
"      Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994; 35:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/60\">",
"      Atefy R, Tettenborn B. Nonconvulsive status epilepticus on treatment with levetiracetam. Epilepsy Behav 2005; 6:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/61\">",
"      Martin Y, Artaz MA, Bornand-Rousselot A. Nonconvulsive status epilepticus in the elderly. J Am Geriatr Soc 2004; 52:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/62\">",
"      Fern&aacute;ndez-Torre JL, D&iacute;az-Castroverde AG. Non-convulsive status epilepticus in elderly individuals: report of four representative cases. Age Ageing 2004; 33:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/63\">",
"      Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000; 54:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/64\">",
"      Chung PW, Seo DW, Kwon JC, et al. Nonconvulsive status epilepticus presenting as a subacute progressive aphasia. Seizure 2002; 11:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/65\">",
"      Thomas P, Giraud K, Alchaar H, Chatel M. Ictal asomatognosia with hemiparesis. Neurology 1998; 51:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/66\">",
"      Olnes MJ, Golding A, Kaplan PW. Nonconvulsive status epilepticus resulting from benzodiazepine withdrawal. Ann Intern Med 2003; 139:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/67\">",
"      Litt B, Wityk RJ, Hertz SH, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia 1998; 39:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/68\">",
"      Mart&iacute;nez-Rodr&iacute;guez JE, Barriga FJ, Santamaria J, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med 2001; 111:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/69\">",
"      Bottaro FJ, Martinez OA, Pardal MM, et al. Nonconvulsive status epilepticus in the elderly: a case-control study. Epilepsia 2007; 48:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/70\">",
"      Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003; 61:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/71\">",
"      Walker MC. Status epilepticus on the intensive care unit. J Neurol 2003; 250:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/72\">",
"      Ali S, Khan MA, Khealani B. Limb-shaking Transient Ischemic Attacks: case report and review of literature. BMC Neurol 2006; 6:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/73\">",
"      Persoon S, Kappelle LJ, Klijn CJ. Limb-shaking transient ischaemic attacks in patients with internal carotid artery occlusion: a case-control study. Brain 2010; 133:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/74\">",
"      Butler CR, Graham KS, Hodges JR, et al. The syndrome of transient epileptic amnesia. Ann Neurol 2007; 61:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/75\">",
"      Tinuper P, Cerullo A, Marini C, et al. Epileptic drop attacks in partial epilepsy: clinical features, evolution, and prognosis. J Neurol Neurosurg Psychiatry 1998; 64:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/76\">",
"      Rozen T, Gordon CD. Vertebral artery dissection in a migraine patient with recurrent drop attacks. Headache 2007; 47:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/77\">",
"      Welsh LW, Welsh JJ, Lewin B, Dragonette JE. Vascular analysis of individuals with drop attacks. Ann Otol Rhinol Laryngol 2004; 113:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/78\">",
"      Dallan I, Bruschini L, Nacci A, et al. Drop attacks and vertical vertigo after transtympanic gentamicin: diagnosis and management. Acta Otorhinolaryngol Ital 2005; 25:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/79\">",
"      Brantberg K, Ishiyama A, Baloh RW. Drop attacks secondary to superior canal dehiscence syndrome. Neurology 2005; 64:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/80\">",
"      Lee H, Yi HA, Lee SR, et al. Drop attacks in elderly patients secondary to otologic causes with Meniere's syndrome or non-Meniere peripheral vestibulopathy. J Neurol Sci 2005; 232:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/81\">",
"      Kellinghaus C, Loddenkemper T, Dinner DS, et al. Non-epileptic seizures of the elderly. J Neurol 2004; 251:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/82\">",
"      Duncan R, Oto M, Martin E, Pelosi A. Late onset psychogenic nonepileptic attacks. Neurology 2006; 66:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/83\">",
"      Behrouz R, Heriaud L, Benbadis SR. Late-onset psychogenic nonepileptic seizures. Epilepsy Behav 2006; 8:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/84\">",
"      Veran O, Kahane P, Thomas P, et al. De novo epileptic confusion in the elderly: a 1-year prospective study. Epilepsia 2010; 51:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/85\">",
"      Drury I, Beydoun A. Seizures and epilepsy in the elderly revisited. Arch Intern Med 1998; 158:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/86\">",
"      McBride AE, Shih TT, Hirsch LJ. Video-EEG monitoring in the elderly: a review of 94 patients. Epilepsia 2002; 43:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/87\">",
"      Normand MM, Wszolek ZK, Klass DW. Temporal intermittent rhythmic delta activity in electroencephalograms. J Clin Neurophysiol 1995; 12:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/88\">",
"      Ramsay, RE, Rowan, AJ, Pryor, FM, et, al. Seizures in the older patient: demographics. Diagnosis and treatment. Epilepsia 2000; 41:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/89\">",
"      Drury I, Beydoun A. Interictal epileptiform activity in elderly patients with epilepsy. Electroencephalogr Clin Neurophysiol 1998; 106:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/90\">",
"      Drury I, Selwa LM, Schuh LA, et al. Value of inpatient diagnostic CCTV-EEG monitoring in the elderly. Epilepsia 1999; 40:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40841/abstract/91\">",
"      Lancman ME, O'Donovan C, Dinner D, et al. Usefulness of prolonged video-EEG monitoring in the elderly. J Neurol Sci 1996; 142:54.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2223 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40841=[""].join("\n");
var outline_f39_56_40841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute symptomatic seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Acute stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Metabolic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epilepsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cryptogenic seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dementia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7836251\">",
"      Seizure type and semiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Convulsive and nonconvulsive status epilepticus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Transient ischemic attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Transient global amnesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Drop attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Psychogenic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7836559\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7836566\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7836573\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7836580\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2223\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2223|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/36/6733\" title=\"figure 1\">",
"      Age related incidence of epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/41/12957\" title=\"figure 2\">",
"      Rates of acute symptomatic seizures by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2223|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/39/20091\" title=\"table 1\">",
"      Causes of seizures in older patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/47/17148\" title=\"table 2\">",
"      Drugs that induce seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36439?source=related_link\">",
"      Differential diagnosis of transient ischemic attack and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32425?source=related_link\">",
"      Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/49/13082?source=related_link\">",
"      Neuroimaging in the evaluation of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=related_link\">",
"      Pathophysiology of symptoms from carotid atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38328?source=related_link\">",
"      Transient global amnesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=related_link\">",
"      Treatment of seizures and epilepsy in the elderly patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=related_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_56_40842="Bisphosphonates in the management of osteoporosis in postmenopausal women";
var content_f39_56_40842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bisphosphonates in the management of osteoporosis in postmenopausal women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40842/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40842/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40842/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/56/40842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/56/40842/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/56/40842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is caused by the cumulative effect of bone resorption in excess of bone formation. Bisphosphonates inhibit bone resorption with relatively few side effects. As a result, they are widely used for the prevention and treatment of osteoporosis.",
"   </p>",
"   <p>",
"    The use of bisphosphonates for osteoporosis in women will be reviewed here. The pharmacology of bisphosphonates, role of bisphosphonates for the treatment of osteoporosis in men and premenopausal women and in the prevention of osteoporosis in women, and an overview of other treatment options for osteoporosis in women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11333?source=see_link\">",
"     \"Pharmacology of bisphosphonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of osteoporosis in men\", section on 'Bisphosphonates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates are also used in the management of hypercalcemia, Paget disease, and in a number of malignancies, including multiple myeloma, breast cancer, and prostate cancer. These topics are all reviewed separately in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several general principles for the use of the bisphosphonates, as outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oral regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are poorly absorbed orally (less than 1 percent of the dose) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/1\">",
"     1",
"    </a>",
"    ], and must be taken on an empty stomach for maximal absorption. The following regimen is recommended to maximize absorption and minimize the risk of esophageal adverse effects. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Gastrointestinal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bisphosphonates should not be given to patients with active upper gastrointestinal disease.",
"     </li>",
"     <li>",
"      Bisphosphonates should be discontinued in patients who develop any symptoms of esophagitis.",
"     </li>",
"     <li>",
"      Bisphosphonates should be taken alone on an empty stomach first thing in the morning with at least 240 mL (8 oz) of water. After administration, the patient should not have food, drink, medications, or supplements for at least one-half hour (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      ) or one hour (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The reason for taking 8 oz of water is to minimize the risk of the tablet getting stuck in the esophagus. The reason for taking the medication while fasting and waiting one-half hour until eating or drinking is that bioavailability may be seriously impaired by ingestion with liquids other than plain water, such as mineral water, coffee, or juice, or by retained gastric contents, as with insufficient fasting time or gastroparesis, or by eating or drinking too soon afterwards.",
"      <br/>",
"      <br/>",
"      The regimen for enteric coated delayed-release risedronate is different from that of other bisphosphonates. The enteric-coated delayed-release formulation is taken immediately after breakfast with 4 oz water. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Weekly dose'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients should remain upright (sitting or standing) for at least 30 minutes after administration to minimize the risk of reflux.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compliance is also important for optimal fracture reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Timing of dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of bisphosphonates first thing in the morning, prior to breakfast, appears to be important for bioavailability and subsequent suppression of bone turnover. This was illustrated in a randomized trial of nursing home residents who were assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    or placebo between meals (after a two-hour fast) for 12 weeks, rather than before breakfast or the first liquid of the day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/5\">",
"     5",
"    </a>",
"    ]. Markers of bone turnover were not suppressed as they typically would be with before-breakfast administration, suggesting that this alternative schedule may not provide the desired effects on BMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Calcium/vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D insufficiency and inadequate calcium intake are common in patients with osteoporosis. In the majority of bisphosphonate trials described below, calcium and vitamin D supplements were also administered. Therefore, patients receiving bisphosphonates should take supplemental calcium and vitamin D. However, calcium supplements can interfere with the absorption of bisphosphonates, and they should not be taken for at least one hour after taking oral bisphosphonates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Calcium/vitamin D'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H25#H25\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Summary and Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     IV regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous bisphosphonates (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ) provide an alternative option for patients who cannot tolerate oral bisphosphonates, or who have difficulty with dosing requirements, including an inability to sit upright for 30 to 60 minutes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to swallow a pill. Zoledronic acid (ZA) is administered yearly and must be infused over a period of at least 15 minutes, whereas ibandronate is administered every three months as a 15 to 30 second intravenous injection.",
"   </p>",
"   <p>",
"    IV bisphosphonates may be associated with flu-like symptoms and hypocalcemia.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    can be administered to prevent or treat flu-like symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/6\">",
"     6",
"    </a>",
"    ]. Hypocalcemia is more likely to occur in those individuals with vitamin D deficiency, and therefore, it can be minimized by vitamin D and calcium supplementation. A serum calcidiol (25-hydroxyvitamin D) concentration should be assessed prior to IV bisphosphonate infusions. Individuals with vitamin D deficiency (25-hydroxyvitamin D &lt;15",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [37",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    should be treated prior to the infusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .) Increasing calcium supplementation (doubling of usual dose) for five to seven days, starting on the day of the infusion, may also minimize hypocalcemia. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There have been isolated reports of renal impairment and acute renal failure after ZA administration, particularly in patients with multiple myeloma but also rarely in those treated for osteoporosis and those receiving concurrent diuretic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. This occurrence may be related to ZA being administered too rapidly. Prior to each ZA infusion, clinicians should measure serum creatinine and make sure that patients are adequately hydrated. ZA should be infused over a period of at least 15 minutes. In patients taking other nephrotoxic drugs or diuretics, periodic post infusion measurement of serum creatinine should be considered. ZA is not recommended for use in patients with creatinine clearance &le;35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Use in chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are generally not recommended for those with CCr below 30 to 35",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Patients with chronic kidney disease with creatinine clearance (CCr) above 30 to 35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    are usually managed similarly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. However, there is little data about fracture prevention efficacy and long-term adverse effects in subjects with reduced renal function.",
"   </p>",
"   <p>",
"    Retrospective analyses of the Fracture Intervention Trial (FIT) data and pooled data from nine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    studies revealed that 7 to 10 percent of subjects had severe renal impairment (defined as an eGFR &lt;30 to 45",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and 37 to 45 percent had moderate impairment (eGFR &ge;30 to 59",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    as estimated by the Cockcroft-Gault formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Compared with placebo treated women,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and risedronate increased BMD and prevented vertebral fracture regardless of degree of renal impairment.",
"   </p>",
"   <p>",
"    There were no differences in the adverse event rate between subjects with normal or reduced renal function in either study. In the FIT study, there was a small increase in creatinine during the three year study, but the increase was similar in those with and without reduced renal function (mean increase in both groups 0.01",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.10) and in those taking placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    . There was no increase in serum creatinine in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    studies (mean exposure of two years).",
"   </p>",
"   <p>",
"    Thus, oral bisphosphonates appear to be effective in individuals with moderately reduced renal function. However, women with serum creatinine &gt;1.27",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (112",
"    <span class=\"nowrap\">",
"     micromol/liter)",
"    </span>",
"    or serum PTH &gt;85",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    were excluded from participation in FIT, ie, women with renal dysfunction resulting in secondary hyperparathyroidism were not treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    . Therefore, there is inadequate data with regard to fracture prevention efficacy in those with more severe kidney disease resulting in secondary hyperparathyroidism and in end-stage renal failure.",
"   </p>",
"   <p>",
"    With progression of renal failure, serum PTH concentrations rise and the bone morphologic features of renal osteodystrophy (osteitis fibrosis cystica [due to secondary hyperparathyroidism], osteomalacia, adynamic bone disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mixed osteodystrophy), rather than osteoporosis, become predominant. The principal goal with regard to bone disease in patients with significant renal dysfunction is to prevent or manage renal osteodystrophy, largely by controlling secondary hyperparathyroidism, preventing oversuppression of PTH, which can lead to adynamic bone disease, and treating acidosis and vitamin D deficiency. In this setting, the diagnosis of osteoporosis should be made only after excluding renal osteodystrophy. The diagnosis and management of renal osteodystrophy and secondary hyperparathyroidism are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28343?source=see_link\">",
"     \"Bone biopsy and the diagnosis of renal osteodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ALENDRONATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Alendronate is also effective for African-American women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/14\">",
"     14",
"    </a>",
"    ] and for men with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized, clinical trials have demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    increases bone mineral density (BMD) and decreases the risk of osteoporotic fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. The optimal suppression of bone turnover and increase in bone density with minimal side effects is achieved at an alendronate dose of approximately 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef63767 \" href=\"mobipreview.htm?38/13/39134\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Fracture Intervention Trial (FIT), one of the largest trials in postmenopausal women with low bone density, there were two study arms comparing daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and placebo.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the vertebral fracture study arm, in 2027 women with a low femoral neck bone density (T-score &lt;-2.1) and at least one vertebral fracture at baseline,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      therapy increased femoral neck and spine BMD by 4.1 and 6.2 percent, respectively, and reduced the risk of vertebral fracture by approximately 50 percent, and hip and wrist fractures by approximately 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clinical fracture study arm included 4432 postmenopausal women with a low femoral neck bone density (T-score &lt;-1.6), but no vertebral fracture at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       Alendronate",
"      </a>",
"      therapy (5 mg per day for two years followed by 10 mg per day for the remainder of the trial) increased bone mineral density and reduced the risk of vertebral fractures (diagnosed by x-ray) by 44 percent, but did not significantly decrease the risk of hip, wrist, or all clinical fractures. However, in a subgroup of the subjects who had osteoporosis (baseline femoral neck T score of -2.5 or less), alendronate reduced the risk of hip and all clinical fractures by 56 and 36 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a meta-analysis of 11 trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    therapy in postmenopausal women, the relative risk (RR) of vertebral fractures in patients given the 10 mg dose was 0.55 (95% CI 0.45-0.67) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/22\">",
"     22",
"    </a>",
"    ]. The RR of nonvertebral fractures in patients given 10 mg of alendronate was 0.84 (95% CI 0.74-0.94). Improvements in bone density with alendronate increased with both dose and time. The risk of side effects was similar for 5 mg and doses &ge;10 mg. For all doses combined, there was no evidence of an excess risk of gastrointestinal side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Elderly women",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    appears to be equally effective in older and younger postmenopausal women with osteoporosis. In the FIT trial, alendronate reduced fracture rate even in women at highest risk for fracture (older than age 75 years, or severe osteoporosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/23\">",
"     23",
"    </a>",
"    ]. The reduction in fracture rate was similar in women older and younger than age 75 years, suggesting that even elderly women benefit from treatment of their osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/23\">",
"     23",
"    </a>",
"    ]. In a randomized, trial of 327 elderly women with osteoporosis in long-term care facilities, alendronate increased bone density when compared with placebo and was well-tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Long-term efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    is well tolerated and effective for at least 10 years. In an extension study of 247 postmenopausal women with osteoporosis, alendronate (5 or 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    resulted in continued increases in bone mineral density over a 10-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The total 10-year increase in lumbar spine density was 13.7 and 9.3 percent for the 10 and 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      groups, respectively. Increases in bone mineral density were greatest in the initial five years of the study (10 and 6.8 percent for the 10 and 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      groups, respectively).",
"     </li>",
"     <li>",
"      Fractures were not a primary outcome, and were captured only as adverse events. However, fracture reduction appeared to be maintained throughout the study.",
"     </li>",
"     <li>",
"      The safety and tolerability of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      were similar to those of placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Weekly dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weekly administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    is as effective as daily dosing. In a two-year randomized trial comparing once-weekly (70 mg) and daily alendronate (10 mg), the regimens were similar for increasing BMD and had similar low rates of side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/26\">",
"     26",
"    </a>",
"    ]. The rates of clinical fractures were captured as adverse experiences, and were similar among the groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although estrogen and bisphosphonates both inhibit bone resorption, they do so through different mechanisms. Their effects on BMD appear to be similar, and the combination of the two may be slightly more effective, although the additional benefit is modest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. The rate of bone loss may be accelerated after withdrawing estrogen therapy, but not after withdrawal of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    has a greater effect on bone mineral density and markers of bone turnover, when compared with either drug alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the benefit of combined versus monotherapy for fracture reduction is unknown.",
"   </p>",
"   <p>",
"    We do not suggest combination bisphosphonate-estrogen therapy or bisphosphonate-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    therapy, as the additional benefits are small. In addition, the indications for using estrogen have been diminished since the results of the Women's Health Initiative were published. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .) Furthermore, there is theoretical concern that combination antiresorptive therapy could over-suppress bone turnover and cause increased skeletal fragility. (See",
"    <a class=\"local\" href=\"#H50\">",
"     'Atypical femur fractures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     With PTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because teriparatide (PTH) stimulates bone formation and bisphosphonates reduce bone resorption, it has been hypothesized that combining the two therapies would increase bone density more than either therapy alone. However, addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    to teriparatide therapy provides no additional benefits for bone mineral density, and reduces the anabolic effect of teriparatide in both women and men. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H17#H17\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Combination therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of osteoporosis in men\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For treatment of osteoporosis, a 10 mg daily or 70 mg once weekly formulation is available. Most patients prefer the convenience of the once-weekly regimen.",
"     </li>",
"     <li>",
"      For prevention of osteoporosis: 5 mg daily or 35 mg once-weekly tablets.",
"     </li>",
"     <li>",
"      Generic formulations have been available since 2008.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Instructions for administration are found above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Oral regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RISEDRONATE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    (Actonel) improves BMD, reduces fracture risk, and is well-tolerated in postmenopausal women with osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This was illustrated in the Vertebral Efficacy with Risedronate (VERT) study of 2458 postmenopausal women with osteoporosis (either two or more vertebral fractures, or one vertebral fracture and lumbar spine T-score of -2.0 or less) who were randomly assigned to risedronate (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for three years with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone density at the lumbar spine, femoral neck, and trochanter increased by 5.4, 1.6, and 3.3 percent, respectively, in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      group, as compared with 1.1 percent, -1.2 percent, and -0.7 percent, respectively, in the placebo group.",
"     </li>",
"     <li>",
"      The risk of vertebral and nonvertebral fractures was reduced by 41 and 39 percent, respectively, with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      . The three-year rates of new vertebral fractures with risedronate versus placebo were 11 and 16 percent, respectively, and 5 and 8 percent, respectively, for nonvertebral fractures.",
"     </li>",
"     <li>",
"      Gastrointestinal and other adverse effects occurred with similar (low) frequency in both groups.",
"     </li>",
"     <li>",
"      In a two-year extension study in 265 subjects, the effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      on vertebral fracture and bone mineral density appeared to be maintained [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second three-year randomized trial in postmenopausal women with osteoporosis, a similar overall reduction in vertebral and nonvertebral fracture risk was observed; the vertebral fracture risk reduction was evident during the first year of the trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    reduces the risk of hip fracture among elderly women with confirmed osteoporosis, but not among elderly women selected primarily on the basis of risk factors. This was illustrated in a randomized trial of 5445 women aged 70 to 79 years with osteoporosis (Group 1), and 3886 women aged 80 years or older selected primarily on the basis of nonskeletal risk factors (poor gait, smoking, propensity to fall) (Group 2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/38\">",
"     38",
"    </a>",
"    ]. Although risedronate decreased overall hip fracture risk by 30 percent, the rate of hip fracture was reduced only in Group 1 (1.9 and 3.2 percent of women experienced hip fracture in the drug and placebo groups, respectively, RR 0.6), but not in Group 2, where hip fracture rate was similar (4.2 and 5.1 percent of women, respectively).",
"   </p>",
"   <p>",
"    A meta-analysis of eight randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    confirmed the fracture risk reduction in early postmenopausal women and in women with established osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/33\">",
"     33",
"    </a>",
"    ]. For risedronate versus placebo, the pooled relative risk (RR) for vertebral and nonvertebral fractures with risedronate was 0.64 and 0.73, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Long-term efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    is effective and well-tolerated for up to seven years, as illustrated in a trial of 164 women, in whom improvements in BMD continued over the seven years of therapy, with no apparent loss of fracture risk reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Weekly dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    (35 mg) is as effective and well tolerated as daily administration of 5 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. An enteric-coated delayed-release formulation of risedronate is also available for weekly administration (35 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/43\">",
"     43",
"    </a>",
"    ]. Unlike immediate-release risedronate and other oral bisphosphonates, delayed-release risedronate is taken immediately after breakfast and with at least four ounces of water. Patients should remain upright (sitting or standing) for at least 30 minutes. Compared with risedronate 5 mg daily, increases in bone density at the lumbar spine and hip were similar with the delayed-release formulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Monthly dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monthly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    (150 mg once monthly) has similar efficacy for increasing spine and hip BMD as daily administration of 5 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Addition of estrogen therapy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    may provide a modest additional benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/46\">",
"     46",
"    </a>",
"    ], but we do not suggest the routine use of combined risedronate-estrogen therapy, given the known risks of estrogen therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Formulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    formulations available for clinical use include: a daily (5 mg), weekly (35 mg), weekly delayed-release (35 mg), and monthly (single 150 mg tablet) dose (all used for the treatment and prevention of postmenopausal and glucocorticoid-induced osteoporosis).",
"   </p>",
"   <p>",
"    In addition, a 30 mg once daily formulation is available for the treatment of Paget disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10602?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of Paget disease of bone\", section on 'Nitrogen-containing bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    is also effective for men with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of osteoporosis in men\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Instructions for administration are found below. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Oral regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Alendronate versus risedronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    have been compared in one prospective randomized and some retrospective observational trials. In the randomized trial, alendronate increased bone density more than risedronate at all sites after 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/47\">",
"     47",
"    </a>",
"    ]. Results persisted in year two of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/48\">",
"     48",
"    </a>",
"    ]. However, there were no differences in the incidence of fractures, which were reported only as adverse events. In one observational study, treatment with risedronate was associated with a decreased risk of fracture in the first year of therapy compared with alendronate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/49\">",
"     49",
"    </a>",
"    ]. However, this study was limited by the inability to accurately characterize fracture risk at baseline between the two groups. Thus, although alendronate may have a greater effect on bone mineral density when compared with risedronate, the clinical relevance of this finding is unclear. A prospective randomized trial with fracture as a defined endpoint is necessary to determine if there is a difference in fracture prevention efficacy between the two bisphosphonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     IBANDRONATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     Ibandronate",
"    </a>",
"    is approved for prevention and treatment of osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/50\">",
"     50",
"    </a>",
"    ]. A daily regimen (2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and intermittent regimen (20 mg every other day for 12 doses every three months) are equally effective for increasing bone mineral density and reducing vertebral fracture risk, when compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/51\">",
"     51",
"    </a>",
"    ]. However, a significant reduction in hip fracture was not seen. The daily formulation was approved for use in 2003, but was never marketed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Monthly dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A once-monthly 150 mg oral formulation is available for both prevention and treatment of osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In a trial of 1609 postmenopausal women with osteoporosis randomly assigned to receive daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (2.5 mg), ibandronate 50 + 50 mg once-monthly (single doses given on consecutive days), 100 mg once-monthly, or 150 mg once-monthly, the following results were seen after two years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases in lumbar spine bone density were observed in all treatment groups (5.0, 5.3, 5.6, and 6.6 percent in the daily, 50 + 50 mg, 100 mg, and 150 mg groups, respectively). The increases in the 50 + 50 and 100 mg group were not statistically different from the daily 2.5 mg group, while the increase in the 150 mg group was significantly greater than the 2.5 mg daily group.",
"     </li>",
"     <li>",
"      Similar results were seen for hip bone density.",
"     </li>",
"     <li>",
"      No differences in adverse events were noted.",
"     </li>",
"     <li>",
"      Fracture data were not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, monthly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (150 mg) appears to improve BMD more than daily administration (2.5 mg). The manufacturer of the monthly formulation will also provide monthly reminders for patients. The monthly formulation may therefore increase overall compliance with therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of consistent clinical trial data that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    reduces hip fracture risk, we continue to suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    as our first choice for bisphosphonate therapy in patients at high risk for fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Intravenous",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intravenous formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (3 mg every three months) appears to improve BMD to a similar or greater degree than daily oral ibandronate (2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. This formulation provides an alternative option for patients who cannot tolerate oral bisphosphonates, or who have difficulty with dosing requirements, including an inability to sit upright for 30 to 60 minutes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to swallow a pill.",
"   </p>",
"   <p>",
"    Meta-analyses of phase III studies, in which fracture data were collected as adverse effects, have shown a reduction in nonvertebral fractures with higher doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (pooled data from IV dosing [2 or 3 mg every two to three months] and oral dosing [150 mg monthly]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. However, there is no direct fracture efficacy data for IV ibandronate. In the absence of this data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    is our first choice for IV bisphosphonate therapy in patients who cannot tolerate oral therapy. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Zoledronic acid'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ZOLEDRONIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    (ZA) is another intravenous bisphosphonate, which is administered once yearly (as a 15 minute infusion) rather than quarterly. It increases BMD and reduces fracture risk. It is approved in many countries, including the United States, for the treatment of osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of ZA for the treatment of osteoporosis is demonstrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of five regimens of intravenous ZA (1 to 4 mg administered as one to four doses over one year), lumbar spine BMD increased similarly in all five groups (4.3 to 5.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Health Outcomes and Reduced Incidence with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       Zoledronic Acid",
"      </a>",
"      Once Yearly (HORIZON) Pivotal Fracture Trial, 7765 postmenopausal women with osteoporosis were randomly assigned to 5 mg of ZA or placebo, administered intravenously (infused over 15 minutes) once yearly for three consecutive years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/60\">",
"       60",
"      </a>",
"      ]. BMD increased at the spine, total hip, and femoral neck and markers of bone turnover decreased in the ZA group compared with placebo.",
"      <br/>",
"      <br/>",
"      In addition, there was a significant reduction in fracture. The three-year incidence of vertebral fracture was 10.9 percent in the placebo group versus 3.3 percent in the ZA group, a reduction of 70 percent (RR 0.30, 95% CI 0.24-0.38). The incidence of hip fracture was 2.5 and 1.4 percent in the placebo and ZA groups, respectively, a 41 percent reduction (hazard ratio 0.59, 95% CI 0.42-0.83).",
"     </li>",
"     <li>",
"      In the HORIZON Recurrent Fracture Trial, 2127 men and women with hip fracture were randomly assigned to receive yearly ZA (5 mg) or placebo within three months of surgical repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/61\">",
"       61",
"      </a>",
"      ]. Subjects also received vitamin D (50,000 to 125,000 IU 14 days prior to infusion, if 25OHD concentration was &lt;15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or unknown, and 800 to 1200 IU daily thereafter) and calcium. After a median follow-up of 1.9 years, new fractures occurred in 8.6 and 13.9 percent of individuals in the ZA and placebo groups, respectively, representing a relative risk reduction of 35 percent (HR 0.65, 95% CI 0.5-0.8). All-cause mortality, a secondary safety endpoint, was lower in the ZA compared with placebo group (HR 0.72, 95% CI 0.56-0.93).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there were no differences in serious adverse events or discontinuation because of adverse events, ZA was associated with an expected increase in post-infusion flu-like symptoms and mild transient hypocalcemia in both HORIZON studies. In addition, in the Pivotal Fracture Trial there was an unexpected increase in atrial fibrillation, which was not seen in the Recurrent Fracture Trial. There were no long-term adverse effects on renal function. A thorough search of the safety database yielded two cases of potential osteonecrosis of the jaw, one in the ZA group and one in the placebo group. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, in the HORIZON studies, yearly IV ZA was associated with an improvement in BMD, a decrease in spine and hip fractures in postmenopausal women with osteoporosis (Pivotal Fracture Trial), and a decrease in recurrent clinical fractures in men and women with recent hip fracture (Recurrent Fracture Trial). The infusions were relatively well tolerated, given the known association between intravenous bisphosphonates and flu-like symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;IV ZA offers an alternative option for individuals who cannot tolerate oral bisphosphonates or who find the yearly dosing regimen more convenient. ZA must be infused over a period of at least 15 minutes.",
"   </p>",
"   <p>",
"    Duration of action, ideal duration of therapy, and long-term safety (&gt;three years) have not been firmly established. In a two-year interim analysis of a three-year trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (single dose of 5 mg) versus placebo in postmenopausal women with osteopenia, markers of bone turnover remained decreased and BMD remained higher in the ZA group compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/62\">",
"     62",
"    </a>",
"    ]. These data suggest that a single 5 mg dose of ZA may have a sustained benefit for up to two years and that less frequent dosing may be needed. However, the antifracture efficacy of such a regimen is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     OTHER BISPHOSPHONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other bisphosphonates are available but are used less often (or not at all) for osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Etidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/23/22902?source=see_link\">",
"     Etidronate",
"    </a>",
"    was the first bisphosphonate used in the treatment of osteoporosis. It increased BMD and decreased vertebral but not nonvertebral fractures, and it was never approved for treating postmenopausal osteoporosis. In addition, there was concern that long-term use may cause osteomalacia. Therefore, it has been superseded by other bisphosphonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Tiludronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/51/38709?source=see_link\">",
"     Tiludronate",
"    </a>",
"    , an effective therapy for Paget disease of bone, has not been demonstrated to be effective for the treatment or prevention of osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10602?source=see_link\">",
"     \"Treatment of Paget disease of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Pamidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    , an intravenous preparation, has been used primarily for the treatment of hypercalcemia and prevention of skeletal complications in multiple myeloma, breast cancer, and prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link&amp;anchor=H5#H5\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    is also effective for osteoporosis, and has been used for patients with osteoporosis who could not tolerate oral bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/63\">",
"     63",
"    </a>",
"    ]. However, it has been superseded by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    and in some cases intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial BMD measurements are performed to assess the clinical response to therapy. BMD that is stable or improving is evidence for a treatment response. The finding of a clinically significant BMD decrease in a treated patient should trigger additional evaluation for contributing factors, which may include poor adherence to therapy, inadequate gastrointestinal absorption, inadequate intake of calcium and vitamin D, or the development of a disease or disorder with adverse skeletal effects. Calcium and vitamin D supplementation should be verified, and some evaluation for secondary causes of bone loss should be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of dual-energy x-ray absorptiometry\", section on 'Interpretation of BMD changes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient is otherwise well and taking the drug and supplements correctly, the correct action is controversial. Some clinicians believe that the decrease in BMD truly reflects a treatment failure and would consider modification of the primary treatment for the osteoporosis. Others believe that the decline in BMD does not necessarily imply inadequate therapy, but could be ascribed to measurement error, especially if bone turnover is appropriately suppressed, and would repeat BMD one year later, taking action only if the decline is reaffirmed.",
"   </p>",
"   <p>",
"    There are few clinical trial data to support either action. When the change in BMD is small (less than 5 percent) and the patient is taking the drug correctly and has a negative evaluation for contributing factors, we suggest continuing the same therapy and repeating the BMD two years later. When the decline in BMD is &gt;5 percent, we suggest switching from an oral bisphosphonate to an intravenous bisphosphonate (typically",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ). If the lack of response is related to poor absorption, switching to an intravenous preparation should result in a more favorable response.",
"   </p>",
"   <p>",
"    Another alternative is switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/22/6501?source=see_link\">",
"     recombinant human parathyroid hormone",
"    </a>",
"    (PTH). We typically favor intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    over PTH because PTH is more costly and is administered by daily subcutaneous injection rather than a once yearly intravenous infusion for zoledronic acid. However, switching to PTH is a good option for patients with severe osteoporosis (T score &lt;-2.5 and at least one fragility fracture) who continue to fracture on oral bisphosphonates. PTH (teriparatide) is effective in increasing BMD in women previously treated with bisphosphonates, although the improvement may be less than in women not previously exposed to bisphosphonates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H19#H19\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'PTH after bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11271424\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no consensus on how long to continue bisphosphonate therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    have demonstrated efficacy for 10, 7, and 6 years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/25,39,64\">",
"     25,39,64",
"    </a>",
"    ]. Stopping therapy after three to five years (a \"drug holiday\") may be reasonable for some women, as there appears to be residual BMD and fracture benefit. For patients taking alendronate or risedronate for five years or who received zoledronic acid once yearly for three years, who have a stable BMD, no previous vertebral fractures, and who are at low risk for fracture in the near future, we suggest discontinuing the drug.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration performed an analysis of the three major bisphosphonate extension studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In two of these trials (described in detail below), postmenopausal women who had taken bisphosphonates for three to five years were randomly assigned to continue bisphosphonates or switch to placebo, and they were followed for three to five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/64,67,68\">",
"     64,67,68",
"    </a>",
"    ]. Femoral neck bone mineral density was maintained in patients who continued to take bisphosphonates. In patients randomly assigned to placebo, femoral neck BMD decreased during the first one to two years of placebo and then stabilized and remained higher than baseline. Bone density of the spine continued to increase in groups taking bisphosphonates and placebo. In a pooled analysis of all data on osteoporotic fractures (vertebral and nonvertebral combined), fracture rates in patients who received bisphosphonate treatment for six or more years were similar to those in patients who switched to placebo (9.3 to 10.6 versus 8.0 to 8.8 percent). The fracture assessment was limited by the small sample size in the extension trials, differences in study design of the individual trials, and post hoc nature of the analysis. Additional data examining of the risk of fracture after discontinuation of bisphosphonate therapy are needed to better define the duration of therapy for individual patients and for the specific bisphosphonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11271460\">",
"    <span class=\"h2\">",
"     Alendronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;For some women, stopping",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    after five years may be reasonable, as there appears to be a residual benefit on BMD and fractures for up to five years. This was illustrated in the Fracture Intervention Trial Long-term Extension (FLEX), in 1099 postmenopausal women who had previously received alendronate for five years in the Fracture Intervention Trial (FIT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the completion of FIT, women were randomly assigned to an additional five years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (5 or 10 mg daily) or placebo. Women at highest risk for fracture were excluded from FLEX (those with FLEX baseline T-scores either below -3.5, or below their FIT baseline). The BMD, bone marker, and fracture data in the women who continued alendronate for 10 years were similar to those described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women who were switched to placebo after five years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A gradual decline in BMD (-2.4 and -3.7 percent, at the total hip and spine, respectively), but mean BMD remained at or higher than levels 10 years earlier.",
"     </li>",
"     <li>",
"      A gradual rise in biochemical markers of bone turnover. However, the values were still lower than 10 years previously.",
"     </li>",
"     <li>",
"      No significant difference between placebo and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      groups in the rate of nonvertebral (18.9 and 19.0 percent) or morphometric vertebral fractures detected by lateral spine radiographs (11.3 and 9.8 percent). However, there was a slightly higher risk of vertebral fractures clinically detected by participant's clinician and spine radiograph (5.3 and 2.4 percent for placebo and alendronate, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two groups did not differ in adverse events. No one developed osteonecrosis of the jaw. Bone biopsy showed no qualitative abnormalities in either group.",
"   </p>",
"   <p>",
"    In a post hoc analysis of women without vertebral fracture at FLEX baseline, continuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    compared with placebo reduced the number of participants with nonvertebral fracture in the subgroup of women with FLEX baseline femoral neck (FN) T-scores of -2.5 or less (16 versus 21 participants) but not with T-scores better than -2.5 (45 versus 27 participants) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/69\">",
"     69",
"    </a>",
"    ]. This study was limited by the small numbers of nonvertebral fractures within the subgroups and the post hoc nature of the analysis.",
"   </p>",
"   <p>",
"    In summary, stopping",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    after five years of therapy results in a gradual decline in BMD and increase in biochemical markers of bone turnover, but no significantly higher risk of fracture (except for clinical vertebral fracture) in most women. Thus, stopping bisphosphonate therapy after five years may be reasonable for some low-risk women (eg, no history of fracture and T-scores better than -2.5) as long as they are followed carefully by BMD and assessment of risk factors.",
"   </p>",
"   <p>",
"    However, the FLEX trial does not address the impact of stopping therapy in women at highest risk for fracture (T-score below -3.5) as they were excluded from the trial. In these women, we suggest continuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    for up to 10 years, as BMD and fracture benefits were maintained with no increased risk of adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11271490\">",
"    <span class=\"h2\">",
"     Risedronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized extension trial data comparing continuous treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    versus switching to placebo. When risedronate is discontinued after three years, its beneficial effects on BMD and markers of bone turnover appear to revert partially or completely within one year, as reported in an extension of the VERT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/35,68\">",
"     35,68",
"    </a>",
"    ]. In this observational extension study, women who received risedronate or placebo for three years were reassessed one year after stopping therapy (but continuing vitamin D supplementation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/68\">",
"     68",
"    </a>",
"    ]. BMD of the lumbar spine and femoral neck decreased (0.83 and 1.23 percent, respectively) in the group previously taking risedronate, although mean values remained higher than baseline (lumbar spine) and placebo (lumbar spine and femoral neck). However, markers of bone turnover returned to baseline and were the same as the placebo group within one year. Nonetheless, the incidence of new vertebral fractures in patients previously treated with risedronate remained lower (6.5 versus 11.6 percent).",
"   </p>",
"   <p>",
"    In the absence of direct evidence, our suggestion for discontinuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    is based upon indirect evidence from the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    extension trial (FLEX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/67\">",
"     67",
"    </a>",
"    ]. We typically discontinue risedronate after five years of use in low-risk women (eg, no history of fracture and T-scores better than -2.5) as long as they are followed carefully by BMD and assessment of risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11271801\">",
"    <span class=\"h2\">",
"     Zoledronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an extension of the HORIZON Pivotal Fracture Trial described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/60\">",
"     60",
"    </a>",
"    ], a subset of women (n = 1233 of 3889) who had received ZA (5 mg yearly) for three years in the core study were randomly assigned to three additional years of ZA or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/64\">",
"     64",
"    </a>",
"    ]. The mean change in femoral neck BMD (the primary endpoint) from year three to six was +0.24 and -0.80 percent, respectively. The mean change in lumbar spine (a secondary endpoint) was +3.2 and +1.18, respectively. There were fewer morphometric vertebral fractures (a secondary endpoint) in the group that received ZA for six years (3 versus 6.2 percent, OR 0.51, 95% CI 0.26-0.95). However, the overall fracture event rate was low, reducing the precision of the analysis. There was no difference in the incidence of nonvertebral, clinical vertebral, or all clinical fractures. Markers of bone turnover remained below pretreatment values in both groups. A greater proportion of patients in the active treatment group had transient increases in serum creatinine (&gt;0.5",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    There were no cases of atypical fractures, and there was one case of osteonecrosis of the jaw in the group receiving ZA for six years. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These data suggest that the beneficial effects of a three year course of ZA (5 mg yearly) are maintained in the subsequent three years. Thus, the majority of patients who receive ZA once yearly for three years do not require subsequent infusions of ZA for at least the next three years. In patients at high risk for fractures (eg, existing vertebral fracture or femoral neck BMD T-score &lt;-2.5 after an initial course of therapy), continuing yearly ZA beyond three years may provide some benefit, but the potential benefits must be considered in light of the potential risks of long-term therapy. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Adverse effects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11271424\">",
"     'Duration of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11271520\">",
"    <span class=\"h2\">",
"     Length of holiday",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data to support one strategy over another for determining when to restart bisphosphonates after a drug holiday. In clinical practice, the decision to resume the drug is often based on a combination of factors, including duration of the holiday, decrease in BMD, clinical risk factors for fracture, and increase in markers of bone turnover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically restart bisphosphonates when there is persistent bone loss (approximately 5 percent) on at least two DXA measurements taken at least two years apart, using the same make and model DXA scanner. As an alternative, bisphosphonates can be restarted after a three to five year holiday in women who showed improvement during their initial course of bisphosphonates and did not have a previous fracture. Some clinicians restart therapy when markers of bone turnover have risen above the normal premenopausal range, although there is no evidence to support this practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=see_link&amp;anchor=H10#H10\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\", section on 'Drug holiday'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal (GI) side effects (reflux, esophagitis, esophageal ulcers) have been the primary concern for patients taking oral bisphosphonates. The incidence of these side effects is very low if proper administration instructions are followed. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Oral regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    From 1995 to 2009, the United States Food and Drug Administration (FDA) received reports of 34 patients in the US who received a diagnosis of esophageal cancer while taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    . In addition, 34 patients from Europe and Japan were reported as having esophageal cancer after using bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Results from observational studies are inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/75\">",
"     75",
"    </a>",
"    ]. Reports using data from European national registers and records of Medicare beneficiaries in the US have not shown an increased risk of esophageal cancer among individuals with osteoporosis or fracture who were receiving oral bisphosphonates compared with those who were not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Studies using data from the United Kingdom General Practice Research Database (UKGPRD) report conflicting results, as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-cohort study, over 46,000 bisphosphonate users were compared with a similar number of age and gender matched controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/78\">",
"       78",
"      </a>",
"      ]. Mean follow-up time was 4.5 and 4.4 years in the bisphosphonate and control cohorts, respectively. All of the bisphosphonate cohort and 9 percent of the control cohort received at least one prescription for oral bisphosphonates during follow-up. There was no difference in the risk of esophageal and gastric cancer combined or esophageal cancer alone (HR 1.07, 95% CI 0.77-1.49) between the two cohorts.",
"     </li>",
"     <li>",
"      In a nested case-control analysis, over 15,000 adults with gastrointestinal cancer (2954 patients with esophageal cancer) were compared with 77,750 controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/79\">",
"       79",
"      </a>",
"      ]. The mean observation period was 7.5 years. Compared with patients who did not receive a prescription for a bisphosphonate, those who received at least one prescription had an increased risk of esophageal cancer (adjusted relative risk 1.30, 95% CI 1.02-1.66). In addition, the risk of esophageal cancer was significantly higher in patients receiving 10 or more prescriptions than in those that received one to nine prescriptions (RR 1.93 and 0.66, respectively), and the risk was also increased with duration of use. The risk of gastric or colorectal cancers was not increased after prescription of bisphosphonates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The discrepancy in the findings may be explained by differences in study design and duration of follow-up. Further research is required to confirm or refute the potential association, particularly the association between esophageal cancer and different types and formulations of bisphosphonates. The reasons for any potential association of esophageal cancer and bisphosphonates are not understood, although crystalline material similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    has been identified in biopsies of patients with erosive esophagitis, suggesting a possible mechanism for chronic inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. At present, the FDA recommends that bisphosphonates not be used in patients with Barrett's esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Alendronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials, the incidence of upper GI problems in women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/19,82\">",
"     19,82",
"    </a>",
"    ] or once weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/83\">",
"     83",
"    </a>",
"    ] was not different from those receiving placebo. However, pill-induced esophagitis and esophageal ulcers can occur, and may be disabling and require hospitalization or rarely lead to esophageal stricture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. In addition, endoscopically apparent gastric ulcers have been described in patients receiving a bisphosphonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/86\">",
"     86",
"    </a>",
"    ]. The risk may be potentiated by concomitant use of a nonsteroidal antiinflammatory drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal complications are infrequent if patients follow the recommendations outlined above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/15,17-19\">",
"     15,17-19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Oral regimen'",
"    </a>",
"    above.) There has been concern that these complications may be more frequent in ordinary practice than in clinical trials, because patients with dyspepsia were excluded from the trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/88\">",
"     88",
"    </a>",
"    ]. However, in a study of 72 patients who discontinued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    because of gastrointestinal side effects and who were then randomly assigned to a rechallenge with either alendronate or placebo, 15 percent of the patients taking alendronate and 17 percent of those taking placebo stopped treatment because of gastrointestinal (GI) side effects. These data suggest that many of the GI side effects seen reflect a high background incidence of GI complaints, rather than an alendronate-specific effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/89-91\">",
"     89-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Risedronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of upper GI side effects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    also appears to be low.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In clinical trials, the incidence of GI side effects was not different from placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a pooled analysis of nine clinical trials that included 10,068 patients randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo for up to three years, upper GI tract adverse events were no different between the two groups (29.8 and 29.6 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/92\">",
"       92",
"      </a>",
"      ]. Unlike clinical trials with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , patients with active GI disease were not excluded from the studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37078?source=see_link\">",
"       \"Medication-induced esophagitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the risk of heartburn, reflux, esophagitis, and ulcers appears to be low with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , even in patients with a history of GI symptoms.",
"   </p>",
"   <p>",
"    The enteric coated delayed-release formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    may cause more lower GI side effects than risedronate (5",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    In an unpublished trial comparing enteric coated delayed-release risedronate (35 mg weekly) with daily risedronate (5 mg), diarrhea (8.8 versus 4.9 percent) and abdominal pain (5.2 versus 2.9 percent) occurred more frequently in patients assigned to the delayed-release formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Risedronate versus alendronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical practice, some patients have fewer GI side effects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    . This observation is supported by the results of short-term endoscopic trials comparing the two drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. As an example, in a trial of 515 postmenopausal women randomly assigned to risedronate (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or alendronate (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for two weeks, significantly fewer patients in the risedronate group had endoscopically diagnosed gastric ulcers (4.1 percent versus 13.2 percent for alendronate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/95\">",
"     95",
"    </a>",
"    ]. In a third trial, in which much larger daily doses (30 to 40 mg) of bisphosphonates were taken for one month, the incidence of gastric ulcers (approximately 3 percent) was similar between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because most patients prefer the convenience of the once-weekly regimen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    are more typically administered weekly rather than daily. In one and two-year randomized trials directly comparing the effects of once weekly risedronate versus alendronate on bone density, there was no difference in the incidence of upper GI side effects (23 versus 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, in a population-based study of gastrointestinal side effects in 10,416 new users of weekly oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , there was no significant difference in rates of hospitalization for upper gastrointestinal bleeding after a mean of 88 days of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/98\">",
"     98",
"    </a>",
"    ]. There were also no differences between the two groups in the outpatient diagnosis of GI diseases (reflux, gastritis, peptic ulcer disease), GI symptoms (heartburn, nausea, vomiting, dyspepsia, abdominal pain), upper GI procedures, or use of proton pump inhibitors or H2-receptor antagonists.",
"   </p>",
"   <p>",
"    However, there was a significantly higher rate of switching between therapies in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    users (5.9 versus 4.0, adjusted HR 0.67, 95% CI 0.49-0.92), which is of uncertain significance. Among women with a known prior history of upper GI events,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    users had lower rates of endoscopy (HR 0.70, 95% CI 0.49-0.99).",
"   </p>",
"   <p>",
"    Thus, for postmenopausal women with osteoporosis, we suggest either weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    as the initial choice of bisphosphonate. For women with a history of gastroesophageal reflux or peptic ulcer disease, initial therapy with either risedronate or alendronate is also acceptable. For women with a history of GI intolerance to alendronate, risedronate can be substituted as some patients may have fewer GI side effects. Oral bisphosphonates should not be used at all in patients with Barrett's esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Flu-like symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous bisphosphonates are often associated with an acute-phase reaction within 24 to 72 hours of the infusion, characterized by low grade fever, myalgias, and arthralgias. Treatment with antipyretic agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ) generally improves the symptoms, and the recurrence of symptoms decreases with subsequent infusions.",
"   </p>",
"   <p>",
"    In the HORIZON trial, the most commonly reported side effects were fever, flu-like symptoms, myalgia, headache, and arthralgia, which occurred within three days after the first infusion in 32 percent of individuals in the ZA group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/60\">",
"     60",
"    </a>",
"    ]. Post-dose symptoms decreased in frequency in the ZA group after the second and third infusion (6.6 and 2.8 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with an oral bisphosphonate lowers serum calcium concentrations, but clinically important hypocalcemia has been reported only in patients with hypoparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/99\">",
"     99",
"    </a>",
"    ]. It might also be expected in patients with vitamin D or calcium deficiency.",
"   </p>",
"   <p>",
"    In the HORIZON trial, hypocalcemia (calcium &lt;8.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.075",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    occurred more commonly with intravenous ZA than with placebo (1.3 versus 0.02 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/60\">",
"     60",
"    </a>",
"    ]. Hypocalcemia was noted 9 to 11 days post infusion and was reported to be transient and asymptomatic. However, hypocalcemia may be more severe and prolonged in individuals who are vitamin D deficient at the time of IV treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'IV regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Musculoskeletal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, some patients have experienced severe musculoskeletal pain (bone, joint,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muscle pain) within days, months, or years after starting a bisphosphonate, and symptoms do not always resolve completely with discontinuation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. An alert by the US Food and Drug Administration advises clinicians prescribing bisphosphonates to discuss musculoskeletal symptoms with their patients, and patients should promptly contact their doctor if such symptoms occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are not recommended for use in patients with creatinine clearance below 30 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ) to 35 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , ZA)",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    There have been isolated reports of renal impairment and acute renal failure after ZA administration, particularly in patients with multiple myeloma but also rarely in those treated for osteoporosis and those receiving concurrent diuretic therapy. Prior to each ZA infusion, clinicians should measure serum creatinine and make sure that patients are adequately hydrated. ZA should be infused over a period of at least 15 minutes. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'IV regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Ocular side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular side effects including pain, blurred vision, conjunctivitis, uveitis, and scleritis have been reported with most bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/105\">",
"     105",
"    </a>",
"    ]. However, these complications appear to be rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/60,106-108\">",
"     60,106-108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Osteonecrosis of the jaw",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis of the jaw (ONJ, avascular necrosis of the jaw), often associated with pain, swelling, exposed bone, local infection, and pathologic fracture of the jaw, has been described in patients receiving chronic bisphosphonate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. Risk factors for developing ONJ include intravenous bisphosphonates, cancer and anti-cancer therapy, duration of exposure, dental extractions, dental implants, poorly fitting dentures, glucocorticoids, smoking, and preexisting dental disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/109,111-113\">",
"     109,111-113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most cases have been in cancer patients or in patients with a compromised immune system (particularly multiple myeloma and metastatic breast cancer) who were treated with high doses of intravenous bisphosphonates, cases have been noted in patients with postmenopausal osteoporosis taking oral bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. It has been estimated that the risk of ONJ is approximately 1 in 10,000 to 1 in 100,000 patient-years in patients taking oral bisphosphonates for osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/109,116,117\">",
"     109,116,117",
"    </a>",
"    ]. There is little data on the risk of ONJ in patients using intravenous bisphosphonates at doses recommended for the treatment of osteoporosis. In two clinical trials of ZA versus placebo for the treatment of osteoporosis, there were two potential cases of ONJ (one in each group). (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Zoledronic acid'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients initiating or receiving treatment with oral bisphosphonates for the treatment of osteoporosis, the American Society of Bone and Mineral Research recommends that clinicians discuss the risk, signs, and symptoms of ONJ, and the risk factors for developing ONJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/109\">",
"     109",
"    </a>",
"    ]. Although good oral hygiene and regular dental visits are encouraged, a dental visit prior to beginning oral bisphosphonates is not necessary.",
"   </p>",
"   <p>",
"    In patients already receiving oral bisphosphonates, there is particular concern for patients scheduled for invasive dental procedures that involve the jaw, such as extractions or implants.",
"   </p>",
"   <p>",
"    The American Association of Oral and Maxillofacial Surgeons suggest performing dentoalveolar surgery, such as extractions and implants, as usual in patients who have been treated with oral bisphosphonates for less than three years. However, if a patient has been treated for more than three years, they recommend discontinuing oral bisphosphonates for three months prior to performing the dental surgery and restarting when the bone has healed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/118\">",
"     118",
"    </a>",
"    ]. These criteria were chosen on the basis of clinical experience and observational data as to which patients are at higher risk for developing ONJ.",
"   </p>",
"   <p>",
"    However, there are no data to suggest that this would lower ONJ risk. In addition, bisphosphonates stay in bone for years, not months. But if a patient chooses to stop the bisphosphonate, it is unlikely that there would be adverse consequences on BMD or fracture risk.",
"   </p>",
"   <p>",
"    Potential complications and recommendations for patients receiving bisphosphonates for the treatment of malignancy are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates in general have not been associated with atrial arrhythmias. However, in the HORIZON Pivotal Fracture Trial, the number of patients who had arrhythmia, including serious atrial fibrillation (AF), was greater in the ZA compared with placebo group (1.3 versus 0.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/60\">",
"     60",
"    </a>",
"    ]. In contrast, an increase in atrial arrhythmia was not seen in the HORIZON Recurrent Fracture Trial, which included older individuals and identical dosing. In addition, an increase in atrial fibrillation was not noted in the HORIZON Pivotal Fracture Extension Trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/64\">",
"     64",
"    </a>",
"    ]. Hypocalcemia may be related to AF. However, most of the events occurred more than 30 days after the infusion, at which time mild, transient hypocalcemia would have resolved. Whether the acute-phase reaction contributes to the risk of AF is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This finding in the HORIZON Pivotal Fracture Trial prompted additional review, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of datasets from four randomized trials of bisphosphonates versus placebo for osteoporosis or fracture, bisphosphonates were associated with risk of atrial fibrillation serious adverse events (OR 1.47, 95% CI 1.01-2.14), but not all atrial fibrillation events (serious and non-serious; OR 1.14, 95% CI 0.96-1.36) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/120\">",
"       120",
"      </a>",
"      ]. In three trial datasets, there was no increase in the risk of stroke or cardiovascular mortality.",
"     </li>",
"     <li>",
"      In a population-based case-control study from Denmark, which evaluated 13,586 patients with atrial arrhythmia and 68,054 population controls, current, former, or new use of bisphosphonates (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/23/22902?source=see_link\">",
"       etidronate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      ) was not associated with an increased risk of atrial fibrillation or flutter (adjusted RR for current use compared with non-use 0.95, 95% CI 0.84-1.07) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another case-control study from the US (719 women with AF, 966 control subjects), ever use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      was associated with a higher risk of AF than never use (odds ratio [OR] 1.86, 95% CI 1.09-3.15) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/122\">",
"       122",
"      </a>",
"      ]. However, the risk of AF was increased in past (OR 3.27, 95% CI 1.43-7.47), not current users (OR 1.42, 95% CI 0.78-2.59). In addition, the risk was not temporally related to the interval since first prescription or dose of alendronate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, data on the potential increased risk of AF with bisphosphonates are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/120-127\">",
"     120-127",
"    </a>",
"    ]. However, the large observational study from Denmark and the absence of an association between current use and AF in the US case-control study suggest that the risk of AF from oral bisphosphonates is small, if it exists at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observed association between intravenous ZA and AF may be plausible, but the studies do not prove causality. Osteoporosis and AF are more common in the elderly and share similar risk factors, which may explain the reported findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. In the absence of more definitive data, the benefits of fracture prevention must be weighed against the potential risk of AF, and some caution should be employed when considering IV bisphosphonates for patients with serious underlying heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h3\">",
"     Atypical femur fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates inhibit bone resorption by suppressing osteoclast activity. Although clinical trial data clearly support the beneficial effect of bisphosphonates on the prevention of osteoporotic fracture, there is theoretical concern that prolonged therapy can lead to oversuppression of bone turnover (\"frozen bone\") and increased skeletal fragility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. In animal studies, high-dose bisphosphonate accumulation results in microscopic damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/131\">",
"     131",
"    </a>",
"    ]. Although similar findings do not appear to be common by histomorphometry in postmenopausal women on long-term bisphosphonate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/132\">",
"     132",
"    </a>",
"    ], individual cases of atypical fracture (particularly subtrochanteric fractures) and severely suppressed bone turnover have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/133-137\">",
"     133-137",
"    </a>",
"    ]. Typically, these cases describe younger women treated for several years with bisphosphonates who report a prodrome of mid-thigh pain, which may be accompanied by cortical thickening on plain radiographs obtained prior to fracture.",
"   </p>",
"   <p>",
"    The results from observational studies are mostly reassuring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/138-141\">",
"     138-141",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a national cohort study using the Danish National Hospital Discharge Register and National Prescription Database, the occurrence of subtrochanteric and diaphyseal femur fractures was similar to that of typical hip fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/138\">",
"       138",
"      </a>",
"      ]. In addition, the risk of typical and atypical fractures was reduced by adherence to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      . These findings suggest that the risk of atypical hip fracture in patients who take alendronate is more likely due to the presence of osteoporosis than to treatment with alendronate.",
"     </li>",
"     <li>",
"      In a population-based, nested case-control study from Canada, over 200,000 women &ge;68 years were evaluated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/139\">",
"       139",
"      </a>",
"      ]. Over the seven year study period, there were 9723 typical hip fractures and 716 atypical subtrochanteric or femoral shaft fractures. Compared with transient use (&lt;100 days), treatment with a bisphosphonate for five or more years was associated with a higher incidence of atypical fracture (adjusted OR 2.74, 95% CI 1.25-6.02) and a lower incidence of typical osteoporotic fractures (OR 0.76, 95% CI 0.63-0.93). Shorter durations of use were not associated with a significant increase in atypical fracture risk. Among the women with at least five years of bisphosphonate use, the estimated absolute risk of having an atypical femur fracture within one to two years was low (0.13 to 0.22 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that long-term use (&ge;five years) of bisphosphonates increases the risk of atypical fractures, but the absolute risk is low. Additional prospective studies are required to determine the subgroups of long-term users at highest risk for atypical fractures. Such data would also influence decisions on duration of therapy. Stopping bisphosphonate therapy after five years (with careful BMD and risk factor assessment follow-up) may be reasonable for women at low risk for fracture in the near future (eg, stable BMD, no previous vertebral fractures, absence of glucocorticoid therapy). However, in the vast majority of women who are at high risk for osteoporotic fracture, concern about oversuppression of bone turnover by bisphosphonates alone is",
"    <strong>",
"     not",
"    </strong>",
"    a reason to stop bisphosphonate therapy.",
"   </p>",
"   <p>",
"    In a 2010 report from an international task force appointed by the American Society of Bone and Mineral Research which was published before the study from Canada, the incidence of atypical fractures associated with bisphosphonate use was acknowledged to be very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/56/40842/abstract/142\">",
"     142",
"    </a>",
"    ]. Although a causal relationship has not been established, there was concern that the risk may rise with duration of bisphosphonate exposure. In addition to further research, the group recommended that clinicians and patients be educated about the possible association between atypical femur fractures and long-term (&gt;five years) bisphosphonate use. Further evaluation was recommended in women with new onset of groin or mid-thigh pain who have been taking bisphosphonates for more than 5 to 10 years. Conventional radiography is usually the initial imaging procedure, followed by MRI or bone scintigraphy if indicated. A patient with an atypical femur fracture in one leg is at risk for a fracture in the other leg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=see_link\">",
"       \"Patient information: Medicines for osteoporosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates, one of the available therapeutic options for the management of osteoporosis, inhibit bone resorption with relatively few side effects. As a result, they are widely used for the prevention and treatment of osteoporosis. Candidates for pharmacologic therapy for prevention and treatment are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For postmenopausal women with established osteoporosis or fragility fracture, we recommend pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Additional information about candidates for pharmacologic therapy is found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For treatment of osteoporosis in postmenopausal women, we suggest bisphosphonates as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      We prefer oral bisphosphonates (over other osteoporosis drugs) as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H40#H40\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Choice of bisphosphonate",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For postmenopausal women with osteoporosis, we suggest either weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      as the initial choice of bisphosphonate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      may be more convenient for patients, a reduction in hip fracture risk has not been established. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ibandronate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a history of gastroesophageal reflux or peptic ulcer disease, we also suggest initial therapy with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Oral bisphosphonates should not be used at all in patients with Barrett's esophagus. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Gastrointestinal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest an intravenous bisphosphonate formulation for patients who cannot tolerate oral bisphosphonates, or who have difficulty with dosing requirements, including an inability to sit upright for 30 to 60 minutes (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      is the only bisphosphonate that when administered intravenously has been demonstrated to prevent fractures in clinical trials. It is therefore our agent of choice. However, long-term safety data in patients with osteoporosis is lacking. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Zoledronic acid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Poor response",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The finding of a clinically significant BMD decrease in a treated patient should trigger additional evaluation for contributing factors, which may include poor adherence to therapy, inadequate gastrointestinal absorption, inadequate intake of calcium and vitamin D, or the development of a disease or disorder with adverse skeletal effects. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have a persistent decrease in BMD (&ge;5 percent) while correctly taking bisphosphonates orally, we suggest switching from an oral to an intravenous bisphosphonate, particularly if bone turnover is not adequately suppressed on oral treatment, rather than to a different bisphosphonate orally or teriparatide (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, in patients with severe osteoporosis (low bone mineral density [T score &lt;-2.5] and at least one fragility fracture) who continue to fracture while taking bisphosphonates orally, we suggest switching to teriparatide (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Response to therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"       \"Parathyroid hormone therapy for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Dental procedures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients scheduled to have an invasive dental procedure, we suggest not stopping bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, the risk of developing ONJ as a rare complication of intravenous or oral therapy should be discussed with patients.",
"      <br/>",
"      <br/>",
"      There are no data to suggest that discontinuing bisphosphonates for dental procedures would lower ONJ risk. In addition, bisphosphonates stay in bone for years, not months. However, if a patient chooses to stop the bisphosphonate, it is unlikely that there would be short-term adverse consequences on BMD or fracture risk. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Osteonecrosis of the jaw'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have taken bisphosphonates for five years and are at high risk of fracture (previous fractures, older age, frail, high risk for fall, etc), we suggest continuing therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11271424\">",
"       'Duration of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11271460\">",
"       'Alendronate'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Residual benefit after stopping therapy has not been demonstrated in this population. In addition, the benefits of continued therapy likely outweigh the risk of ONJ or atypical femur fractures, extremely rare complications. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have been taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      for five years, have a stable BMD, no previous vertebral fractures, and are at low risk for fracture in the near future, we suggest discontinuing the drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We then monitor BMD. The drug should be resumed if BMD decreases on at least two consecutive DXA measurements performed at least two years apart. (See",
"      <a class=\"local\" href=\"#H11271424\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      once yearly for three years and have a stable BMD, have no previous vertebral fractures, and are at low risk for fracture in the near future, we suggest discontinuing the drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We then monitor BMD. The drug should be resumed if BMD decreases on at least two consecutive DXA measurements performed at least two years apart. (See",
"      <a class=\"local\" href=\"#H11271424\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/1\">",
"      Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/2\">",
"      Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/3\">",
"      Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007; 120:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/4\">",
"      Patrick AR, Brookhart MA, Losina E, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 2010; 95:3251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/5\">",
"      Agrawal S, Krueger DC, Engelke JA, et al. Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 2006; 54:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/6\">",
"      Wark JD, Bensen W, Recknor C, et al. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5&nbsp;mg. Osteoporos Int 2012; 23:503.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA Drug Safety Newsletter, Postmarket Reviews - Volume 2, Number 2, 2009 file://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm167883.htm (Accessed on October 08, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/8\">",
"      Kuehn, BM. Zoledronic acid risks. JAMA 2009; 302:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/9\">",
"      Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/10\">",
"      Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/11\">",
"      Linnebur SA, Milchak JL. Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function. Am J Geriatr Pharmacother 2004; 2:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/12\">",
"      Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/13\">",
"      Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/14\">",
"      Bell NH, Bilezikian JP, Bone HG 3rd, et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002; 87:2792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/15\">",
"      Liberman UA, Weiss SR, Br&ouml;ll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/16\">",
"      Harris, ST, Gertz, BJ, Genant, HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993; 76:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/17\">",
"      Chesnut CH 3rd, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/18\">",
"      Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996; 101:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/19\">",
"      Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/20\">",
"      Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/21\">",
"      Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/22\">",
"      Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; :CD001155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/23\">",
"      Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997; 157:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/24\">",
"      Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 136:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/25\">",
"      Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/26\">",
"      Rizzoli R, Greenspan SL, Bone G 3rd, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/27\">",
"      Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995; 99:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/28\">",
"      Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/29\">",
"      Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/30\">",
"      Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999; 84:3076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/31\">",
"      Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/32\">",
"      Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/33\">",
"      Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/34\">",
"      Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/35\">",
"      Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/36\">",
"      Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/37\">",
"      Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/38\">",
"      McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/39\">",
"      Mellstr&ouml;m DD, S&ouml;rensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/40\">",
"      Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/41\">",
"      Gordon MS, Gordon MB. Response of bone mineral density to once-weekly administration of risedronate. Endocr Pract 2002; 8:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/42\">",
"      Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom 2003; 6:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/43\">",
"      In brief: delayed-release risedronate (Atelvia). Med Lett Drugs Ther 2011; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/44\">",
"      Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 2008; 42:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/45\">",
"      Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008; 19:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/46\">",
"      Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001; 86:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/47\">",
"      Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/48\">",
"      Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006; 91:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/49\">",
"      Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/50\">",
"      Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/51\">",
"      Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/52\">",
"      Pyon EY. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin Ther 2006; 28:475.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Highlights of prescribing information - Boniva. file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021455s011lbl.pdf (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/54\">",
"      Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/55\">",
"      Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/56\">",
"      Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/57\">",
"      Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008; 24:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/58\">",
"      Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009; 20:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/59\">",
"      Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/60\">",
"      Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/61\">",
"      Lyles KW, Col&oacute;n-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/62\">",
"      Grey A, Bolland MJ, Wattie D, et al. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009; 94:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/63\">",
"      Miller RG, Chretien KC, Meoni LA, et al. Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol 2005; 11:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/64\">",
"      Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27:243.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf (Accessed on June 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/66\">",
"      Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med 2012; 366:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/67\">",
"      Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/68\">",
"      Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/69\">",
"      Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010; 25:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/70\">",
"      Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/71\">",
"      Lewiecki EM, Bilezikian JP, Khosla S, et al. Osteoporosis update from the 2010 santa fe bone symposium. J Clin Densitom 2011; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/72\">",
"      McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/73\">",
"      Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/74\">",
"      Wysowski DK. Oral bisphosphonates and oesophageal cancer. BMJ 2010; 341:c4506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/75\">",
"      Andrici J, Tio M, Eslick GD. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer. Aliment Pharmacol Ther 2012; 36:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/76\">",
"      Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360:1789; author reply 1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/77\">",
"      Abrahamsen B, Pazianas M, Eiken P, et al. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 2012; 27:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/78\">",
"      Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/79\">",
"      Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341:c4444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/80\">",
"      Ribeiro A, DeVault KR, Wolfe JT 3rd, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998; 47:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/81\">",
"      Abraham SC, Cruz-Correa M, Lee LA, et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999; 12:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/82\">",
"      Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000; 160:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/83\">",
"      Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002; 77:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/84\">",
"      de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/85\">",
"      Levine J, Nelson D. Esophageal stricture associated with alendronate therapy. Am J Med 1997; 102:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/86\">",
"      Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Am J Gastroenterol 1997; 92:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/87\">",
"      Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/88\">",
"      Kelly R, Taggart H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 1997; 315:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/89\">",
"      Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000; 22:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/90\">",
"      Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002; 162:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/91\">",
"      Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002; 77:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/92\">",
"      Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/93\">",
"      McClung MR. BMD response to delayed-release risedronate 35 mg once-a-week formulation taken with or without breakfast. J Clin Densitom 2010; 13:132; Poster number 067.",
"     </a>",
"    </li>",
"    <li>",
"     Highlights of prescribing information - Atelvia file://www.wcrx.com/pdfs/pi/pi_atelvia.pdf (Accessed on April 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/95\">",
"      Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/96\">",
"      Thomson AB, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002; 29:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/97\">",
"      Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95:3112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/98\">",
"      Cadarette SM, Katz JN, Brookhart MA, et al. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int 2009; 20:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/99\">",
"      Schussheim DH, Jacobs TP, Silverberg SJ. Hypocalcemia associated with alendronate. Ann Intern Med 1999; 130:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/100\">",
"      Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003; 348:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/101\">",
"      Maalouf NM, Heller HJ, Odvina CV, et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006; 12:48.",
"     </a>",
"    </li>",
"    <li>",
"     The Pink Sheet 2005; 67:6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/103\">",
"      Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005; 165:346.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm (Accessed on September 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/105\">",
"      Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ 2012; 184:E431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/106\">",
"      Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med 2003; 348:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/107\">",
"      Fietta P, Manganelli P, Lodigiani L. Clodronate induced uveitis. Ann Rheum Dis 2003; 62:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/108\">",
"      Sharma NS, Ooi JL, Masselos K, et al. Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 2008; 359:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/109\">",
"      Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/110\">",
"      Fedele S, Porter SR, D'Aiuto F, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010; 123:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/111\">",
"      Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/112\">",
"      Khan AA, S&aacute;ndor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/113\">",
"      Favia G, Pilolli GP, Maiorano E. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol 2009; 36:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/114\">",
"      Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/115\">",
"      Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008; 121:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/116\">",
"      Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med 2006; 355:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/117\">",
"      Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/118\">",
"      Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/119\">",
"      Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 2010; 25:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/120\">",
"      Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009; 32:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/121\">",
"      S&oslash;rensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008; 336:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/122\">",
"      Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008; 168:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/123\">",
"      Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007; 356:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/124\">",
"      Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007; 357:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/125\">",
"      Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009; 265:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/126\">",
"      Bunch TJ, Anderson JL, May HT, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009; 103:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/127\">",
"      Grosso A, Douglas I, Hingorani A, et al. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009; 4:e4720.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Update of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates. file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm (Accessed on March 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/129\">",
"      Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/130\">",
"      Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010; 362:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/131\">",
"      Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/132\">",
"      Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007; 22:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/133\">",
"      Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/134\">",
"      Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93:2948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/135\">",
"      Odvina CV, Levy S, Rao S, et al. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010; 72:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/136\">",
"      Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011; 22:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/137\">",
"      Meier RP, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/138\">",
"      Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009; 24:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/139\">",
"      Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/140\">",
"      Kim SY, Schneeweiss S, Katz JN, et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2011; 26:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/141\">",
"      Schilcher J, Micha&euml;lsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/56/40842/abstract/142\">",
"      Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25:2267.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2030 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40842=[""].join("\n");
var outline_f39_56_40842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H53\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oral regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Timing of dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Calcium/vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IV regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Use in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALENDRONATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Elderly women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Long-term efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Weekly dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - With PTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RISEDRONATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Long-term efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Weekly dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Monthly dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Formulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Alendronate versus risedronate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      IBANDRONATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Monthly dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Intravenous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ZOLEDRONIC ACID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      OTHER BISPHOSPHONATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Etidronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Tiludronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Pamidronate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11271424\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11271460\">",
"      Alendronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11271490\">",
"      Risedronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11271801\">",
"      Zoledronic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11271520\">",
"      Length of holiday",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Alendronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Risedronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Risedronate versus alendronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Flu-like symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Musculoskeletal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Renal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Ocular side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Osteonecrosis of the jaw",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      - Atypical femur fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Choice of bisphosphonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Poor response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Dental procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2030|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/13/39134\" title=\"figure 1\">",
"      Alendronate dose osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28343?source=related_link\">",
"      Bone biopsy and the diagnosis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=related_link\">",
"      Patient information: Medicines for osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/22/10602?source=related_link\">",
"      Treatment of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_56_40843="Medications for spasticity";
var content_f39_56_40843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral medications commonly used for spasticity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Starting dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baclofen",
"       </td>",
"       <td>",
"        5 mg, three times daily",
"       </td>",
"       <td>",
"        80 mg daily, in divided doses",
"       </td>",
"       <td>",
"        Muscle weakness, sedation, dizziness, withdrawal syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tizanidine",
"       </td>",
"       <td>",
"        2 mg daily",
"       </td>",
"       <td>",
"        36 mg daily in divided doses",
"       </td>",
"       <td>",
"        Sedation, weakness, dizziness, reversible elevation of transaminase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diazepam",
"       </td>",
"       <td>",
"        2 mg twice daily or 5 mg at hs",
"       </td>",
"       <td>",
"        40 to 60 mg daily, in divided doses",
"       </td>",
"       <td>",
"        Sedation, cognitive impairment, dizziness, potential for dependence and withdrawal syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dantrolene",
"       </td>",
"       <td>",
"        25 mg",
"       </td>",
"       <td>",
"        100 mg, four times daily",
"       </td>",
"       <td>",
"        Potentially irreversible hepatotoxicity requires regular monitoring, weakness, sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonidine",
"       </td>",
"       <td>",
"        0.05 mg, twice daily",
"       </td>",
"       <td>",
"        0.1 mg, four times daily",
"       </td>",
"       <td>",
"        Hypotension, bradycardia, dizziness, constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabapentin",
"       </td>",
"       <td>",
"        100 mg three times daily",
"       </td>",
"       <td>",
"        3600 mg daily in divided doses",
"       </td>",
"       <td>",
"        Sedation, dizziness",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40843=[""].join("\n");
var outline_f39_56_40843=null;
var title_f39_56_40844="Key points emergency birth";
var content_f39_56_40844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key points in emergency delivery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. Call for help. The mother and the baby should each have at least one clinician caring for them.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Briefly assess the mother to determine if delivery is imminent (baby's head is visible or distending the perineum). Ask her if there are obstetrical or medical problems of which you should be aware, such as twin gestation, preterm fetus, congenital anomalies, or maternal bleeding diathesis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Position the mother on pillows or towels so her hips are raised, flexed, and abducted.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Use an antibacterial cleanser to clean your hands and the perineum. Put on gloves.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Ask the mother to pant or make only modest expulsive efforts in an attempt to achieve a controlled delivery.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Place one hand on the baby's head and apply gentle downward pressure to maintain it in a flexed position and keep it from popping out of the vagina, and use the other hand to ease the perineum over the baby's face. Don't pull on the head, let the mother gradually push it into your hands.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7. Feel for a loop of umbilical cord around the baby's neck. If present, gently slip it over the head. If it resists, either doubly clamp and cut it or leave it alone.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8. With the next push, guide the head slightly downward so that the anterior shoulder slips under the symphysis pubis and delivers, then guide the head slightly upward to deliver the posterior shoulder over, rather than through, the perineum. Once both shoulders have delivered, the rest of the baby immediately follows.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9. The mouth and nose should be suctioned with a bulb syringe or wiped out with a clean cloth if no bulb is available. The mouth is suctioned before the nose to decrease the risk for aspiration. Do not raise the baby higher than the mother's abdomen to avoid backflow of blood into the placenta.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10. Doubly clamp the umbilical cord and cut between the clamps.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       11. Dry the baby to reduce heat loss. Keep the baby warm by swaddling in warm towels/blankets, providing \"skin to skin\" contact with the mother, and keeping the room temperature warm.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12. Do not pull on the cord to deliver the placenta. The three classic signs of placental separation are: (1) lengthening of the umbilical cord, (2) a gush of blood from the vagina signifying separation of the placenta from the uterine wall, and (3) change in the shape of the uterine fundus from discoid to globular with elevation of the fundal height. Placental separation occurs naturally, usually within 30 to 60 minutes of expulsion of the infant.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If the placenta is not expelled naturally, ask the mother to bear down and gently tug on the umbilical cord to deliver it. Place a hand on the abdomen to secure the uterine fundus to prevent uterine inversion. The postpartum fundus is palpable as a soft or firm mass at about the level of the umbilicus.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       13. After placental expulsion, massage the uterine fundus to help it contract into a firm globular mass. A flabby fundus suggests atony, which is the most common cause of postpartum hemorrhage.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       14. Administer oxytocin 10 units intravenously or intramuscularly.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15. Inspect the perineum for lacerations. Deep lacerations should be evaluated and treated by an obstetrician. Apply pressure to lacerations that are bleeding briskly until these lacerations can be repaired.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40844=[""].join("\n");
var outline_f39_56_40844=null;
var title_f39_56_40845="Pharyngeal swallow timeline";
var content_f39_56_40845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Timing of events within the pharyngeal swallow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time line showing volume-induced modifications in the timing of events within the pharyngeal swallow. Each horizontal bar depicts the period during which one of the oropharyngeal valves is in a swallowing configuration as opposed to a respiratory configuration. Events at the onset and offset of pharyngeal reconfiguration bear a fixed time relationship to each other, regardless of swallow bolus volume. The stereotypy of these phases is demonstrated by referencing of onset events from time 0 counting forward and of offset events from time 0 counting forward or backward. This timing scheme defines the volume-dependent middle portion of the time line (black), which has a value of 0 for 1-mL swallows and 0.2 seconds for 20-mL swallows.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Adapted from: Cook IJ, Kahrilas PJ. AGA: Technical review: Management of oropharyngeal dysphagia. Gastroenterology 1999; 116:455.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40845=[""].join("\n");
var outline_f39_56_40845=null;
var title_f39_56_40846="Checklist chronically ill child";
var content_f39_56_40846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Sample parent-professional worksheet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 430px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trachtenberg S, Lewis D. Interdisciplinary team process. In: Handbook of Developmental Disabilities: Resources for Interdisciplinary Care, Kurtz L, Dowrick P, Levy SE, et al (Eds), Aspen Publishers, Inc, 1996. p.206. Figure 36.1. Copyright &copy; 1996 Aspen Publishers, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40846=[""].join("\n");
var outline_f39_56_40846=null;
var title_f39_56_40847="TB pleural effusion x-ray";
var content_f39_56_40847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Culture-positive tuberculous pleural effusion in a 9-year-old patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a culture-positive tuberculous pleural effusion in a 9-year-old girl. The source case was a school janitor. The child complained only of a mild cough and was discovered through a contact investigation of the school case.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey R Starke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_56_40847=[""].join("\n");
var outline_f39_56_40847=null;
